









The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 



























THE IMPACT OF OBESITY AND INFLAMMATION ON METABOLIC RISK 
FACTORS FOR CARDIOVASCULAR DISEASE AND TYPE TWO DIABETES IN 
BLACK AND WHITE SOUTH AFRICAN WOMEN 
By 
Juliet P. Evans 
 
This thesis is presented for the degree of 
DOCTOR OF PHILOSOPHY 
In the Department of Human Biology 
 




MRC/UCT Research Unit for Exercise Science and Sports Medicine 
Sports Science Institute of South Africa 





























TABLE OF CONTENTS 
LIST OF TABLES AND FIGURES ................................................................................... VII 
ACKNOWLEDGEMENTS ................................................................................................... X 
RELATIVE CONTRIBUTION TO THIS THESIS ......................................................... XII 
DECLARATION................................................................................................................. XIII 
PUBLICATIONS ................................................................................................................ XIV 
ABBREVIATIONS ............................................................................................................. XVI 
GLOSSARY OF TERMS ................................................................................................ XVIII 
ABSTRACT ......................................................................................................................... XIX 
CHAPTER ONE 
LITERATURE REVIEW ....................................................................................................... 1 
1.1. INTRODUCTION ..................................................................................................... 1 
1.2. ETHNIC DIFFERENCES IN CARDIOVASCULAR DISEASE AND TYPE TWO 
DIABETES .................................................................................................................... 3 
1.2.1. Metabolic risk factors for cardiovascular disease and type two diabetes .............. 4 
1.2.2. Obesity and body fat distribution in relation to metabolic risk ............................. 6 
1.2.3. Thresholds of central obesity measures as determinants of metabolic risk 
variables ............................................................................................................... 14 
1.2.4. Impact of socioeconomic status on disease outcome and metabolic risk ............ 19 
1.2.5. Summary .............................................................................................................. 20 
1.3. INFLAMMATION IN OBESITY, CARDIOVASCULAR DISEASE AND TYPE 















1.3.1. Circulating inflammatory proteins as markers of cardiovascular disease and type 
two diabetes risk .................................................................................................. 22 
1.3.1.1. Acute Phase Reactant C-reactive protein (CRP) ......................................... 22 
1.3.1.2. Cytokines ..................................................................................................... 24 
1.3.1.2.1. Interleukin-18 (IL-18) .............................................................................. 24 
1.3.1.2.2. Interleukin-6 (IL-6) .................................................................................. 26 
1.3.1.2.3. Tumor necrosis factor-α (TNF- α) ........................................................... 27 
1.3.1.3. Adipocyte Hormones ................................................................................... 32 
1.3.1.3.1. Adiponectin .............................................................................................. 32 
1.3.1.3.2. Leptin ....................................................................................................... 33 
1.3.1.4. Other inflammatory markers shown to differ by ethnicity .......................... 34 
1.3.2. Adipose tissue as an inflammatory organ ............................................................ 35 
1.3.2.1. Adipose tissue inflammation in obesity, cardiovascular disease and type two 
diabetes ........................................................................................................ 35 
1.3.2.1.1. Depot-specific adipose tissue inflammation ............................................ 39 
1.3.2.1.2. Ethnic differences in adipose tissue-derived inflammation ..................... 40 
1.3.3. Summary .............................................................................................................. 41 
1.4. LITERATURE CONCLUSIONS ............................................................................ 41 
1.5. AIMS AND OBJECTIVES ...................................................................................... 43 
1.6. THESIS OUTLINE .................................................................................................. 45 
CHAPTER TWO 
ETHNIC-SPECIFIC OBESITY THRESHOLDS ASSOCIATED WITH METABOLIC 
RISK FACTORS FOR CARDIOVSCULAR DISEASE AND TYPE TWO DIABETES 
IN SOUTH AFRICAN WOMEN ......................................................................................... 46 















2.2. INTRODUCTION ................................................................................................... 47 
2.3. METHODS .............................................................................................................. 48 
2.3.1. Subjects ................................................................................................................ 48 
2.3.2. Body composition assessment ............................................................................. 49 
2.3.3. Blood Pressure ..................................................................................................... 49 
2.3.4. Blood sampling and analysis ............................................................................... 49 
2.3.5. Insulin Resistance (IR) ......................................................................................... 50 
2.3.6. Metabolic Risk factors ......................................................................................... 50 
2.3.7. Statistical Analysis ............................................................................................... 50 
2.4. RESULTS ................................................................................................................ 51 
2.4.1. Subject characteristics .......................................................................................... 51 
2.4.2. Metabolic outcomes ............................................................................................. 51 
2.4.3. Relationship between central obesity with metabolic risk factors ....................... 54 
2.4.4. Central obesity thresholds for metabolic risk factors .......................................... 55 
2.5. DISCUSSION .......................................................................................................... 60 
CHAPTER THREE 
RELATIONSHIP BETWEEN CIRCULATING INFLAMMATORY MARKERS IL-18 
AND HSCRP WITH METABOLIC RISK FACTORS FOR CARDIOVASCULAR 
DISEASE AND TYPE TWO DIABETES IN SOUTH AFRICAN WOMEN .................. 64 
3.1. ABSTRACT ............................................................................................................. 64 
3.2. INTRODUCTION ................................................................................................... 65 
3.3. METHODS .............................................................................................................. 67 
3.3.1. Subjects ................................................................................................................ 67 
3.3.2. Socioeconomic status and health behaviour/lifestyle measures .......................... 67 















3.3.4. Inflammatory markers .......................................................................................... 68 
3.3.5. Statistical analysis ................................................................................................ 69 
3.4. RESULTS ................................................................................................................ 69 
3.4.1. Basic subject characteristics ................................................................................ 69 
3.4.2. Ethnic differences in circulating inflammatory markers ..................................... 72 
3.4.2.1. Socioeconomic status (SES) ........................................................................ 72 
3.4.2.2. Behavioural/lifestyle variables ..................................................................... 72 
3.4.2.3. Central obesity ............................................................................................. 75 
3.4.2.4. Metabolic risk factors .................................................................................. 75 
3.4.3. Multivariate associations with metabolic risk factors for cardiovscular disease 
and type two diabetes ........................................................................................... 75 
3.4.3.1. Black women ............................................................................................... 75 
3.4.3.2. White women ............................................................................................... 76 
3.5. DISCUSSION .......................................................................................................... 83 
CHAPTER FOUR 
ASSOCIATION BETWEEN IL-18 -137G/C POLYMORPHISM WITH 
CIRCULATING IL-18 CONCENTRATIONS AND METABOLIC RISK FACTORS 
FOR CARDIOVSC LAR DISEASE AND TYPE TWO DIABETES IN SOUTH 
AFRICAN WOMEN .............................................................................................................. 88 
4.1. ABSTRACT ............................................................................................................. 88 
4.2. INTRODUCTION ................................................................................................... 89 
4.3. METHODS .............................................................................................................. 90 
4.3.1. Subjects ................................................................................................................ 90 
4.3.2. Testing Procedures ............................................................................................... 91 















4.3.4. Statistical Analysis ............................................................................................... 92 
4.4. RESULTS ................................................................................................................ 93 
4.4.1. Subject characteristics .......................................................................................... 93 
4.4.2. Distribution of IL-18 genotype among ethnic groups.......................................... 93 
4.4.3. Association between IL-18 genotype with circulating IL-18 concentrations ...... 94 
4.4.4. Differences in IL-18 -137G/C genotypes, body composition and metabolic risk 
factors for cardiovascular disease and type two diabetes between black and white South 
African women................................................................................................................. 95 
4.5. DISCUSSION .......................................................................................................... 99 
CHAPTER FIVE 
DEPOT- AND ETHNIC-SPECIFIC ASSOCIATIONS BETWEEN ADIPOSE TISSUE 
INFLAMMATION AND INSULIN SENSITIVITY ........................................................ 102 
5.1. ABSTRACT ........................................................................................................... 102 
5.2. INTRODUCTION ................................................................................................. 103 
5.3. METHODS ............................................................................................................ 105 
5.3.1. Subjects .............................................................................................................. 105 
5.3.2. Testing procedures ............................................................................................. 105 
5.3.2.1. Body composition assessment ................................................................... 105 
5.3.2.2. Fat biopsies ................................................................................................ 105 
5.3.2.3. Adipocyte area ........................................................................................... 106 
5.3.2.4. Insulin sensitivity (SI) ................................................................................ 106 
5.3.2.5. Biochemical Analysis ................................................................................ 107 
5.3.2.6. RNA extraction, reverse transcription, and real-time PCR........................ 107 
5.3.2.7. Measurement of protein expression in adipose tissue ................................ 108 















5.3.3.1. Univariate data analysis ............................................................................. 109 
5.3.3.2. Multivariate data analysis .......................................................................... 109 
5.4. RESULTS .............................................................................................................. 110 
5.4.1. Body composition, fat distribution, insulin sensitvity and circulating adipokines
 110 
5.4.2. Subcutaneous adipose tissue gene expression ................................................... 111 
5.4.3. Relationship between insulin senstivity and subcutaneous adipose tissue gene-
expression and circulating concentrations ......................................................... 116 
5.4.4. Subcutaneous adipose tissue protein expression ................................................ 118 
5.4.5. Relationship between subcutaneous adipose tissue gene expression, protein 
levels and corresponding circulating adipokine concentrations ........................ 118 
5.4.6. Relationship between adipocyte size and circulating inflammatory markers and 
inflammatory gene expression ........................................................................... 120 
5.5. DISCUSSION ........................................................................................................ 120 
5.5.1. Ethnic differences in gene expression ................................................................ 121 
5.5.2. Depot differences in gene expression ................................................................ 123 
CHAPTER SIX 
SUMMARY AND CONCLUSIONS .................................................................................. 125 
REFERENCES.....................................................................................................................136 















LIST OF TABLES AND FIGURES 
Figure 1.1. Impact of ethnicity on the relationship between obesity, adipose tissue 
distribution, inflammation and metabolic risk factors for cardiovascular disease and type two 
diabetes mellitus......................................................................................................................... 3 
Table 1.1. Metabolic syndrome criteria for women .................................................................. 5 
Figure 1.2. Visceral adipose tissue vs. waist circumference in African American, West 
African and South African women [50]..................................................................................... 9 
Figure 1.3. Relationship in black and white South African women between the insulin 
sensitivity index (SI) and body fat distribution [12] ................................................................ 12 
Table 1.2. Evidence for ethnic differences in central obesity thresholds as determinants of 
T2DM in women ...................................................................................................................... 17 
Table 1.3. Ethnic differences in circulating inflammatory markers. ....................................... 29 
Figure 1.4. Inflammation in obesity and potential link to insulin resistance in adipose tissue, 
muscle and the liver. ................................................................................................................ 38 
Figure 1.5. Thesis outline. ....................................................................................................... 45 
Table 2.1. Subject characteristics and body composition of black and white South African 
women ...................................................................................................................................... 52 
Table 2.2. Metabolic outcomes of black and white South African women ............................ 53 
Figure 2.1. Percentage of black and white South African women presenting with metabolic 















Table 2.3. Pearson correlation coefficients (r) between central obesity measures and 
metabolic outcomes in black and white South African women ............................................... 57 
Table 2.4. WC, WHtR and VAT thresholds for metabolic risk variables in black and white 
South African women. ............................................................................................................. 58 
Table 3.1. SES, health behaviour, health status and circulating inflammatory markers of 
black and white South African women .................................................................................... 71 
Figure 3.1. Circulating hsCRP and IL-18 concentrations in black (a, b) and white (c, d) 
women across socioeconomic status categories. ..................................................................... 73 
Figure 3.2. Relationship between behaviour/lifestyle variables and circulating hsCRP and IL-
18 concentrations in black women (a, b) and white women (c,d). .......................................... 74 
Figure 3.3. Correlations between WC and circulating hsCRP and IL-18 in black and white 
women. ..................................................................................................................................... 75 
Table 3.2. Regression models for metabolic risk factors in black women, including serum IL-
18, hsCRP, lifestyle/behavioural factors and body composition ............................................. 78 
Table 3.3. Regression models for metabolic risk factors in white women, including serum IL-
18, hsCRP, lifestyle/behavioural factors and body composition ............................................. 81 
Figure 4.1. Genotype frequency of the IL-18-137G/C polymorphism in black and white 
women.. .................................................................................................................................... 94 
Figure 4.2. Ethnic differences in circulating IL-18 concentrations according to IL-18 -
137G/C genotype.  . ................................................................................................................. 95 
Table 4.1. Subject characteristics for genotypes of the -137 G/C polymorphism within the IL-















Table 4.2. Metabolic outcomes for IL-18-137G/C genotypes and serum IL-18 concentrations 
in black South African women ................................................................................................ 98 
 Table 5.1. Subject characteristics of normal-weight and obese, black and white South 
African women....................................................................................................................... 112 
Figure 5.1. Adipose tissue chemokine gene expression........................................................ 113 
Figure 5.2. Adipose tissue macrophage marker gene expression.. ....................................... 114 
Figure 5.3. Adipose tissue cytokine and adipokine gene expression. ................................... 115 
Figure 5.4. Relationship between adipose tissue gene expression and insulin sensitivity (SI) 
in white women (a) and black women (b).. ........................................................................... 117 
Table 5.2. Adipose tissue protein expression levels in normal-weight and obese, black and 
white women .......................................................................................................................... 119 

















I wish to acknowledge the support and contributions of the following people, without whom 
this thesis would not have been possible: 
Julia Goedecke, my supervisor. Thank you for your expert support, guidance, inspiration 
and hard work. Thank you for creating opportunities for me and challenging me to do better. 
Tommy Olsson, my co-supervisor. Thank you for your guidance and encouragement with 
my thesis and your kindness and generosity in Sweden.  
Vicki Lambert, Dinky Levitt, Malcolm Collins and Lisa Micklesfield for your conceptual 
guidance and assistance with interpretation of the data. 
Courtney Jennings and Yael Joffe for recruitment and testing of the large cohort of black 
women and Madelaine Carstens for your help with recruitment and testing of the large 
cohort of white women. 
Hendriena Victor, for your assistance with recruitment and biochemical analysis of the 
smaller cohort of black and white women included in Chapter 5, Judy Belonje for measuring 
the blood glucose and free fatty acid concentrations and Ingegerd Soderstrom, for 
measuring the serum inflammatory markers, guidance with protein extraction and 
determination techniques, and general support in Sweden. 
Caroline Blomquist and Jonas Buren for measuring mRNA expression of the inflammatory 
genes from adipose tissue samples in the small cohort of black and white women included in 
Chapter 5. 
Lize van der Merwe, for helping with the statistical analysis of the genotype results, and 
Fredrik Jonsson for performing and helping with interpretation of the Partial Least Squares 
regression analysis used in Chapter 5. 
Morea Pederson, for assistance with the cell size methodology. Thank you to Nick Tam, 
Tikshan Cheung and Samantha Bacon for help with capturing cells on the Axiocam. 
 
Linda Berwuringe, for completing the DXA scans and Naomi Fenton and Symington 















Phillip Hayes and Kevin Adams for performing the fat biopsies and Joel Dave for help with 
the frequently sampled intravenous glucose tolerance tests. 
Novonordisk Fonden, the National Research Foundation of South Africa, the Medical 
Research Council of South Africa, the International Atomic Energy Agency, and the 
University of Cape Town for providing sources of funding for this thesis. 
My friends, Collid, Pauli, Sez, Pips, Cecil and Umz, thank you for your love and enthusiasm. 
Thank you to Kotryna, Malin and Caroline from Umeå University for your help and support 
in Sweden. Thank you to the staff and students at ESSM, with particular mention to Flos, 
Tina, Ash, Mark, Rob and Nick for providing me with daily support and entertainment.  
My family, Mum, Dad, Melly, Charlie, Shawn, Rick and Aoife, I love you all so much. 
Thank you for never doubting that I could do this, for your emotional (and financial) 
support, and for keeping me grounded. 
Lex, without your support, patience and understanding I would never have been able to do 
my PhD. Thank you for being the person who you are and for making me aspire to be the 















RELATIVE CONTRIBUTION TO THIS THESIS 
My role and contribution to each chapter of this thesis is presented below. My supervisors Dr 
Julia Goedecke and Professor Tommy Olsson helped me define my research questions and 
construct the study designs. 
Chapter 2. 
I drafted the research hypothesis and collected all the data on the white women. I analysed 
and interpreted the data and drafted the main body of the chapter.  
Chapter 3. 
I drafted the research hypothesis and collected all the data on the white women. I analysed 
and interpreted all the data and drafted the whole chapter.  
Chapter 4.  
I drafted the research hypothesis and performed the genotyping of the IL-18 -137G/C 
polymorphism on the whole cohort under the guidance of Dr Malcolm Collins. I was assisted 
with the statistical analyses and interpretation of the data. I drafted the whole chapter. 
Chapter 5.  
I drafted the research hypothesis and performed the adipose tissue protein quantification and 
determination and cell size analysis. I performed all univariate statistical analyses, and was 

















I, Juliet Evans, do hereby declare that the experiments presented in this thesis were 
conceived and executed by myself except where otherwise indicated. 
Neither the substance nor any part of this thesis has been submitted in the past, or is being, or 
is to be submitted for a degree in the university or any other university. 
This thesis is presented in fulfilment of the requirements for the degree of PhD. 
I hereby grant the University of Cape Town free licence to reproduce this thesis in part or 


















Peer reviewed publications related to this thesis 
Evans J, Goedecke JH. Inflammation in relation to cardiovascular disease risk: A 
comparison of black and white women from the United States, United Kingdom and South 
Africa. 2011 March Current Cardiovascular Risk Reports (In press). 
Evans J, Micklesfield LK, Jennings C, Levitt NS, Lamber EV, Olsson T, Goedecke JH. 
Diagnostic ability of obesity measures to identify metabolic risk in South African women. 
2011 April Metabolic Syndrome and Related Disorders (In press). 
Evans J, Goedecke JH, Söderström I, Búren J, Alvehus M, Blomquist C, Jonsson F, Hayes 
PM, Adams K, Dave JA, Levitt NS, Lambert EV, Olsson T. Depot- And Ethnic-Specific 
Differences In The Relationship Between Adipose Tissue Inflammation And Insulin 
Sensitivity. 2011 Clin Endocrinol (Oxf);74:51-59. 
Evans J, Collins M, Jennings C, van der Merwe L, Söderström I, Olsson T, Levitt NS, 
Lambert EV, Goedecke JH. The association of interleukin-18 genotype and serum 
concentrations with metabolic risk factors for cardiovascular disease. 2007 Nov Eur J 
Endocrinol;157(5) 633-40. 
Sumner AE, Micklesfield LK, Ricks M, Tambay AV, Avila NA, Thomas F, Lambert EV, 
Levitt NS, Evans J, Rotimi CN, Tulloch-Reid MK, Goedecke JH. Waist Circumference, 
BMI, and Visceral Adipose Tissue in White Women and Women of African Descent. Obesity 
(Silver Spring). 2011 Mar;19(3):671-4. 
Goedecke JH, Levitt NS, Lambert EV, Utzschneider KM, Faulenbach MV, Dave JA, West S, 















abdominal adipose tissue distribution on insulin sensitivity in black and white South African 
women. 2009 Aug. Obesity (Silver Spring); 17(8):1506-12.  
International conference presentations related to this thesis 
Evans J, Micklesfield LK, Jennings C, Levitt NS, Lambert EV, Olsson T, Goedecke JH. 
Association between central obesity measures and metabolic risk variables: a study of black 
and white South African women. EASD, Stockholm, Sweden. September 2010 (Poster 
presentation). 
Evans J, Goedecke JH, Söderström I, Búren J, Alvehus M, Blomquist C, Jonsson F, Hayes 
PM, Adams K, Dave JA, Levitt NS, Lambert EV, Olsson T. Depot- And Ethnic-Specific 
Differences In The Relationship Between Adipose Tissue Inflammation And Insulin 
Sensitivity. NAASO, Washington DC, USA. October 2009 (Poster presentation). 
Local conference presentations related to this thesis 
Evans J, Micklesfield LK, Jennings C, Levitt NS, Lambert EV, Olsson T, Goedecke JH. 
Association between central obesity measures and metabolic risk variables: a study of black 
and white South African women. SEMDSA, January 2010 (Oral presentation) 
Evans J, Goedecke JH, Söderström I, Búren J, Alvehus M, Blomquist C, Jonsson F, Hayes 
PM, Adams K, Dave JA, Levitt NS, Lambert EV, Olsson T. Depot- And Ethnic-Specific 
Differences In The Relationship Between Adipose Tissue Inflammation And Insulin 


















AT  Adipose tissue 
ARIC  Atherosclerosis Risk in Communities 
AUC  Area Under the Curve 
BP  Blood pressure 
BMI  Body mass index 
CCL2  Chemokine C-C motif ligand 2 
CCR2  Chemokine C-C motif receptor 2 
CSF-1  Colony stimulating factor 
CT  Computer tomography  
CVD  Cardiovascular disease 
DSAT  Deep subcutaneous adipose tissue 
DXA  Dual x-ray absorptiometry 
FFA  Free fatty acids 
FSIGT  Frequently sampled intravenous glucose tolerance test 
HDL-C High density lipoprotein cholesterol 
HOMA-IR Homeostasis model of insulin resistance 
hsCRP  High sensitivity C-reactive protein 
HSE  Health Survey for England 
IDF  International Diabetes Federation 
IFN   Interferon gamma 
IRAS  Insulin Resistance Atherosclerosis Study 
GENOA Genetic Epidemiology Network of Arteriopathy 
IL-  Interleukin- 
IR  Insulin resistance 
LDL-C Low density lipoprotein cholesterol 
MIF  Macrophage inhibitory factor 
MRI  Magnetic resonance imaging 















NHANES National Health and Nutritional Examination Survey 
OR  Odds ratio 
PA  Physical activity 
POWIRS Profiles of Obese Women with Insulin Resistance Syndrome 
ROC  Receiver operator characteristic 
SADHS South African Demographic Health Survey 
SAT  Subcutaneous adipose tissue 
SES  Socioeconomic status 
SI  Insulin Sensitivity 
SAT  Subcutaneous adipose tissue 
SSAT  Superficial subcutaneous adipose tissue 
SNP  Single nucleotide polymorphism 
SVF  Stromal vascular fraction 
T2DM  Type 2 Diabetes Mellitus 
TC  Total cholesterol 
TG  Triglyceride 
THUSA Transition and Health during Urbanisation of South Africa 
TNF-α  Tumor necrosis factor alpha 
TNFR  Tumor necrosis factor receptor 
UK  United Kingdom 
VAT  Visceral adipose tissue 
WC  Waist circumference 
WHtR  Waist-height ratio 















GLOSSARY OF TERMS 
Obesity 
Obesity is viewed as excess accumulation of body fat, and was defined based on the 











Dyslipidemia is a disorder of lipoprotein metabolism, and for the purpose of my thesis 
classified as elevated triglycerides (TG), elevated total cholesterol (TC), and/or reduced high 
density lipoprotein cholesterol (HDL-C).  
Insulin sensitivity (SI)/Insulin resistance (IR) 
Insulin sensitivity refers to the ability of endogenous insulin to promote glucose clearance 
and inhibit hepatic glucose output. Insulin resistance is defined as decreased insulin 
sensitivity. 
Adipose tissue secretory products 
Macrophage Markers    CD68, CD14, CD163 
Pro-inflammatory cytokines   IL-18, IL-6, TNF-α, CSF-1, MIF 
Anti-inflammatory cytokine  IL-10 
Pro-inflammatory chemokines CCL2 and its receptor CCR2 
Pro-inflammatory adipokine   Leptin 
















Abdominal obesity, particularly accumulation of visceral adipose tissue (VAT), is 
characterised by a chronic low-grade inflammatory response and is associated with increased 
risk of insulin resistance (IR), type two diabetes mellitus (T2DM) and cardiovascular disease 
(CVD). Importantly, body fat distribution, inflammation (at both a genetic and circulating 
level), metabolic risk factors for CVD and T2DM, as well as socioeconomic status (SES) and 
behavioural/lifestyle factors, have been shown to differ across ethnic groups. However, the 
ethnic-specific association between body fat distribution, inflammation and risk for CVD and 
T2DM, and the interaction with SES and behavioural/lifestyle factors, has not been 
comprehensively explored in a South African population and is required to identify potential 
mechanisms underlying these diseases and highlight specific areas for intervention.  
There is currently limited data on the effectiveness of central obesity measures, including 
VAT, and its anthropometric proxies (waist circumference (WC), waist- to hip ratio (WHR) 
and waist-to-height ratio (WHtR)), for early detection of CVD risk factors in different ethnic 
groups in South Africa. Furthermore, several studies have examined circulating inflammatory 
markers, in particular the high sensitivity measure of the acute phase protein C-reactive 
protein (hsCRP), as an inflammatory biomarker of increased CVD risk. There is less 
consistent information available on other inflammatory biomarkers. Interleukin (IL)-18, a 
proinflammatory cytokine known to be associated with T2DM and CVD risk, has been 
suggested as a novel biomarker of risk. However, this has not been examined in a multi-
ethnic population, such as South Africa, nor is it known how ethnic differences in SES, 
behavioural/lifestyle and genetic factors influence circulating IL-18 concentrations. Further, 
given the differences in body fat distribution between black and white women it remains to 
be explored if there are ethnic differences in the depot-specific expression of inflammatory 















if a depot-specific AT inflammation could explain ethnic differences in metabolic risk factors 
for CVD and T2DM in black and white women. 
Therefore, the overall aim of this thesis was to investigate the ethnic-specific role of 
inflammation in obesity and related metabolic risk factors associated with T2DM and CVD in 
apparently healthy black and white premenopausal South African women. More specifically, 
the objectives were to; i) compare the discriminative ability of central obesity measures to 
identify black and white South African women with or without known metabolic risk factors 
for CVD and T2DM, including elevated blood pressure (BP), dyslipidaemia (defined by 
elevated triglyceride (TG), high total cholesterol (TC)/high density lipoprotein cholesterol 
(HDL-C) ratio, and/or reduced HDL-C concentrations), and IR (estimated using the 
homeostasis model of insulin resistance (HOMA-IR) and defined by the upper tertile for the 
whole cohort); ii) investigate the association between circulating inflammatory markers, 
namely IL-18 and hsCRP with metabolic risk factors for CVD in black and white South 
African women, taking into account socioeconomic and behavioural/lifestyle factors known 
to influence both inflammation and CVD risk; iii) investigate whether ethnic variation in the 
distribution of  the  -137 G/C polymorphism within the IL-18 gene is associated with 
differences in serum IL-18 concentrations and metabolic risk factors for CVD in black and 
white South African women; iv) determine the ethnic- and depot-specific associations 
between AT inflammatory gene and protein expression with insulin sensitivity (SI), a major 
risk factor for T2DM, in black and white South African women. 
In summary, this thesis has important novel findings regarding the ethnic specific role of 
obesity and inflammation (at a circulating, genetic and AT-specific level) with metabolic risk 
factors for CVD and T2DM in apparently healthy black and white South African women. The 















variables in black compared to white women. Furthermore, basic, cost-effective 
anthropometric measures of obesity (WC and WHtR) were able to identify an equivalent 
amount of risk compared to CT-derived VAT. The data also show that increased circulating 
concentrations of the inflammatory markers hsCRP and IL-18 were associated with obesity, 
low SES, smoking, contraceptive use and metabolic risk factors for CVD in both black and 
white women. The relationship between circulating IL-18 and hsCRP with risk was largely 
due to the effects of obesity and not SES, supporting the role of AT-derived inflammation in 
linking obesity to increased CVD and T2DM risk. However, differences in circulating IL-18 
concentrations between black and white women could not be explained by ethnic differences 
in the distribution of the IL-18 -137G/C gene polymorphism. Further investigation is 
therefore needed into other factors influencing circulating concentrations of IL-18. The data 
also showed that although black women have higher inflammatory gene expression within 
the abdominal SAT and gluteal depots, this was not able to explain their lower SI. In 
conclusion, despite an up-regulation of inflammation at a circulating, genetic and AT-specific 
level in black women, this could not explain ethnic differences in metabolic risk factors 
between black and white South African women. Future research should investigate the 
contribution of inflammation from other tissues which may affect metabolic risk factors in 
black populations.  Compared to other factors explored in this thesis, central obesity 
explained the greatest proportion of variance in metabolic risk factors. However, a large 
proportion of risk still remained unexplained. Therefore future studies should focus on other 
factors involved, in particular exploring more objective measures of lifestyle, such as 
physical activity and dietary intake. Furthermore, prospective studies are also required to 



















Data from this chapter have been published in part in: Evans J, Goedecke JH. 
Inflammation in relation cardiovascular disease risk: A comparison of black and white 
women from the United States, United Kingdom and South Africa. 2011 March Current 
Cardiovascular Risk Reports (In press). 
 
1.1. INTRODUCTION 
Obesity (defined by a body mass index (BMI)>30kg/m
2
) is highly prevalent in South African 
women [1] and is associated with increased risk of non-communicable diseases, including 
cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) [2;3]. In addition to 
being an independent risk factor for CVD and T2DM, obesity also increases the risk of other 
metabolic risk factors, namely insulin resistance (IR), hypertension and dyslipidaemia [4]. 
The metabolic effects of excess adipose tissue (AT) are exerted partly via increased release of 
free fatty acids (FFA) and the production of adipose-derived proteins, including adipocyte 
hormones, inflammatory cytokines, chemokines and acute phase proteins, which have both 
metabolic and inflammatory functions [5]. The distribution of AT influences its metabolism 
and thereby disease risk, independently of the size of the AT stores. Accumulation of fat in 
the abdominal area, particularly in the visceral fat compartment (VAT), is associated with 
increased risk of IR, T2DM, hypertension, dyslipidaemias and atherosclerosis [6], whereas 
fat stored in the lower body is associated with a more favourable metabolic profile [7]. It is 
hypothesised that the differential effects of body fat distribution on metabolic risk outcome 
















Studies in developed countries have highlighted the importance of ethnicity in the 
relationship between obesity and disease risk [9;10]. Subsequently, apparent ethnic 
differences in body composition, fat distribution, inflammation, and metabolic risk factors for 
CVD and T2DM have been shown in South African women [11-13] (Figure 1.1). 
Furthermore, it must also be recognised that developmental influences (such foetal nutrition) 
have lifelong effects on cardiovascular and metabolic function, and that this may be 
especially relevant in a developing country such as South Africa undergoing epidemiological 
transition (as reviewed by Hanson and Gluckman [14]).  To add to the complexity of the 
association between obesity, inflammation and metabolic risk, are inherent ethnic differences 
in socioeconomic status (SES) and environmental/lifestyle factors, which may influence 
disease risk and outcome [15]. Although these differences are mainly a result of the socio-
political history of the country, genetic variability and/or epigenetic differences between 
ethnicities may also be involved [16-18]. Of particular relevance to this thesis are ethnic 
differences in inflammation, which have been shown at both a genetic and circulating level. 
A better understanding of the relevant predisposing factors associated with metabolic disease 
risk in South African women is important for early disease detection and prevention. Notably, 
ethnic differences in the aetiology of cardiovascular disease and type two diabetes are 
multifactorial, included in which are interactions of both AT endocrine and immune 
abnormalities with non-AT organs (as reviewed by Lee et al. [19]). However, for the purpose 
of this thesis, the following review focuses on studies investigating the associations between 
obesity, inflammation at a circulating, genetic level and AT-specific level, and metabolic risk 
factors for CVD and T2DM, with particular focus on differences in black and white 

















Figure 1.1. Impact of ethnicity on the relationship between obesity, adipose tissue distribution, 
inflammation and metabolic risk factors for cardiovascular disease and type two diabetes 
mellitus. VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TC, total 
cholesterol;TG, triglyceride; HDL-C, high density lipoprotein cholesterol; SES, socioeconomic 
status. 
 
1.2. ETHNIC DIFFERENCES IN CARDIOVASCULAR DISEASE AND TYPE 
TWO DIABETES 
It is estimated that the burden of disease attributable to non-communicable diseases, 
including CVD and T2DM, constituted the second most important cause of death in South 
African adults in 2000 [20]. Earlier population based surveys in South Africa show a high 
prevalence of hypertension (14-33%) and T2DM (4.8-6%) [21;22], with variation in 
















as likely to present with T2DM compared to white women (7.0% vs. 3.6%) [23;24] and white 
South African women displayed a higher prevalence of dyslipidaemia [25] and ischemic 
heart disease [21;26;27], compared to black women.  
Similar black-white differences in the prevalence of CVD and T2DM have been found in 
America and the United Kingdom (UK). According to American national prevalence data 
published in 2007, the prevalence of T2DM was 6.6% in white versus 11.8% in black women 
[28], and the prevalence of coronary heart disease was 6.6% in white compared to 5.2% in 
black women [29].  Data from the Health Survey for England (HSE) in 2006 showed the 
prevalence for T2DM and CVD was 7.6% and 9.2% in black Afro-Caribbean, 2% and 5.5% 
in black Africans, and 3.1% and 13% in the white population, respectively [30]. 
1.2.1. Metabolic risk factors for cardiovascular disease and type two diabetes 
Established metabolic risk factors for CVD and T2DM include central obesity, hypertension, 
hyperglycaemia, IR, dyslipidaemia and a chronic low-grade inflammatory response [31]. The 
clustering of these factors, known as the metabolic syndrome, occurs more commonly in 
insulin resistant/hyperinsulinaemic individuals, and is associated with a further increased risk 
for CVD and T2DM [32]. As a result, diagnostic criteria for the metabolic syndrome have 
been developed in European populations to help identify individuals at increased risk for 
T2DM and CVD, and include thresholds for elevated blood pressure (BP), dyslipidaemia 
(characterised by high triglyceride concentrations (TG) and reduced high density lipoprotein 
cholesterol (HDL-C) concentrations), hyperglycaemia and obesity (assessed by waist 
circumference, WC) (Table 1.1) [31;33]. The International Diabetes Federation (IDF) 
estimates that individuals with the metabolic syndrome (classified as having greater than 3 of 
















experience CVD events compared to people without the metabolic syndrome. In addition, 
individuals with the metabolic syndrome have a 5 fold greater risk of developing T2DM [33]. 
Insulin resistance, through direct effects of vessel walls and indirect effects on lipids and BP 
is regarded by some, to be the underlying factor linking the clustering of metabolic risk 
factors (metabolic syndrome) to CVD and T2DM [31;33;34]. Black American and South 
African women have been shown to be more insulin resistant than their white counterparts 
[12;35-38]. However, despite this, the prevalence of the metabolic syndrome is lower in 
black compared to white individuals. Data from the Profiles of Women with Insulin 
Resistance Syndrome (POWIRS) study [39], which compared age and body mass index 
(BMI)-matched black (n=102) and white (n=115) apparently healthy South African women, 
showed the prevalence of the metabolic syndrome (IDF criteria) to be higher in white 
(30.4%) compared to black (24.8%) women. Similarly, Kalk et al. found higher prevalence of 
the metabolic syndrome (IDF criteria) in white (74.1%) compared to black (46.5%) diabetic 
patients [2]. A higher prevalence of the metabolic syndrome has also been found when 
comparing apparently healthy white (23.5%) compared to black (8.2%) Americans [40].  
Table 1.1. Metabolic syndrome criteria for women 
Risk Factor Defining Level 
Central obesity, given as a WC ≥80cm (IDF) 
>88cm (NCEP ATP III) 
Triglycerides ≥1.7 mmol/L 
High density lipoprotein cholesterol <1.29 mmol/L 
Blood Pressure ≥130/85 mmHg 
Fasting glucose ≥5.6mmol/L  
IDF, International Diabetes Federation; NCEP ATPIII, National Cholesterol Education Program 

















Further investigation has shown that there is an atypical presentation of components of the 
metabolic syndrome in black individuals, with a very low percentage presenting with 
hypertriglyceridaemia compared to their white counterparts [2;41]. Furthermore, Goedecke et 
al. have shown that whilst increased TG and reduced HDL-C concentrations are associated 
with lower insulin sensitivity (SI) in a cross sectional sample of white South African women 
as has been previously shown in European populations, lipids were not related to SI in black 
women. The failure of association between lipids and SI has also been shown in black 
American women [42]. These findings suggest that the use of the current metabolic syndrome 
criteria may not be appropriate in black populations. However, due to the lack of prospective 
data identifying risk factors that predispose black populations to CVD and T2DM, the current 
cut-points for the individual risk factors established by the National Cholesterol Education 
Program Adult Treatment Panel (NCEP ATP) III will be used to identify risk in my thesis 
[31]. 
1.2.2. Obesity and body fat distribution in relation to metabolic risk 
Obesity is not only an independent risk factor for CVD [43], it also increases the incidence of 
other risk factors associated with CVD and T2DM, notably elevated BP, dyslipidaemia and 
IR [6;44]. Obesity is highly prevalent in South Africa, and results from the first South 
African Demographic and Health Survey (SADHS) conducted in 1998, showed that 56% of 
adult women and 26% of men were overweight or obese, with the highest prevalence shown 
in black women (58.5%), followed by women of mixed ancestry (52%) and then white 
women (49.2%) [1]. Cross-sectional studies in South Africa have shown that a high 
percentage of patients with T2DM and CVD are overweight or obese [2;45]. Whilst the 
prevalence of obesity is high in both black and white South African women, ethnic 
















American women have less central fat mass, specifically VAT, and more peripheral (femoral 
and gluteal) fat [11]compared to white women. 
The distribution of body fat is an important determinant of the metabolic consequences of 
obesity. Abdominal accumulation of AT (central obesity), in particular VAT, is associated 
with a greater risk of cardiovascular complications [6] compared to accumulation of AT in 
the femoral-gluteal region (peripheral obesity), which is associated with a lower risk of 
metabolic complications [7]. Using imaging techniques (computer-tomography, CT and 
magnetic resonance imaging, MRI) to quantify abdominal VAT and subcutaneous AT (SAT), 
cross-sectional studies have demonstrated strong correlations between VAT and individual 
metabolic risk factors, including IR, dyslipidaemia and elevated BP, independent of total fat 
and abdominal SAT [46;47]. The added risk of VAT over SAT is thought to be due to the 
direct release of FFA and adipose-derived proteins, including pro-inflammatory cytokines, 
and decreased delivery of anti-inflammatory factors such as adiponectin from VAT into the 
hepatic portal system (known as the portal hypothesis) [48] resulting in reduced hepatic 
insulin clearance, increased gluconeogenesis and increased dyslipidaemia [49]. Indeed, 
visceral adipocytes have been shown to be more sensitive to lipolytic stimuli, and less 
sensitive to anti-lipolytic stimuli (such as insulin), compared with subcutaneous adipocytes 
[50-52].  
Sumner et al. [53] compared the waist circumference (WC)-VAT relationship in black 
(n=186) and white (n=148) South African women and black women from America (n=99) 
and West Africa (n=23). White South African women (n=148) had a significantly higher 
increase in cross sectional VAT per unit increase in WC than all black populations. Further, 
no difference was found in the WC-VAT relationship between black South African, 
















American and South African women.  In small groups of obese black and white women 
matched for body mass index (BMI), van der Merwe and Puyandeera et al. have 
demonstrated that black women had significantly smaller VAT area (5 level slice) than white 
women (72mm vs. 140mm) [35;54]. Similar findings were shown by Conway et al. [55] 
when comparing obese black (n=9) and white (n=11) American women. Although, WC 
correlated significantly with VAT  in both ethnic groups, black women had less VAT (cross 
sectional area at level of L2-L3) than white women, and similar levels of SAT. In this study, 
black American women had significantly lower fasting TG and glucose concentrations and 
lower diastolic BP than their white counterparts [55]. Conway et al. [55] concluded that 
obesity might not be associated with as severe health consequences in black compared to 
white women. Contrary to this, when examining ethnic differences in the relationship 
between VAT volume and blood lipids, BP, and IR (assessed by the homeostasis model of 
insulin resistance, HOMA-IR) in apparently healthy premenopausal (~ 37 years old) 
overweight black (n=30) and white (n=36) American women matched for SES, physical 
activity levels, age and BMI, Perry et al. [56] found no difference in insulin or glucose 
concentrations between ethnic groups, despite lower levels of VAT in the black women.  
However, black women had lower TG concentrations than white women, which were 
attributed to their lower VAT. The authors concluded that a critical level of VAT was not 

















Figure 1.2. Visceral adipose tissue vs. waist circumference: scatter plots and linear regression 
line for each group. Equations for white South Africans: VAT = −185 + 3.18 WC; African 
Americans: VAT = −111 + 1.65 WC; black South Africans: VAT = −50 + 1.38 WC; black 
Africans in United States: VAT = −115 + 1.88 WC. VAT, visceral adipose tissue; WC, waist 
circumference. Figure from Sumner et al. [53]. 
 
However, whilst there is consensus that VAT has a strong association with CVD risk factors, 
particularly dyslipidaemia and hyperinsulinaemia [47], abdominal SAT has also been shown 
to contribute to obesity-related co-morbidities, particularly IR. Specifically, both VAT and 
abdominal SAT volume were significantly associated with BP, fasting glucose, TG and 
HDL-C concentrations and increased odds of hypertension, impaired fasting glucose, T2DM 
and clustering of metabolic risk factors in older, apparently healthy women (n=1452) 
included in the Framingham Heart study [57]. Furthermore, when comparing the relationship 
of VAT and abdominal SAT volume with SI (frequently sampled intravenous glucose 
tolerance test, FSIGT), BP and lipid levels in a cross-sectional sample of obese non-diabetic 
black American women, Tulloch-Reid et al. [58] found that both VAT and abdominal SAT 
















TG and systolic BP. Statistical comparison of correlation coefficients between VAT and 
abdominal SAT revealed no differences in the strength of association with SI or lipids. In 
obese premenopausal black and white American women, Lovejoy et al. [59] reported lower 
VAT area (L4-L5) in black (n=23), but similar SAT, compared to white (n=15) women. 
Comparing the association of abdominal SAT and VAT with SI (FSIGT), blood lipids and 
BP, their results showed that for a lower level of VAT, black women had higher BP and 
fasting insulin concentrations and lower SI than white women. VAT correlated significantly 
with SI, but not with BP or lipid profiles in both black and white women. Furthermore, in this 
study, abdominal SAT was significantly associated with SI in black but not white women. 
The authors concluded that ethnic differences may exist in the sensitivities of VAT and 
abdominal SAT to an insulin stimulus. In agreement with this, a recent study on normal-
weight and obese black (n=30) and white (n=30) apparently healthy South African women 
showed that despite lower levels of VAT area (L4-L5), black South African women were 
more insulin resistant than their white counterparts [12]. While both VAT and abdominal 
SAT depots were similarly correlated to SI in white women, abdominal SAT was more 
closely related to SI in black women [12]. 
In addition to differences in VAT, some studies have shown greater amounts of abdominal 
SAT in black compared to white women. Notably, abdominal SAT is anatomically separated 
by a stromal fascia into superficial (SSAT) and deep subcutaneous adipose tissue (DSAT) 
[60], and ethnic differences in abdominal SAT are possibly due to a greater proportion of 
superficial SAT (SSAT) rather than deep SAT (DSAT). 
Ethnic differences in body composition were investigated in a baseline analysis of 
overweight healthy middle aged black (n=55) and white (n=103) American women from the 

























) compared to white women. In agreement with these findings, Goedecke 
et al. found higher abdominal SAT in obese black compared to obese white women, with 









) [12]. Notably, in black women, the relationship between SI and abdominal DSAT 
was stronger than for SSAT (Figure 1.3). Abdominal DSAT has previously been shown to 
have as strong a positive relationship with IR as VAT, and therefore possibly metabolically 
distinct to superficial SSAT [61;62]. 
The relative size of VAT compared to abdominal SAT is very small, accounting for only     
5-8% of total fat stores, whereas abdominal SAT accounts for up to 80% of total fat stores 
[47]. Further, Nielsen et al. showed that between 50-60% of hepatic FFA delivery is from the 
systemic circulation, with the contribution of VAT lipolysis to hepatic FFA delivery ranging 
from only 10% in lean (those with less VAT) to about 30% in obese (those with greater 
VAT) individuals. This suggests that abdominal SAT is probably the main source of 


















Figure 1.3. Relationship in black and white South African women between the insulin sensitivity 
index (SI) and a) body fat percentage, b) visceral adipose tissue are (VAT), c) deep subcutaneous 
adipose tissue area (SAT), d) superficial SAT. Solid regression lines are for black women and 
broken regression lines for white women. When the relationship is not significant, no regression 
line is shown. Figure from Goedecke et al. [12] 
 
In contrast to abdominal obesity, the accumulation of gluteal SAT has been regarded as 
protective, with some [7;17;63;64], but not all [46;65;66], studies showing a positive 
association between increasing hip circumference and/or leg fat mass and favourable 
metabolic risk profiles. It has been suggested that the femoral-gluteal fat depot plays a 
protective role by acting as a ‘sink’ for circulating FFA [67]. In contrast to abdominal VAT 
and SAT, adipocytes in the femoral region are relatively insensitive to lipolytic stimuli and 
have a high sensitivity for anti-lipolytic stimuli [52;68]. Therefore, the femoral-gluteal SAT 
















release them readily. As a result, ectopic fat storage in the liver, skeletal muscle and pancreas, 
as well as VAT accumulation may be prevented [69].  
The added metabolic risk of VAT in comparison to abdominal and gluteal SAT, has in part, 
been attributed to their apparent higher expression and/or secretion of inflammatory 
mediators [70;71]. Numerous studies have shown that in comparison to abdominal SAT, 
abdominal VAT has greater expression and secretion of a number of key inflammatory 
mediators shown to be associated with IR, dyslipidaemia and elevated BP [71]. However the 
production of inflammatory proteins in SAT has also been linked to metabolic complications 
[72-74]. Although there is a paucity of data confirming this, DSAT has been shown to have 
an inflammatory gene expression greater than SSAT [75;76] and in the case of tumor 
necrosis factor (TNF)-α expression, similar to that of VAT [75]. It is further hypothesized 
that the protective effects of peripheral fat accumulation are mediated by a more favourable 
inflammatory profile [7], though there is a lack of evidence to support this. The inflammatory 
properties of different adipose tissue depots will be discussed in more detail in section 1.3. 
In summary, there are ethnic differences in body fat distribution and the relationship between 
abdominal VAT and SAT with metabolic risk variables. Notably, advanced imaging 
techniques, such as CT, are not always available in a primary health care setting and exposure 
to radiation makes this a high-risk method of risk screening. On the other hand, 
anthropometric proxy measures of VAT, including WC, waist-height ratio (WHtR) and 
waist-hip ratio (WHR) are more cost-effective and less high risk, and are frequently used 
indicators of central obesity. However, as discussed previously, the same level of WC does 
not reflect the same amount of VAT or SAT between black and white women, and may have 
















1.2.3. Thresholds of central obesity measures as determinants of metabolic risk 
variables 
As discussed in section 1.2.1 and in accordance with the IDF [77] and the NCEP ATP III 
[31], central obesity is a major modifiable risk factor for CVD and T2DM, and should be a 
target for clinical interventions. Subsequently, thresholds of central obesity measures, 
including WC, WHR, WHtR and BMI, and less frequently VAT, are used for the early 
identification of individuals at increased risk for CVD and T2DM [78].  
The most common cut-points used to identify increased risk are those of a WC of 80cm and 
88cm, as recommended by the IDF and NCEP ATP III, respectively (Table 1.1). 
Furthermore, the IDF criteria specify that different WC thresholds should be used for 
different ethnic groups and/or populations, and have further defined ethnic specific WC cut-
points for Europid, Chinese, South Asian and Japanese populations [77]. However, currently 
there is no central obesity threshold defined for Sub-Saharan populations, and it is 
recommended that a WC of 80 cm be used until more specific data is available. Considering 
the differences in the association between body composition and metabolic risk in different 
ethnic groups as discussed in section 1.2.2, using current thresholds derived from European 
populations for risk screening may lead to inadequate screening in high-risk ethnic groups.  
Several cross-sectional studies have evaluated the use of IDF and NCEP ATPIII WC cut-
points in black and white American populations. Okusan et al. [79] compared the ability of a 
WC >88cm for identifying the clustering of hypertension, T2DM and dyslipidaemia in black 
and white Americans from the National Health and Nutritional Survey (NHANES) III study. 
The odds ratio (OR) associated increased CVD risk due to a WC>88cm was higher in white 
(OR=6.21 for 2 or more risk factors and OR=14.2 for 4 or more risk factors) compared to 
















Although the effectiveness of these cut-points has not been explored in white South African 
women, Jennings et al. compared the sensitivity and specificity of the IDF and NCEP ATPIII 
WC thresholds for predicting IR (as estimated by HOMA-IR > 2.60) in a sample of young, 
apparently healthy black South African women [41]. There was no difference in the 
sensitivity or specificity between the WC cut-points. However, the IDF cut-point of 80cm 
had a positive predictive value of 86.1% compared to 78.4% for the NCEP ATPIII cut-point 
of 88cm. This suggests that lower obesity thresholds may be needed for early risk detection 
in black populations.  
Approaches based on receiver operator characteristic (ROC) curve analyses are frequently 
used for defining obesity thresholds, though only a few studies in America and UK have 
investigated the ethnic-specific level of obesity that predicts incidence of T2DM (Table 1.2). 
Using data from NHANES 2003-2004 and HSE 2003-2004 [80], Diaz et al. explored 
thresholds of BMI, WC and WHR that best predicted the development of T2DM in black and 
white men and women. BMI thresholds did not differ across countries or between ethnicities, 
with BMI thresholds ranging between 26 and 28 kg/m
2
. Conversely, WC thresholds were 
higher in American compared to British women, with a higher (~3cm) WC threshold in the 
black compared to white American women. In contrast, a lower WC (~3cm) threshold was 
found in black compared to white British women. The optimal WHtR thresholds were similar 
between black American and white and black British women, but were higher in white 
American women. WC thresholds for identifying the development of T2DM from the 
Atherosclerosis Risk in Communities (ARIC) cohort were lower than those identified in the 
NHANES cohort, but similarly, black women had higher WC thresholds compared to white 
women (101 vs. 95cm, respectively). BMI thresholds were also higher in black compared to 
white women, but no difference in WHR was found [81].  Sargeant et al. investigated the 
















of self-reported African ancestry [82]. Although BMI thresholds for black women in the 
different studies (ARIC, NHANES, HSE) were similar, those for WC and WHtR were much 
lower in the Jamaican cohort compared to those reported for black women from the ARIC, 
NHANES and HSE cohorts. These findings highlight the variability in obesity thresholds for 
identifying metabolic risk across ethnic groups and/or populations. 
 
In addition to identifying the level of obesity that best predicts risk for CVD and T2DM, 
numerous investigations have sought to find the anthropometric measure (WC, WHR, WHtR 
or BMI) that can achieve the best discrimination of risk. Lee et al. conducted a meta analysis 
including more than 88 000 individuals from several countries (including Germany, Hong 
Kong, Taiwan, Jamaica, Thailand and Japan), to determine which of four indices of 
overweight and obesity (BMI, WC, WHtR or WHR) was the best discriminator of 
hypertension, T2DM and dyslipidaemia [83]. For hypertension, T2DM and dyslipidaemia, 
WHtR had the highest, and BMI the lowest pooled ROC area under the curve (AUC). 
However, only small differences were observed between WC, WHR and WHtR. Although 
they were unable to perform sub-group analysis of ethnic groups, results from NHANES, 
HSE and ARIC cohorts discussed previously suggest that WC and WHtR are the best 
measures for predicting T2DM in these populations, irrespective of ethnicity. T2DM and 
hypertension have been shown to be more prevalent in short-stature individuals compared 
with taller individuals [84] and when matched for WC, shorter individuals have been shown 
to have a higher risk for CVD [85]. It has therefore been suggested that WHtR may still be a 
better measure of metabolic risk than WC, especially in populations that vary in height 
[86;87]. This may be of particular relevance to the South African context, since black South 















Table 1.2. Evidence for ethnic differences in central obesity thresholds as determinants of T2DM in women 
Study Population Outcome Ethnicity Threshold (ROC AUC)  Additional Comments 


















ROC AUC for WC and 
WHtR significantly 
greater than ROC AUC 
for BMI in all groups 


























T2DM (9 year follow 










ROC AUC for WC 
significantly greater than 
ROC AUC for BMI in 







Incident T2DM (4 year 
follow up): Fasting 
glucose ≥7mM and/or 










No difference in ROC 
AUC between measures 
NHANES, National Health and Nutritional Examination Survey; HSE, Health Survey for England; ARIC, Atherosclerosis Risk in Communities study; T2DM, 
type two diabetes mellitus; WC, waist circumference; WHR, waist-hip ratio; WHtR, waist-height ratio; BMI, body mass index; ROC AUC, receiver operator 
















As discussed in section 1.2.2, for the same level of WC white women accumulate more VAT 
whereas black women accumulate more SAT [53]. Although VAT is considered to be a better 
marker of risk compared to SAT in some populations, both VAT and SAT are associated 
with risk in black populations [12]. However, it is not known what level of VAT, if any, best 
predicts increased risk for CVD and T2DM in black populations.  Furthermore, as WC, is 
reflective of both VAT and SAT, WC may be superior to VAT for prediction of risk factors. 
However, only a few studies have examined the effectiveness of VAT compared to 
anthropometric measures for the identification of individuals at increased risk for CVD. In a 
cross-sectional sample of obese Korean women, WC and CT-derived VAT were equivalent 
in predicting a combination of at least two metabolic risk factors for CVD [78]. Further, in a 
subgroup of patients from the Diabetes Prevention Programme, Bray et al. compared the 
ability of VAT, SAT, BMI, WHR and WC for prediction of T2DM [88]. WC, WHR, BMI 
and VAT, but not SAT, were significant predictors of T2DM, with little difference between 
the discriminative ability of the other measures [78]. Although they adjusted for ethnicity, it 
is not known whether there were ethnic differences in the ability of CT-derived compared to 
anthropometric measures for identifying T2DM. Further investigation of the effectiveness of 
anthropometrics compared to more direct measures of VAT is therefore needed, particularly 
given the ethnic differences in the relationship between WC and VAT [53] and the 
differential relationship between AT distribution and metabolic risk in South African women 
[12]. 
In summary, the most optimal measure of central obesity, as well as the level of central 
obesity that best predicts metabolic risk factors for CVD and T2DM has not been explored in 
















1.2.4. Impact of socioeconomic status on disease outcome and metabolic risk 
A low SES has been shown to be associated with increased risk for non-communicable 
diseases, including CVD and T2DM [15;89;90]. Results from the Interheart study, a large 
case-control study designed to investigate risk factors associated with acute myocardial 
infarction across 52 countries, including Africa [91], showed that a low level of educational 
attainment (≤ 8yrs) was associated with higher odds of acute myocardial infarction compared 
to higher educational attainment (≥9yrs) [91]. Furthermore, the association between low SES 
and increased risk for myocardial infarction was present in both low/middle and high income 
countries. A lower educational attainment has also been shown to be associated with longer 
time to first diagnosis of T2DM [92]. 
Notably, studies in America have shown that ethnic minority groups (which include black 
populations) are more likely to be less well-educated than the majority white population 
[93;94]. As a result, it has been suggested that ethnic differences in disease outcome 
discussed previously may be due to differences in SES rather than ethnicity per se. This is 
highlighted by recent analysis of NHANES data [94].  Results of this study showed that SES, 
which was lower in black women, was inversely associated with estimated 10-year CVD and 
T2DM risk in both black and white American women. However, when comparing ethnic 
groups stratified for level of SES (low-high), only black women in the middle SES had 
higher odds (OR=2.4) of T2DM compared to white women. In support of these findings, 
matching black and white participants in the Boston Area Community Health survey 
according to SES status (assessed by education and income), T2DM prevalence no longer 
differed between ethnicities [93]. This study concluded that SES, which they classed as a 
potentially modifiable risk factor, was more important in identifying T2DM than the non-
















context, where the majority of blacks, although the majority population group, live in poorer 
areas [89]. As this is largely a result of the socio-political history of the country, data 
comparing health related variables between black and white South Africans matched for SES 
have yet to be shown. 
Although the exact biological mechanisms are not fully understood, it is believed that 
negative behavioural/lifestyle factors (including smoking, alcohol consumption, 
contraceptive use, sedentary behaviour and poor dietary patterns) characteristic of low SES 
communities may, in part, mediate the relationship between low SES and increased CVD and 
T2DM risk [90]. Indeed, in the Interheart study [91], approximately half of the risk due to 
low SES was explained by modifiable behavioural/lifestyle variables, including smoking, 
higher WHR, lower consumption of fruit and vegetables and lower levels of exercise. In 
addition, results from NHANES data showed that irrespective of ethnicity, a large proportion 
of the association between SES and CVD risk was explained by health behaviours (physical 
activity and smoking) and central obesity characteristic of lower SES groups [94]. 
In summary, there is evidence to suggest that SES and behavioural/lifestyle factors impact on 
metabolic risk outcomes in both black and white populations. These findings highlight the 
importance of including SES and behavioural variables when investigating risk for CVD and 
T2DM, and will be explored in Chapter 3 of this thesis.  
1.2.5. Summary 
Differences in the prevalence of CVD and T2DM between ethnicities are possibly related to 
differences in risk factor burden, differential clustering of risk factors and SES and/or 
behavioural variables. Prospective studies are needed to identify which metabolic risk factors 
















Furthermore, it remains unclear whether traditional risk factor profiling adequately identifies 
all persons at high risk for CVD and T2DM, or whether additional novel risk markers, such 
as inflammatory proteins, are of added benefit for early risk identification. 
 
1.3. INFLAMMATION IN OBESITY, CARDIOVASCULAR DISEASE AND TYPE 
TWO DIABETES 
It is now well established that a state of chronic low-grade inflammation is present in obesity, 
T2DM and CVD [95-97]. Increased circulating concentrations of inflammatory proteins, such 
as proinflammatory cytokines, acute phase proteins, chemokines and adipocyte hormones, are 
found in obese individuals [98], and in patients with T2DM and CVD ([99]. In contrast, anti-
inflammatory proteins, such as adiponectin, have been shown to be lower in obese 
individuals and in patients with CVD and T2DM [100;101]. As a result, it is hypothesised 
that this low grade inflammatory response may be central to the development of CVD and 
T2DM [96]. Indeed, some markers of inflammation have shown potential for improved 
disease risk prediction, and in some cases as potential therapeutic targets for clinical 
intervention [102;103].  
Several factors, both environmental and genetic, have been shown to influence circulating 
concentrations of inflammatory proteins, and may impact on the relationship between 
inflammatory markers and metabolic risk factors for CVD and T2DM. Specifically, a low 
SES (assessed by lower income, asset ownership and education) and negative health 
behaviour/lifestyle variables (smoking, sedentary behaviour, poor dietary intake and 
contraceptive use) are associated with increased circulating inflammatory markers [104]. 
Genetic variants within inflammatory genes have been shown to influence circulating 
















for CVD and T2DM [105]. Furthermore, studies in America, the UK and South Africa have 
shown ethnic differences in inflammation at both a circulating and genetic level 
[13;106;107]. Studies exploring the relationship between circulating inflammatory markers 
and risk factor for CVD and T2DM in black and white populations are summarized in Table 
1.3 and discussed in further detail below.  
1.3.1. Circulating inflammatory proteins as markers of cardiovascular disease and 
type two diabetes risk 
1.3.1.1. Acute Phase Reactant C-reactive protein (CRP) 
Of the inflammatory proteins, the most extensive data have been shown with high sensitivity 
C-reactive protein (hsCRP). CRP is an acute phase protein secreted by the liver in response to 
inflammatory cytokines, mainly interleukin (IL)-6, IL-1 and TNF-α [97]. Cross-sectional 
studies have shown that hsCRP concentrations increase with increasing adiposity [108] and 
are associated with metabolic risk factors for CVD and T2DM, including IR, elevated BP and 
dyslipidaemia [97;108;109].  
Studies in America have shown that a lower SES (assessed by education and income) is 
associated with increased circulating hsCRP concentrations [104;110]. This association has 
been shown to be largely due to behavioural/lifestyle variables which also influence hsCRP. 
Specifically, excessive alcohol consumption [111], smoking [112], sedentary behavior 
[113;114], poor dietary patterns [115] and use of oral contraceptives [116] have all been 
associated with increased circulating hsCRP concentrations. Furthermore, studies in America, 
UK and South Africa have shown that hsCRP concentrations are higher in black compared to 
white populations (Table 1.3). These differences have been shown to be largely due to 
differences in obesity and/or SES and behavioural/lifestyle factors. Data from the 1999-2000 
















black compared to white women, however these differences were not statistically significant 
after adjusting for WC, TG concentration and systolic BP [117]. Data from the Women’s 
Health Study [118] indicated that hsCRP concentrations were 44.6% higher in black 
compared to white women. However, adjusting for BMI reduced this difference to 10.2%. 
Despite differences in hsCRP concentrations between ethnicities, there is evidence to suggest 
that it remains a good overall marker of risk in both black and white populations, though 
associations with specific risk factors have been shown to differ between ethnicities. A 
comparison of the association between hsCRP and metabolic risk factors in women included 
in the POWIRS study [13] revealed that hsCRP levels correlated significantly with BP and 
cardiac output in both black and white women, yet only with TG in white women. Results 
from the Insulin Resistance Atherosclerosis Study (IRAS), demonstrated that the relationship 
between hsCRP and BMI, fasting insulin and SI were consistent across ethnic groups though 
the association was not as strong among black women [96].  
Earlier prospective studies have shown that high concentrations of hsCRP (>3mg/L) were of 
added prognostic value for CVD risk in individuals with no known disease, the metabolic 
syndrome and diabetic patients [103;119;120]. As a result, it was suggested that hsCRP be 
added to the diagnostic criteria for metabolic syndrome [103]. However this has recently 
been challenged due to a number of studies showing that, after adjusting for traditional risk 
factors, circulating hsCRP concentrations do not offer a marked improvement in risk 
prediction for CVD [121]. Specifically, in a patient population scheduled for diagnostic 
coronary arteriography, traditional CVD risk factors (based on metabolic syndrome 
components) were associated with a higher degree of CVD irrespective of hsCRP 
concentration [121]. Similarly, after adjusting the NCEP ATP III criteria to include 
circulating hsCRP concentrations >3mmol/L, Hanley et al. found no improvement in  the 
















It must be noted that hsCRP is a non-specific indicator of inflammation [123], and it is 
therefore possible that higher hsCRP concentrations are caused by unknown inflammatory 
conditions. Therefore, other inflammatory markers involved in the initiation of inflammatory 
responses may be a more accurate reflection of pathways underlying CVD and T2DM. 
1.3.1.2. Cytokines 
1.3.1.2.1. Interleukin-18 (IL-18) 
IL-18 is a pro-inflammatory and pro-atherogenic cytokine which amplifies the TH1 immune 
response by inducing the production of pro-inflammatory cytokines and chemokines [124]. In 
addition, IL-18 has been shown to induce the TH2 response, including IL-10 production 
[125]. IL-18 is produced by several cell types, including activated macrophages, epithelial 
cells, endothelial cells and adipocytes [126]. Circulating IL-18 levels have been shown to 
correlate with a number of metabolic risk factors for CVD, including WC, fasting TG, HDL-
C, insulin and elevated BP and hyperglycaemia, in apparently healthy populations [127-129], 
and in patients with acute coronary syndromes [130]. Although the exact mechanisms linking 
IL-18 to disruption of metabolic pathways are not known, there is evidence to suggest IL-18 
is involved in atherogenic pathways through activation of essential proteins involved in 
atherogenesis, e.g.,vascular adhesion molecules (VCAM-1), chemokines (IL-8), cytokines 
(IL-6), and matrix metalloproteinases (MMP-1/-9/-13) [131]. Furthermore, upregulation of 
IL-18 gene expression has been shown to involve NF B, which in turn has been implicated 
in disruption of insulin signalling pathways [132]. 
To my knowledge, the impact of SES on circulating IL-18 concentrations has not been 
explored. Furthermore, there is limited data on the impact of behavioural/lifestyle factors on 
circulating concentrations of IL-18, though both regular exercise [133] and a Mediterranean 
















studies have investigated ethnic differences in IL-18 concentrations [135;136]. Results from 
the Dallas Heart Study [136] revealed that subjects with higher concentrations of IL-18 
(upper quartile for whole study group) were more likely to be of older age, male, white and 
obese. In agreement with this, circulating IL-18 concentrations were significantly higher in 
white compared to black hypertensive women participating in the Genetic Epidemiology 
Network in Arteriopathy (GENOA) study [135]. Black American ethnicity in this study was 
associated with lower IL-18 concentrations independent of age, sex, BMI, conventional risk 
factors and lifestyle factors (β=-0.17, P<0.001). However, the authors did caution that results 
of this study could not be extrapolated to younger, healthy populations. Ethnic differences in 
circulating IL-18 concentrations could potentially be explained by ethnic differences in the 
IL-18 gene. Ness et al. compared the distribution of functional single nucleotide 
polymorphisms (SNPs) in 9 cytokine genes, including IL-18, between black (n=179) and 
white (n=396) American women [106].  Their results showed that the G allele of the -137G/C 
polymorphism, which has previously been associated with higher IL-18 concentrations [137], 
had a higher frequency in black compared to white women. However it remains to be 
established if ethnic differences in the distribution of this polymorphism are associated with 
ethnic differences in circulating IL-18 concentrations.  
Despite ethnic differences in IL-18 concentrations in the Dallas Heart study, no difference in 
the relationship between IL-18 and CVD risk was observed between ethnicities. Geometric 
mean concentrations of IL-18 rose progressively with increasing CVD risk (metabolic 
syndrome), with strong associations shown with HOMA-IR and glucose concentrations in 
both ethnic groups [136]. Furthermore, there is evidence to suggest that IL-18 is a good 
independent marker of CVD and T2DM risk. Data from the Women’s Health Study study 
showed that baseline concentrations of IL-18 above a threshold of 442 pg/ml (90
th
 percentile) 
















healthy women [138]. This association remained significant after adjusting for age, obesity 
(BMI), smoking, T2DM, family history of CVD and hormone use. Hivert et al. found that 
high circulating IL-18 concentrations (>4.5pg/ml) were associated with future T2DM 
incidence in a healthy cohort of middle aged women from the Nurses’ Health Study [139], 
and this association was independent of traditional risk factors for T2DM, including obesity 
(BMI and WC), dietary intake, and other inflammatory proteins. These findings suggest that 
IL-18 is a promising independent marker of metabolic risk. However, currently there is 
limited data on the impact of SES on circulating IL-18 and its relationship with CVD and 
T2DM risk. Furthermore, these associations have not been explored in a South African 
population. 
1.3.1.2.2. Interleukin-6 (IL-6) 
The pro-inflammatory cytokine IL-6 is secreted by a number of cell types, and is an 
important regulator of the acute phase response, in particular CRP synthesis by the liver 
[140]. Circulating concentrations of IL-6 increase in proportion to fat mass [141], and are 2-3 
times higher in obese T2DM patients compared to non-diabetic controls [142]. Peripheral 
administration of IL-6, that mimics the level in obesity, has been shown to induce 
hyperlipidaemia, hyperglycaemia and IR [143]. IL-6 is thought to promote IR through 
inhibition of insulin-stimulated glucose transport [144] and by increasing hepatice glucose 
production [145]. Notably, due to portal theory of metabolic risk, the metabolic impact of IL-
6 release from VAT may be of particular importance since IL-6 has also been shown to 
increase hepatic triglyceride secretion and therefore contribute to hypertriglyceridaemia 
associated with VAT [146]. 
 
Circulating IL-6 concentrations are influenced by SES gradients [104], and similar to studies 
















variables, including alcohol consumption [111;147], smoking [104;148] and sedentary 
behavior [104;113]. Circulating concentrations of IL-6 have been shown to be higher in black 
compared to white women [149;150], and these differences appear to persist after adjustment 
for differences in body fatness [135;151]. The distributions of IL-6 gene variants have also 
been shown to differ across ethnicities [106].  Results showed that the G allele of the -
174G/C genotype, which has previously been associated with higher IL-6 concentrations 
[152], had a higher frequency in black compared to white women. Similar to IL-18, there is 
limited data on whether this is associated with ethnic differences in circulating IL-6 
concentrations. 
Few studies have investigated whether the association between IL-6 and metabolic risk is 
different between ethnic groups. Although Hyatt et al. [37] found no ethnic differences in IL-
6 between overweight black and white American women, IL-6 concentrations correlated with 
SI in the white women only. However, the association with SI in the white women was not 
significant after adjusting for VAT, supporting VAT as being a significant contributor to IL-6 
levels and that the association with risk is largely due to the effects of obesity. In agreement 
with this, inclusion of IL-6 into traditional risk factor models did not improve the prediction 
of T2DM development in a large prospective multi-ethnic cohort of post-menopausal women 
[153].  
1.3.1.2.3. Tumor necrosis factor-α (TNF- α) 
TNF-α, is a pleiotropic cytokine whose primary role is regulation of immune cells, which 
exerts its effects by binding to its receptors, tumor necrosis factor receptor (TNFR)1 and 
TNFR2, present in a large number of cell membranes [154]. Studies showing an association 
between circulating TNF-α concentrations and metabolic risk factors are conflicting. A few 
















compared to normal weight individuals [155;156], and associated with glucose uptake and 
HOMA-IR [157]. However, other studies have found no association between circulating 
TNF-α and increased CVD and T2DM risk [37]. Indeed, evidence for a mechanistic role of 
TNF-α in CVD and T2DM is shown mainly at the AT level, where it has been shown to 
inhibit glucose uptake in lean individuals [158], suggesting that most effects of TNF-α are 
exerted in a paracrine fashion. 
Studies exploring the association between SES and behavioural factors with circulating 
concentrations of TNF-α are limited. In older men and women, low SES (education and 
income), smoking and alcohol consumption were associated with increased circulating TNF-
α concentrations [110]. Evidence for ethnic differences in TNF-α are conflicting. A few 
studies [37;135;149] have found higher circulating concentrations of TNF-α in white 
compared to black American women, whereas Kalra et al. found that the concentration of 
TNF-α was higher in black Afro-Caribbean compared to whites [159]. Schutte et al. found 
that black South African women tended (p=0.06) to have lower circulating TNF-α 
concentrations compared to BMI and age-matched white South African women [160]. In the 
study by Hyatt et al. [37], adjusting for differences in VAT between black and white women 
reduced the ethnic difference in TNF-α concentrations (P=0.054). Despite ethnic differences, 
none of these studies showed an association between circulating TNF-α concentrations and 
metabolic risk factors in either ethnic group. These findings suggest that circulating TNF-α is 
not a reliable marker of risk in both black and white women. Instead it appears that local 
tissue effects of TNF-α may be more important and future research needs to establish whether 















Table 1.3. Ethnic differences in circulating inflammatory markers. 
Study 






Moderating factors Association with risk 
Women’s Health Study [118] 
Black (n=475) and white 
(n=24 455) older ( 55yrs) 
women 
hsCRP Black>White 
BMI decreased the difference 
from 44% to 10% 
Not defined 
SWAN [161] 




Decrease in difference from 
82% in unadjusted model to 
68% with SES and 18% with 
BMI. Fully adjusted resulted in 
15% difference (P=0.01) 
Significant associations with 
BMI, WHR, SBP, HDL-C and 
TG in both ethnicities. 
Association with TC and LDL-C 
only in white women 
Texas City Stress and Health 
Study [150] 
Black (n=150) and white 









No difference in CRP after 
adjustment for BMI 
Not defined 
POWIRS [13] 
Black (n=102) and white 
(n=115) women; Matched 










BMI not ethnicity significant 
predictor of CRP 
Leptin and fibrinogen significant 
predictors of CRP in separate 
models for black and white 
Significant correlations with 
obesity and cardiovascular 















Table 1.3. Continued 
Study 






Moderating factors Association with risk 
CARDIA [104] 







Age-adjusted CRP and IL-6 
increased with decreasing 
education and income in both 
ethnic groups. Relationship not 
significant after adjusting for 
health variables in white only 
Dallas Heart Study [136] 
2 231 black, white and 





Significant associations with 
BMI, IR, glucose in both black 
and white 
GENOA [135] 
Black (n=936) and White 
















Differences remained significant 
after adjusting for age and BMI 
Not defined 
Health ABC [149] 
Black (n=592) and White 









CRP and IL-6 correlated with 
VAT and SAT in both 
ethnicities. TNF-α correlated 
















Table 1.3. Continued 
Study 






Moderating factors Association with risk 
Carroll et al. [151] 
Black (n=54) and white 






Difference remained significant 
after adjustment for age, VAT 
and SAT 
SAT and VAT significantly 
correlated with CRP and IL-6 
Kalra et al. [159] 
Black (n=78) and White 







Not defined Not defined 
Ferris et al. [162] 
Black (n=19) and white 
(n=22) South African 





Still significant after adjustment 
for age, BMI or WHR 
Significant associations with 
BMI, IR and HDL-C in white 
only 
 
Hulver et al. [163] 
Non-obese and obese 
black (n=13, n=24) and 







BMI, insulin and HOMA-IR 
correlated with adiponectin in 
white women only 
SWAN, Study of Women’s Health Across the Nation ; POWIRS,Profile of Women with Insulin Resistance Syndrome ;CARDIA, Coronary Artery Development 
in Young Adults ;GENOA, Genetic Epidemiology Network of Arteriopathy ;hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; IL-18, interleukin-
18; IL-10, interleukin-10; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; TNF-α, tumor necrosis factor alpha; BMI, 
body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; WHR, waist-hip ratio; SES, socio-economic status; SBP, systolic blood 
pressure; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, 
















1.3.1.3. Adipocyte Hormones 
1.3.1.3.1. Adiponectin 
Adiponectin is produced exclusively by adipocytes [164] and has anti-inflammatory, anti-
atherogenic and insulin-sensitising properties [165;166]. Circulating concentrations of 
adiponectin are positively correlated with SI [167] and are decreased in obese individuals and 
in patients with T2DM and CVD [100;101;168]. Adiponectin seems to regulate the 
expression of several anti- and pro-inflammatory cytokines, such as TNF-α, and the 
inhibitory controls of pro-inflammatory cytokine production are speculated to be disturbed 
with decreased synthesis of adiponectin [169]. 
In a cross-sectional investigation on the impact of SES and behavioural factors on circulating 
adiponectin concentrations in black American adults, Schootman et al. found higher 
adiponectin concentrations in individuals with better housing conditions, but no impact of 
income level, smoking status or alcohol consumption [170]. The majority of studies have 
shown higher adiponectin in white compared to black individuals [37;162;163;171]. There is 
evidence to suggest that ethnic differences in adiponectin are largely dependent of the level of 
obesity of the population studied. For example, in South African women in the POWIRS 
study [171], ethnic differences in adiponectin were only observed when comparing normal-
weight white and black women, but not overweight or obese women. In agreement with these 
findings, higher circulating adiponectin concentrations were found in normal-weight but not 
obese white compared to black American women [163]. Results from this study also showed 
that the association between adiponectin levels and metabolic risk factors for CVD and 
T2DM was not consistent across ethnicities. Specifically, adiponectin concentrations were 
associated with a more favourable metabolic profile in the white women only, correlating 
















South African women, adiponectin concentrations correlated with HOMA-IR in the white 
women only [162]. 
In contrast to these findings, results from prospective studies suggest that circulating 
adiponectin concentrations are good predictors of T2DM irrespective of ethnicity and 
independent of other confounding/mediating factors. Specifically, results from the ARIC 
study showed higher adiponectin concentrations were associated with a lower incidence of 
T2DM, with a similar magnitude of association in black and white individuals [100]. In a 
prospective European cohort, increasing quintiles of adiponectin were significantly associated 
with the development of diabetes independent of age, level of education, smoking, physical 
activity level, alcohol consumption, diet and obesity (assessed by BMI and WC) [172].  
1.3.1.3.2. Leptin 
Leptin is a true marker of AT mass and is involved mainly in energy homeostasis, acting at 
the level of the central nervous system to regulate food intake and energy expenditure [173]. 
Leptin is also involved in the propagation of the inflammatory response by regulating the 
secretion of chemokines and cytokines from monocytes [174-176]. Leptin is secreted in 
response to fat cell hypertrophy [177], and circulating levels increase with obesity and are 
associated with individual risk factors for CVD [101;178]. 
Earlier studies in South African women showed no difference in circulating leptin 
concentrations between small samples of black and white women [54]. However more 
recently, leptin concentrations in normal-weight (BMI <25 kg/m
2
) and overweight (BMI: 25-
30 kg/m
2
) women in the POWIRS study were significantly higher in black compared to white 
women [171]. In agreement, results from the GENOA study showed higher leptin in black 
compared to white women [135]. Despite these ethnic differences, circulating leptin 
















black and white women [171]. However, although leptin has been shown to be involved in 
blood pressure regulation [179], it is not known higher leptin concentrations found in black 
populations relates to a higher prevalence of hypertension. In addition, although leptin 
appears to be a good independent marker of CVD and T2DM risk in cross-sectional studies, 
analysis of prospective data from the British Women’s Heart and Health study [180] showed 
no association between circulating leptin concentrations and incident CVD. 
1.3.1.4. Other inflammatory markers shown to differ by ethnicity 
In addition to the inflammatory markers discussed above, circulating concentrations of 
several coagulation factors and adhesion molecules have been shown to differ between 
ethnicities. Black individuals have beens shown to have higher concentrations of fibrinogen, 
factors VII and VIII and plasminogen-activator inhibitor-1, and lower concentrations of 
VCAM-1, endolthelial leukocyte adhesion molecule-1, and intracellular adhesion molecule-1 
(as reviewed in [181;182]). However the details of this are beyond the scope of this review. 
In summary, circulating inflammatory markers have been shown to be associated with 
individual metabolic risk factors for CVD and T2DM. However, it still remains unclear 
whether inflammatory markers are of added diagnostic value beyond traditional risk criteria 
for the early identification of susceptible individuals at high risk for CVD and T2DM, 
especially when considering the potential confounding and/or mediating factors, such as 
ethnicity, SES and lifestyle variables that influence circulating concentrations of these 
proteins. Notably, ethnic differences in some circulating inflammatory proteins (such as IL-
18 and CRP) have been shown to remain even after adjustment for these potential 
confounding/mediating variables. Whether genetic differences in inflammatory gene 
polymorphisms and/or tissue-specific production of inflammation can explain these 
















considered to be one of the main sources of chronic low-grade inflammation present in 
obesity, CVD and T2DM.  
1.3.2. Adipose tissue as an inflammatory organ 
AT comprises several different cell types including adipocytes and immune cells, whose 
products, through autocrine, paracrine and endocrine mechanisms, are actively involved in 
metabolism (including energy homeostasis, adipocyte differentiation, and insulin sensitivity) 
and inflammation (including innate and adaptive inflammatory control, cardiovascular 
protection and vascular inflammation) [5;183]. As discussed previously, obesity is an 
independent risk factor for CVD and T2DM. There is increasing evidence showing that the 
pathogenic potential of excess AT is exerted partly via the increased release of FFA and the 
altered production of adipose-derived proteins, which include inflammatory cytokines, acute 
phase proteins and chemokines [5]. As a result, the chronic low-grade inflammation 
characteristic of obesity, T2DM and CVD is thought to have a putative origin in AT. 
1.3.2.1. Adipose tissue inflammation in obesity, cardiovascular disease and type two 
diabetes 
AT of obese individuals and patients with T2DM or CVD is characterized by increased 
expression and/or secretion of several inflammatory proteins [158]. Compared to lean, 
healthy controls, obese individuals have been shown to have greater expression of pro-
inflammatory cytokines including TNF-α [156], IL-18 [184], IL-6 [72], chemokines such as 
C-C motif ligand (CCL) 2 and macrophage markers CD68 and CD14 [184;185]. Whilst the 
exact mechanisms still need to be elucidated, it is postulated that a disruption of normal 
adipogenic pathways, either leading to/or resulting from excessive increases in fat cell size 
(adipocyte hypertrophy), due to increase TG storage in the adipocyte, leads to an infiltration 
















and protein secretion of several inflammatory markers from cultured human subcutaneous 
adipocytes. Their results showed that secretion of pro-inflammatory proteins, including 
leptin, IL-6, IL-8, TNF-α, CCL2 and colony stimulating factor (CSF)-1 were positively 
correlated with adipocyte size, whilst secretion of the anti-inflammatory protein IL-10 was 
decreased.  
Increased inflammation in AT has been shown to be associated with increased risk for CVD 
and T2DM. Apovian et al. showed that individuals with inflamed SAT (characterised by 
increased gene expression of inflammatory proteins and presence of crown like structures) 
are more hyperinsulinaemic and insulin resistant compared to BMI matched individuals 
without inflamed SAT [187]. In addition, in a small cross-section sample of obese women, 
those who were insulin resistant (n=14) had greater SAT expression of macrophage marker 
CD68, cytokines  IL-8, IL-6 and the chemokine CCL2 compared to those who were insulin 
sensitive [72]. Disruption of insulin signalling pathways by inflammatory proteins was first 
shown by Hotamsiligil et al. [188] who demonstrated that TNF-α inhibits the insulin receptor 
tyrosine kinase in AT of obese insulin resistant rats (Zucker model). Subsequently, activation 
of several other inflammatory kinases, including IKKβ, ERK, mTOR, and S6K have been 
linked to IR, as reviewed in [189].  
Although the adipocyte fraction of AT has been shown to be directly involved in 
inflammatory protein release, the increased inflammation in obesity (with the exception of 
adipocyte derived hormones like leptin and adiponectin) mainly originates from the non-
adipose fraction (stromal vascular fraction, SVF), which contains mainly immune cells 
[184;190]. Evidence for immune cell infiltration into AT was first shown in studies on obese 
mice, showing the percentage of macrophages in a given AT depot correlated positively with 
















within the AT encoded for macrophagic proteins [191;192]. Similar relationships have 
subsequently been shown in human SAT [193], with weight loss resulting in a regression in 
adipocyte hypertrophy and macrophage infiltration, accompanied with an improvement in 
inflammatory profile [194].  
It is hypothesised that macrophage recruitment and infiltration into AT during the obese state 
is mainly a result of chemotactic signals originating from enlarged adipocytes. Chemotactic 
cytokines, such as CCL2 (also known as monocyte chemoatractant protein 1) are secreted 
from adipocytes in both mice [195;196] and human subjects [197], with a greater release 
from larger adipocytes [186].  The expression of chemokines in AT along with chemokine 
receptors in newly-recruited macrophages are increased in AT of obese individuals 
[185;198].  
Furthermore, results from in vitro experiments on mouse and human macrophages suggest 
that AT macrophages are present in several di ferent activation states in the tissue. Among 
them are the classic M1/proinflammatory polarisation state that initiates the inflammatory 
reaction and the M2/anti-inflammatory state that counteracts or terminates the inflammatory 
process [199]. From isolated mature adipocytes and SVF cells from SAT of healthy women 
undergoing elective fat removal surgery, Bourlier et al. [200] showed that AT expresses both 
M1 and M2 macrophages, evidenced by the expression of both pro-inflammatory (eg. TNF-α. 
IL-6, CCL2) and anti-inflammatory (eg. IL-10) factors.  However, it appears that with 
increasing fat mass there is a phenotypic switch from M1 to M2 state, shown by a decrease in 
M1 markers. Bourlier et al. also found that treatment of AT macrophages with leptin led to 
decreased expression of M1 markers suggesting that leptin may be involved in the 
modulation of the AT macrophage phenotype with increasing adiposity. These findings 
















environment in the tissue, and the relative presence of these states characterise the 
inflammatory phenotype. 
 
Figure 1.4. Inflammation in obesity and potential link to insulin resistance in adipose tissue, 
muscle and the liver.  
With increasing weight gain there is an expansion of adipose tissue mass and adipocyte size within 
the adipose tissue and ectopic tissues such as muscle. With this expansion, increased free fatty 
acids are released into the circulation and oxygen delivery to the adipocyte is decreased. The 
combination of nutrient excess and hypoxia results in an inflammatory response within the 
adipocyte. Through increased secretion of chemokines and cytokines, and down regulation of anti-
inflammatory proteins, macrophages are recruited into the adipose tissue and resident immune 
cells are activated. The ensuing inflammatory response activates intracellular inflammatory 
pathways (JNK and IKK) in neighbouring cells and distal tissues through paracrine and endocrine 
















1.3.2.1.1. Depot-specific adipose tissue inflammation 
As discussed in section 1.2.2, the distribution of AT influences its metabolism and thereby 
disease risk, independently of the adipose tissue stores. Subsequently, it is hypothesised that 
the differential effects of body fat distribution, in particular that of VAT and SAT, on 
metabolic outcome are, in part, mediated via a differential inflammatory profile. The added 
risk of VAT may be due to higher expression and/or secretion of key inflammatory proteins. 
Alvehus et al. [76] compared the gene expression of macrophage migratory inhibitory factor 
(MIF), CCR2, CCL2 in whole tissue samples of VAT and SAT from a small sample (n=17) 
of apparently healthy women. VAT appeared as a distinct depot, with significantly greater 
expression of MIF and CCR2 compared to SAT. In agreement with this, Liu et al. [202] 
compared paired samples of abdominal VAT and SAT from obese non-diabetic women 
(n=11). VAT had higher expression of CCL2, IL-6 and IL-8, whilst SAT had higher 
expression of leptin. Similarly, Samaras et al. compared inflammatory gene expression from 
paired samples of abdominal VAT and SAT in diabetic patients (n=6) and healthy age- and 
gender-matched controls (n=10). SAT had higher expression of leptin, adiponectin and NFkB 
[203].  
 
Several studies have shown an increased AT macrophage infiltration in VAT compared to 
SAT, possibly explaining the higher inflammatory gene expression [194;204]. Comparing 
gene expression in the SVF from human VAT and SAT of morbidly obese patients 
undergoing bariatric surgery, O’Rourke et al. [204] showed that the number of CD14 positive 
AT macrophages and CD3 and CD56 positive T cells were higher in VAT compared to SAT, 
and VAT had higher expression of inflammatory genes characteristic of M1 macrophages. 
















inflammatory cytokines compared to other immune cells, having a greater relative expression 
of IL-6, IL-8, CCL2 and IL-10. 
In contrast, lower body obesity (fat stored in the femoral-gluteal region), which is associated 
with a lower risk of metabolic complications [64] has been suggested to be protective due to a 
more favourable metabolic profile [7]. However, this has not been comprehensively studied. 
Only two studies have explored differences in adiponectin gene expression between 
abdominal SAT and gluteal (n=5) [205] or thigh (n=3) [206] SAT.  Both studies showed no 
depot-specific differences in adiponectin mRNA levels. Importantly, to our knowledge, it is 
not known if gluteal and abdominal SAT differ with regards to the expression of other 
inflammatory genes, and this will be explored in Chapter 5 of this thesis. 
1.3.2.1.2. Ethnic differences in adipose tissue-derived inflammation 
Given the depot-specific expression inflammatory proteins, ethnic differences in circulating 
inflammatory markers and the relationship between abdominal AT tissue depots and 
metabolic risk factors might be explained, in part, by differences in depot-specific 
inflammation. However, only a few studies have examined ethnic differences in the 
inflammatory profile of AT. In a sample of morbidly obese black (n=26) and white (n=46) 
women undergoing bariatric surgery, Madan et al. [207] reported no ethnic differences in 
mRNA levels or in vitro release of IL-6, IL-8 and prostaglandin E2 from VAT.  In line with 
this, Smith et al. [208] found that the mRNA levels of abdominal SAT CD68, leptin and 
retinol binding protein-4 were similar between obese black (n=29) and white (n=29) 
American women, matched for BMI and SI.  
In summary, the relationship between inflammation within AT and CVD and T2DM risk is, 
in part, mediated by the distribution of the AT stores. However, whether depot-specific 
















depots and metabolic risk factors for CVD and T2DM, especially in a South African 
population, is unknown, and will be explored in Chapter 5 of this thesis.  
1.3.3. Summary 
Chronic low-grade inflammation at a circulating, genetic and AT level is associated with 
increased risk for CVD and T2DM. These associations are partly mediated by differences in 
underlying genetic variation, body fat and its distribution, SES and lifestyle factors, as well as 
their interactions. Notably, the impact of these factors on the relationship between 
inflammation at a circulating, genetic and AT level, with risk for CVD and T2DM in South 
African women is not known. 
 
1.4. LITERATURE CONCLUSIONS 
Obesity is highly prevalent in South African women and is associated with increased risk for 
CVD and T2DM. Determining what level of obesity is associated with risk is important for 
early identification of individuals at increased risk for CVD and T2DM. Importantly, these 
associations need to be ethnic and population specific, as both body composition and 
metabolic risk factors for CVD, differ between ethnic groups. Currently, there are no 
recommendations for the level of obesity that best predicts women at increased risk for CVD 
and T2DM in South Africa. Furthermore, results from America and the UK suggest that basic 
anthropometric measures are able to predict an equivalent amount of risk as more precise 
measures of fat distribution such as CT or MRI. This may have important implications in the 
South African context, where resources are often limited. 
It remains unclear whether all persons at high risk for CVD and T2DM are adequately 
















such as the inflammatory proteins, is therefore required. Importantly, it appears that not all 
circulating inflammatory proteins, such as TNF-α and IL-6, are of added benefit to risk 
prediction in both black and white populations. In contrast, the pro-inflammatory and pro-
atherogenic cytokine IL-18 has been shown to provide added risk prediction of CVD beyond 
traditional risk facts, and this has been shown in both black and white American women. 
However, it is not known if SES and behavioural/lifestyle factors known to alter 
inflammation, impact on the relationship between circulating IL-18 and CRP concentrations 
and metabolic risk factors for CVD, particularly in South African women. A better 
understanding of the factors affecting the relationship between inflammatory markers and 
metabolic risk in different populations may be important for future disease detection and 
prevention. 
Ethnic differences shown in the distribution of cytokine gene polymorphisms suggests that 
black populations have an up-regulation of inflammatory risk alleles. It is however, not 
known if differences in the distribution of these polymorphisms impact on circulating 
concentrations of inflammatory markers and metabolic outcomes. In particular, the IL-18 -
137G/C polymorphism has previously been shown to be associated with CVD outcome, and 
the distribution of the risk allele of this polymorphism has been shown to be more frequent in 
black compared to white American women. Whether ethnic differences in this gene 
polymorphism are present in South African women, and whether this polymorphism is 
associated with ethnic differences in circulating IL-18 concentrations and metabolic risk 
factors for CVD is not known. 
It has been suggested that depot-specific differences in the metabolic risk profile of 
abdominal AT-depots are possibly related to depot-specific differences in AT inflammatory 
















a lower inflammatory gene expression than that of abdominal depots. A better understanding 
of the inflammatory profiles of these depots may provide further insight into AT distribution 
in relation to disease risk. Furthermore, ethnic differences in inflammation and metabolic risk 
factors may be explained by ethnic and depot-specific differences in AT inflammation. 
However, to my knowledge it is not known if there are ethnic differences in the depot-
specific AT inflammation or how this is related to metabolic risk in different populations.  
1.5. AIMS AND OBJECTIVES 
Accordingly, the primary aim of this thesis was to investigate the ethnic-specific association 
between inflammation at a circulating, genetic and AT level, and obesity and its related 
metabolic risk factors for T2DM and CVD in apparently healthy black and white 
premenopausal South African women. In order to achieve these aims, I completed four 
studies, which are presented as separate chapters as described below: 
1. The first study (Chapter 2) tested the hypothesis that central obesity thresholds 
relating to metabolic risk factors for CVD and T2DM are different in black and white 
South African women. Therefore the aim of this study was to compare the 
discriminative ability of central obesity measures to identify black and white South 
African women with or without known metabolic risk factors for CVD and T2DM, 
including elevated BP, elevated TG and reduced HDL-C levels, and IR. 
2. The second study (Chapter 3) tested the hypothesis that circulating inflammatory 
markers hsCRP and IL-18 would be of added benefit than central obesity (measured 
by waist circumference) for identifying black and white women at increased risk for 
CVD and T2DM. Therefore the aim of the second study was to investigate the 
association between circulating inflammatory markers, namely IL-18 and hsCRP with 
















taking into account socioeconomic and behavioural/lifestyle factors known to 
influence both inflammation and CVD risk. 
3. The third study (Chapter 4) tested the hypothesis that ethnic difference in circulating 
IL-18 levels and metabolic risk factors could be explained, in part, by ethnic 
differences in the distribution of the IL-18 -137G/C polymorphism. Therefore, the 
aim of the third study was to investigate whether ethnic variation in the distribution of 
the -137 G/C polymorphism within the IL-18 gene is associated with differences in 
serum IL-18 levels and metabolic risk factors for CVD in black and white South 
African women. 
4. In the final chapter of this thesis (Chapter 5), three hypotheses were tested: a) SAT 
inflammatory gene expression is greater in black compared to white South African 
women; b) SAT inflammatory gene expression is greater in the abdominal compared 
to the gluteal depot; and c) a depot-specific inflammatory profile is associated with 
differential SI in black and white South African women. Therefore, the aim of the 
fourth study was to determine the ethnic- and depot-specific associations between AT 
inflammatory gene and protein expression with insulin sensitivity (SI), a major risk 
















1.6.  THESIS OUTLINE 
An outline of the subject recruitment and sample sizes for each study are summarised in 
Figure 1.5. In total, the main cohort consisted of 241 black and 188 white South African 
women. However, not all measurements (such as circulating inflammatory markers, IL-18 
genotyping, and fat biopsies) were performed on the whole cohort. As a result, sample sizes 
varied according to the different studies. The methods and statistical analysis are explained 
individually for each study in the relevant chapters. Importantly, the age and waist 
circumference (as a measure of abdominal obesity) of those subjects included in the 
individual studies did not differ significantly to the whole cohort.  
 
Figure 1.5. Thesis outline. Schematic showing the sample size of the whole thesis cohort and the 
sample sizes of the individual studies. CT, computer-tomography; DXA, dual x-ray absorptiometry; 
SES, socioeconomic status; hsCRP, high sensitivity C-reactive protein; IL-18, interleukin-18; FSIGT, 
frequently sampled intravenous glucose tolerance test; DSAT, deep subcutaneous adipose 

















ETHNIC-SPECIFIC OBESITY THRESHOLDS ASSOCIATED WITH METABOLIC 
RISK FACTORS FOR CARDIOVSCULAR DISEASE AND TYPE TWO DIABETES 
IN SOUTH AFRICAN WOMEN 
 
Data from this chapter have been published in part in: Evans J, Micklesfield LK, 
Jennings C, Levitt NS, Lamber EV, Olsson T, Goedecke JH. Diagnostic ability of obesity 
measures to indentify metabolic risk in South African women. 2011 April Metabolic 
Syndrome and Related Disorders (In press). 
2.1. ABSTRACT 
Thresholds of VAT, and its anthropometric proxies including WC, WHR and WHtR, aid in 
the early identification of individuals at increased risk for CVD and T2DM. Importantly, 
ethnicity alters the relationships between body fat distribution and metabolic risk factors for 
T2DM and CVD. However, the effectiveness of central obesity measures for identifying 
women with or without metabolic risk factors for CVD and T2DM has not been explored in a 
South African population. The aim of the first study of this thesis was to compare the extent 
to which measures of central obesity can optimally differentiate black and white South 
African women with or without metabolic risk variables for CVD and T2DM, including 
elevated BP, dyslipidaemia and IR. 
Body composition, including weight, height, WC, hip circumference, and computer 
tomography (CT)-derived VAT, BP, fasting insulin, glucose and lipids were measured in 241 
black and 188 white South African women, with no known disease and not taking 
















(ROC) curve analyses were performed to determine the discriminative ability of WC, WHtR 
and VAT to identify subjects above metabolic risk thresholds. WC, WHtR and VAT were 
significant discriminators of all metabolic risk variables in both ethnic groups (P<0.05), 
however, for all metabolic risk variables the ROC area under the curve (AUC) was greater in 
white compared to black women (P<0.01). Compared to WC, the ROC AUC for VAT was 
greater for identifying elevated TG concentrations in white women (P<0.05), and elevated BP 
in black women (P<0.05). Conversely, the ROC AUC for WC was greater than VAT for 
identifying IR in both ethnicities (P<0.05). WC and VAT thresholds were lower in black 
compared to white women, whereas WHtR thresholds varied the least between ethnicities. 
In conclusion, all central obesity measures were better at identifying elevated BP, 
dyslipidaemia and IR in white compared to black women. These findings highlight the need 
to explore other factors contributing to increased metabolic risk in black South African 
women. WHtR thresholds varied less between ethnicities than WC and VAT, and may 
therefore be more useful for ethnic comparisons of risk. Long-term prospective studies are 
required to examine whether these relationships are similar in groups with known disease or 
pathophysiology. 
2.2. INTRODUCTION 
Central obesity, particularly the accumulation of VAT, is linked to the development of 
several metabolic diseases, including hypertension, dyslipidaemia and IR [6;209]. Thresholds 
of WC, as a proxy measure for VAT, aid in the early identification of individuals who 
develop these diseases [81].  However, ethnic differences exist in the relationship between 
WC and VAT and in the relationship between VAT and metabolic risk variables. With 
















lower TG and TC concentrations than white women,  yet paradoxically the former are more 
insulin resistant [10;12;210].  
Although many studies have examined the validity of anthropometric measures as proxies for 
central obesity, few have taken it one step further and examined the ability of central obesity 
measures, both CT-derived VAT and anthropometric measures, to identify metabolic risk 
factors, particularly in Southern African populations [211;212]. In addition, recent studies in 
Europeans and Asians have shown that WHtR and WHR have a greater ability than WC 
alone to identify patients with hypertension, dyslipidaemia and T2DM [83;213]. This may be 
of particular relevance to the South African context, since black South African women are 
shorter and have greater peripheral fat than white South African w men [11]. Similar to WC 
and VAT, the ethnic-specific associations between WHtR and WHR with known metabolic 
risk factors remains to be explored in a South African population. 
Therefore, this fist study tested the hypothesis that central obesity thresholds relating to 
metabolic risk factors for CVD and T2DM are different in black and white South African 
women. Specifically, the aims of this study were to compare the level of obesity (WC, WHR, 
WHtR and VAT) that identifies black and white South African women with or without 
elevated BP, dyslipidaemia and IR, and to determine which measure of obesity has the 
strongest association with metabolic risk thresholds.  
2.3. METHODS 
2.3.1. Subjects 
The study population consisted of a convenience sample of 241 black and 188 white 
apparently healthy premenopausal South African women. Ethnicity was self-reported. 
















included in the study if they were 18 to 45 years old, with no known disease, and not taking 
any chronic medications for the management of obesity, T2DM, dyslipidaemia, hypertension 
or inflammatory disorders, were not currently pregnant, lactating or post-menopausal. The 
Health Sciences Research Ethics Committee of the University of Cape Town gave the study 
ethics approval. Written informed consent was obtained from all subjects. 
2.3.2. Body composition assessment 
Basic anthropometric measurements including weight (in light clothing without shoes), 
height, waist (at level of the umbilicus; WC) and hip (largest gluteal area) circumference 
were taken.  WC was divided by hip circumference to calculate WHR, and by height (cm) to 
calculate WHtR.  CT-derived abdominal VAT area (Toshiba X-press Helical Scanner, Japan) 
was measured by a single slice scan at the level of L4-L5 lumbar vertebrae in 183 black and 
143 white women. 
2.3.3. Blood Pressure 
After at least 5 minutes of seated rest, BP was measured 3 times at 1-minute intervals using 
an appropriate sized cuff and an automated BP monitor (Omron 711, Omron Health Care, 
Hamburg, Germany). An average of the last 2 readings was used in the analyses.  
2.3.4. Blood sampling and analysis 
Blood samples were drawn after an overnight fast (10-12 hours) for the determination of 
plasma glucose and serum insulin, TC, HDL-C and TG concentrations. Fasting plasma 
glucose concentrations were determined using the glucose oxidase method (Glucose Analyzer 
2, Beckman Instruments, Fullerton, CA, USA). Serum insulin concentrations were 
determined by a Microparticle Enzyme Immunoassay (MEIA) (AxSym Insulin Kit, Abbot, 
















insulin concentrations were 0.6 and 2.5%, and 4.5 and 12.2%, respectively. Serum lipids were 
analyzed using the Roche Modular auto analyzer and enzymatic colorimetric assays were 
used to analyze TC, TG, and HDL-C concentrations.  
2.3.5. Insulin Resistance (IR) 
The homeostasis model of insulin resistance (HOMA-IR), an estimation of basal insulin 
sensitivity first described by Matthews et al. [214], was used to estimated insulin resistance 
by applying the following formula: HOMA-IR= fasting glucose (mmol/L) x fasting insulin 
(mU/L) / 22.5). 
2.3.6. Metabolic Risk factors 
Thresholds for elevated BP (systolic BP≥130mmHg and/or diastolic BP≥85 mmHg), elevated 
TG concentrations (TG≥1.7mmol/L) and HDL-C concentrations (HDL-C≤1.29mmol/L) were 
based on the definition by NCEP ATPIII criteria [31]. Thresholds for TC/HDL-C ratio and 
HOMA-IR were based on the upper tertile for the whole cohort (TC/HDL-C≥3.27; HOMA-
IR≥2.09) and comparable with those reported previously [215-217]. 
2.3.7. Statistical Analysis 
Normally distributed data are presented as means ± SD with ranges in parentheses. Non-
normally distributed parameters were logarithmically transformed for parametric analysis and 
are presented as geometric means with 95% confidence intervals.Analysis of covariance 
(ANCOVA), adjusting for age, was used to compare means for black and white women. 
Pearson correlations were used to explore associations between central obesity measures with 
metabolic risk factors. Chi-squared tests were used to compare the percentage of black and 
white women above the metabolic risk factor thresholds. ROC curve analyses were 
















with IR, elevated BP, elevated TG, elevated TC/HDL-C ratio and reduced HDL-C 
concentrations.  A ROC AUC <0.60 was considered to have poor discriminative ability [218]. 
In separate analyses for black and white women, a non-parametric test was used to compare 
the ROC AUC for VAT, WHtR and WHR of each metabolic risk variable with that obtained 
using WC [219]. The Youden index (J) [maximum (specificity-sensitivity)-1] [220] was 
calculated to explore thresholds for central obesity measures as determinants of metabolic 
risk variables. Data were analyzed with STATISTICA version 9 (StatSoft Inc., Tulsa, OK, 
USA).  
2.4. RESULTS 
2.4.1. Subject characteristics 
White women were significantly older than black women, and as a result all subsequent 
analyses included age as a covariate (Table 2.1). There were no ethnic differences in body 
weight; however the white women were significantly taller, and had a lower BMI and WHtR 
than the black women. There were no ethnic differences in WC or WHR; however, black 
women had less VAT than white women.  
2.4.2. Metabolic outcomes 
Adjusting for age, there were no differences in systolic and diastolic BP between black and 
white women (Table 2.2). Fasting glucose concentrations were within normal ranges for both 
black and white women. However white women had higher mean fasting glucose and lower 
fasting insulin concentrations than black women, but there was no ethnic difference in 
HOMA-IR. White women had significantly higher TG, TC and HDL-C concentrations, but a 
















Table 2.1. Subject characteristics and body composition of black and white South African 
women 
 Black  Women (n=241) White Women (n=188) P value 
Age (years) 
27 ± 7 
(18-45) 











76.2 ± 20.5 
(43.0-140.1) 













89.7 ± 18.2 
(59.5-138.5) 
90.2 ± 15.9 
(65.0-138.2) 
0.150 
Hip circumference (cm) 
112.2 ± 15.8 
(60.5-166.0) 

























Values are unadjusted means ± standard deviation, with ranges in parentheses. VAT had a skewed 
distribution, therefore the median and interquartile range is displayed in parenthesis. All P-values 
adjusted for age. BMI, body mass index; WC, waist circumference; WHR, waist-to-hip-ratio; WHtR, 
















Table 2.2. Metabolic outcomes of black and white South African women 
 Black  Women (n=241) White women (n=188)  
 
Mean ± SD 
(range) 
Mean ± SD 
(range) 
P value 
Systolic BP (mmHg) 
110.5 ±14.3 
(80.5-160.0) 
110.8 ± 11.5 
(80.5-156.0) 
0.090 
Diastolic BP (mmHg) 
74.9 ± 10.0 
(47.5-103.5) 











11.2 ± 7.7 
(1.7-45.6) 




































Values are unadjusted means ± standard deviation, with ranges in parentheses. HOMA-IR, TG and 
TC/HDL-C ratio had a skewed distribution, therefore the median and interquartile ranges are 
displayed in parenthesis. All P-values adjusted for age. BP, blood pressure; HOMA-IR, homeostasis 
model for insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipoprotein 
cholesterol; TC/HDL-C, total cholesterol-high density lipoprotein cholesterol ratio.  
The percentage of subjects above each metabolic risk threshold is shown in Figure 2.1. There 
were no differences between ethnic groups in the proportion of women above the risk 
threshold for elevated systolic and diastolic BP (p=0.14 and p=0.21, respectively) and 
HOMA-IR (P=0.07). A significantly higher proportion of white women had elevated TG 
















black women had reduced HDL-C concentrations compared to white women (P<0.001). As 
the very high proportion (over 45%) of black women with low HDL-C concentrations is most 
likely related to low TC concentrations in this population, we analysed TC/HDL-C ratio > 
3.27 (upper tertile for whole cohort), which has been used previously as a diagnostic criteria 
for the metabolic syndrome [221].  There was no significant ethnic difference in the 



































































Figure 2.1. Percentage of black and white South African women presenting with metabolic risk 
factors. Black women; White women. SBP, systolic blood pressure; DBP, diastolic blood 
pressure; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; TC/HDL-C, total 
cholesterol-high density lipoprotein cholesterol ratio; HOMA-IR, homeostasis model of insulin 
resistance. * P<0.01. 
2.4.3. Relationship between central obesity with metabolic risk factors 
Correlations between obesity measures and metabolic risk factors for black and white women 
are presented in Table 2.3. In white women, WC, WHtR and VAT correlated significantly 
















correlated significantly with all metabolic variables except TC concentrations. WHR 
correlated with all metabolic variables except for systolic and diastolic BP in white women 
and systolic BP and TC in black women. 
2.4.4. Central obesity thresholds for metabolic risk factors  
ROC AUC, sensitivities and specificities of optimal thresholds (based on the Youden index) 
of WC, WHtR and VAT for metabolic risk variables are presented in Table 2.4. WHR was a 
poor measure for discriminating between black and white women with or without metabolic 
risk (ROC AUC’s<0.60) and hence the data are not shown. Similarly, none of the central 
obesity measures were significant discriminators for elevated TG in black woman (ROC 
AUC<0.60), as a result no thresholds were established in black women. 
For elevated blood pressure, dyslipidaemia and insulin resistance, the ROC AUC of WC, 
WHtR and VAT were significantly greater in white compared to black women (P<0.05). 
There were no differences in ROC AUC between WC and WHtR for all metabolic risk 
variables in both black and white women (P>0.05). In white women, compared to the AUC 
for WC, there was no difference in the VAT AUC for elevated BP and reduced HDL-C 
concentrations; however the VAT AUC was significantly greater for elevated TG and 
TC/HDL-C ratio and significantly smaller for HOMA-IR. In black women, the AUC for 
VAT was significantly greater than WC for elevated BP, but significantly lower for HOMA-
IR, HDL-C concentrations and TC/HDL-C ratio. 
The Youden index (J), a measure of the maximum sensitivity (the fraction of women below 
the risk variables threshold correctly identified by the test) and specificity (the fraction of 
women above the risk variable threshold correctly identified by the test) of a variable, was 
















IR, elevated BP, TG concentrations, TC/HDL-C ratio and reduced HDL-C concentrations in 
black and white women (Table 2.4). When comparing ethnicities, WC thresholds were 
similar for HOMA-IR and TC/HDL-C ratio, but lower for BP and HDL-C concentrations in 
black compared to white women. VAT thresholds were also lower for HOMA-IR, HDL-C 
concentrations and TC/HDL-C ratio in black compared to white women, but were similar for 
BP. Conversely, WHtR thresholds were similar for all metabolic risk variables between black 
and white women. The sensitivities and specificities of these thresholds also differed 
according to ethnicity. Compared to black women, white women had higher sensitivities for 
optimal thresholds for elevated BP, HOMA-IR and TC/HDL-C ratio, and lower sensitivities 
for thresholds for reduced HDL-C. The specificities for all thresholds were lower in black 
compared to white women for all metabolic risk factors.  
Thresholds and their sensitivities and specificities also varied across metabolic risk variables. 
In black women, the lowest WC, WHtR and VAT thresholds were for identifying reduced 
HDL-C concentrations. Conversely, the highest WC and WHtR thresholds in black women 
were for HOMA-IR and TC/HDL-C ratio, and highest VAT threshold was for elevated BP. In 
white women, lower WC thresholds were observed for elevated BP, elevated TG and 
TC/HDL-C ratio, whereas the highest thresholds of all central obesity measures were 















Table 2.3. Pearson correlation coefficients (r) between central obesity measures and metabolic outcomes in black and white South African women 
    SBP DBP Glucose Insulin HOMA-IR TG TC HDL-C TC/HDL-C 
WC (cm) 







































































































































WC, waist circumference; WHR, waist-hip ratio; WHtR, waist-height ratio; VAT, visceral adipose tissue; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HOMA-IR, homeostasis model of insulin resistance; TG, triglyceride; TC, total cholesterol; HDL-C high density lipoprotein cholesterol. TC/HDL-















Table 2.4. WC, WHtR and VAT thresholds for metabolic risk variables in black and white South African women. 












































- > 80 88.6 42.8 0.31  
0.79 ± 
0.05 




0.675 > 0.57 73.1 61.5 0.34  
0.80  
0.03 







0.028 > 107 83.3 51.9 0.35  
0.80 ± 
0.08 
0.750 > 107 94.4 52.6 0.47 





- > 94 66.7 75.3 0.42  
0.85 ± 
0.03 




0.720 > 0.62 59.7 85.1 0.44  
0.84  
0.03 







0.033 > 78 56.6 79.1 0.36  
0.81 ± 
0.04 
0.037 > 100 72.1 75.3 0.47 





- > 77 83.1 45.7 0.29  
0.79 ± 
0.04 




0.882 > 0.47 88.2 42.3 0.30  
0.78  
0.05 







0.039 > 48 82.7 39.6 0.22  
0.79 ± 
0.05 















Table 2.4. Continued. 










































- > 91 67.5 68.7 0.36  
0.82 ± 
0.03 




0.771 > 0.54 76.2 61.1 0.37  
0.83  
0.03 







0.048 > 74 56.1 69.4 0.25  
0.86 ± 
0.03 
0.043 > 108 74.0 87.8 0.62 





 n/a     
0.75 ± 
0.04 




 n/a     
0.74  
0.05 







 n/a     
0.79 ± 
0.05 
0.049 > 88 94.7 59.3 0.54 
ROC, receiver operator characteristic; AUC, area under the curve; SE, standard error; WC, waist circumference; WHtR, waist-to-height ratio; VAT, visceral 
adipose tissue; BP, blood pressure; HOMA-IR, homeostasis model of insulin resistance; HDL-C, high density lipoprotein cholesterol; TC/HDL-C, total 
















The main finding of this chapter was that all measures of central obesity (WC, WHtR and 
VAT) were better indicators of metabolic risk (elevated BP, dyslipidaemia and IR) in white 
compared to black South African women. This is in line with Stevens et al., who have 
previously shown that BMI, WC and WHR had a greater ability to predict diabetes in white 
compared to black American women [81]. Further, a recent study comparing French and 
Cameroonian nationals showed for the same increase in WC, French individuals had a greater 
increase in metabolic risk [212]. These findings may suggest that factors other than body 
composition, such as inflammation or environmental factors, contribute to an increased risk 
of metabolic disease in black women. 
A second important finding is that there were significant differences in the discriminative 
ability between VAT and anthropometric measures for identifying black and white South 
African women above metabolic risk thresholds. Although several studies have compared the 
discriminative ability between anthropometric measures for identifying individuals above 
metabolic risk thresholds, few have compared anthropometrics to a direct measurement of 
VAT [78;88]. Notably, we found that WC was better than VAT for identifying black and 
white women with IR (upper tertile of HOMA-IR). Although WC is normally used as a proxy 
measure for VAT, it reflects both VAT and abdominal SAT. Further, we, and others, have 
shown a similar magnitude of association between IR and VAT and SAT in both black and 
white women [12;58;222]. These findings suggest that central accumulation of fat, whether it 
is visceral or subcutaneous, is important in the development of IR.  
Conversely, VAT was significantly better than WC for identifying elevated TG 
concentrations and the upper tertile of TC/HDL-C ratio in white women, and for identifying 
elevated BP in black women. Our data support the findings of Vega et al. who have shown in 
















for TG/HDL-C ratio and systolic BP beyond that of total fat and abdominal SAT [223]. VAT 
is thought to have a greater contribution than SAT to increased metabolic risk through direct 
release of fatty acids into the hepatic portal system [49], thereby explaining the greater ability 
of VAT to identify white women with elevated TG concentrations and TC/HDL-C ratio. 
Furthermore, VAT is reported to be associated with increased sympathetic nervous system 
activity [224] and higher expression of angiotensinogen [225], both of which are associated 
with elevations in BP.  
Despite WC and VAT differing significantly in their ability to discriminate between 
metabolic risk variables, the physiological relevance of this difference is unknown as the 
ROC AUC’s differed by a maximum of only eight percent. Given the high cost and risk 
associated with exposure to radiation with CT, and considering that WC and WHtR can be 
used to identify an equivalent amount of metabolic risk, we recommend using these simple 
anthropometric measures over VAT for identifying metabolic risk variables, particularly in 
developing countries with limited financial and human resources such as South Africa. 
In agreement with my original hypothesis, the results also show that optimal central obesity 
thresholds were different across ethnicities. Recently, several reviews have highlighted the 
need for ethnic-specific thresholds of obesity measures to identify individuals at increased 
metabolic risk, and that there is currently insufficient evidence to do so in black sub-Saharan 
populations [211;226]. In general, WC and VAT thresholds were lower in black compared to 
white South African women. Notably, although adjusting WC for height did not affect the 
ability of the measure to identify risk, it did narrow the difference in WHtR thresholds 
between black and white women. In a cross-sectional study of central obesity thresholds 
across eight different ethnicities, Diaz et al. also showed that WHtR thresholds were narrower 
















thresholds, specific to the risk criterion being examined, could be used in studies where 
ethnic comparisons are made.  
Cameron et al. have highlighted that defining obesity thresholds using the Youden index, 
even in longitudinal studies, is dependent on the prevalence of obesity in that population, at a 
given point in time [227]. As the prevalence of obesity increases in a population, so does the 
‘optimal’ threshold derived from the Youden index. In line with this, Stevens et al. [81] have 
shown that the distribution of the central obesity measure impacts on the sensitivity and 
specificity of the measure, and hence the optimal threshold. Although the distribution of 
central obesity measures, in particular VAT, was different in the black and white women in 
this study, this did not seem to impact on the sensitivity and specificity of the measure as 
sensitivity was not consistently higher in the white compared to the black women, in whom 
the VAT distribution was skewed to the right. Long-term prospective studies are required to 
examine whether individuals from these ethnic groups who exceed the central obesity 
thresholds develop CVD and diabetes and/or whether these relationships are similar in groups 
with known disease or pathophysiology. 
As the relationship between obesity and increased metabolic risk is continuous, creating 
specific thresholds may be arbitrary and only appropriate to the setting in which it is used 
[81]. Thresholds may vary according to the prevalence of the risk factor in each ethnic group, 
with a higher prevalence of a risk factor relating to a lower obesity threshold. For example, 
over 45% of black women had HDL-C concentrations below 1.29 mmol/L, and this 
corresponded to the lowest WC and VAT thresholds in this group. The low HDL-C 
concentrations in the black women may possibly reflect differences in lipid metabolism 
between ethnic groups [228].  Using a ratio of TC/HDL-C, the percentage of women above 
the threshold for risk (upper tertile) was reduced (compared to HDL-C) and the optimal 
















concentrations, a higher percentage of women fell above the upper tertile of the TC/HDL-C 
ratio, and corresponding thresholds were reduced.  
Notably, it is not known whether the risk factor thresholds used in the present study translate 
to equal risk in black and white women. Although this data is unavailable, the percentage of 
women above metabolic risk thresholds was comparable to other cross-sectional study 
cohorts from South Africa [3;13]. Due to the lower percentage of black women with elevated 
TG, we were unable to define meaningful central obesity thresholds for elevated TG in black 
women. It has previously been suggested that the thresholds for TG that relate to risk for 
CVD in black South Africans should be lowered [13], or that elevated TG is not associated 
with increased metabolic risk in black populations [42]. Supporting this, Kalk et al. have 
shown that the prevalence of elevated TG in diabetic black South Africans was also lower 
than that of white South Africans [2]. Importantly, prospective studies are required to 
determine the risk factors associated with CVD and T2DM in both ethnic groups. 
In conclusion, in our sample of black and white South African women, all central obesity 
measures were better at identifying elevated BP, dyslipidaemia and IR in white compared to 
black women. These findings highlight the need to explore factors other than obesity that 
contribute to increased metabolic risk in black South African women. Overall, due to the 
cost, access and radiation exposure, CT is not recommended above the use of simple 
anthropometric measures for the determination of metabolic risk. As thresholds for WC 
varied more than WHtR between ethnicities, WHtR may be more useful for ethnic 
comparisons of thresholds for risk. Prospective studies including both black and white South 
African women are required to establish the level of obesity and other metabolic risk factors 

















RELATIONSHIP BETWEEN CIRCULATING INFLAMMATORY MARKERS IL-18 
AND hsCRP WITH METABOLIC RISK FACTORS FOR CARDIOVASCULAR 
DISEASE AND TYPE TWO DIABETES IN SOUTH AFRICAN WOMEN 
3.1. ABSTRACT 
Chronic low-grade inflammation, characterized by altered circulating concentrations of 
inflammatory proteins including IL-18 and hsCRP, has been suggested as a key link between 
obesity, IR, T2DM and CVD. Several environmental factors including SES and 
behavioural/lifestyle factors such as smoking, alcohol, contraception and sedentary 
behaviours have previously been shown to influence circulating inflammatory marker 
concentrations. To my knowledge the impact of SES and behavioural/lifestyle factors on the 
relationship between circulating inflammatory markers and metabolic risk factors for CVD 
has not been explored in a South African population. Therefore the aims of the second study 
of this thesis were to investigate the association between SES, health behaviour/lifestyle 
factors and central obesity and circulating concentrations of IL-18 and hsCRP, and to 
determine the ethnic-specific associations between circulating concentrations of IL-18 and 
hsCRP and metabolic risk factors for CVD in black and white South African women, taking 
into account the impact of obesity, SES and behavioural/lifestyle factors known to influence 
both inflammation and CVD risk. 
Central obesity (WC), BP, IR (as estimated from homeostasis model of insulin resistance, 
HOMA-IR), fasting lipids, level of SES (assessed by education, asset index and housing 
density), behavioural/lifestyle variables (smoking status, alcohol intake, contraceptive use 
and physical activity), and circulating concentrations of IL-18 and hsCRP were measured in 
















obesity (WC) was used to compare circulating concentrations of IL-18 and hsCRP between 
ethnic groups and across categories of SES and health behaviours. Multiple regression 
analysis with a forward selection procedure was performed to determine whether 
inflammatory markers are associated with metabolic risk factors independent of SES, 
behavioural/lifestyle variables and obesity (WC), in separate analysis for black and white 
women. Black women had significantly higher circulating concentrations of IL-18 compared 
to white women, independent of WC and age (P<0.01), however there was no ethnic 
difference in circulating hsCRP concentrations (P=0.32). Obesity, lower level of education, 
smoking and contraceptive use were associated with higher circulating concentrations of IL-
18 and hsCRP (P<0.05), which in turn were associated with metabolic risk factors for CVD 
and T2DM in both black and white women. The associations between IL-18 (in black women 
only) and hsCRP (black and white women) and metabolic risk factors were independent of 
SES, contraception and smoking, but not WC. 
 In conclusion, SES, behavioural/lifestyle factors and central obesity were associated with 
increased circulating concentrations of IL-18 and hsCRP in both black and white South 
African women.  The association between these inflammatory markers and risk was mainly 
mediated by the effects of adiposity, suggesting that the measurement of circulating 
inflammatory proteins provides no added benefit to WC for identifying women at increased 
risk for CVD and T2DM. Furthermore, these results support the hypothesis that AT may be 
involved in the early stages of the inflammatory response associated with CVD and T2DM 
3.2. INTRODUCTION 
It is now well established that a state of chronic low-grade inflammation is present in obesity, 
T2DM and CVD [95]. Increased circulating concentrations of inflammatory proteins, such as 
















present in obese individuals [98], and in patients with T2DM and CVD [99]. Subsequently, 
markers of inflammation have shown potential for improved disease risk prediction, and in 
some cases, have been investigated as potential therapeutic targets for clinical intervention 
[103]. Circulating inflammatory proteins investigated as potential risk markers include the 
acute phase protein hsCRP and the pro-inflammatory cytokines IL-18, IL-6 and TNF-α. 
Increased circulating concentrations of these proteins have been shown to be associated with 
a number of metabolic risk factors for CVD and T2DM, including central obesity, 
dyslipidaemia, hypertension and IR [97;108;109;127;129;141;142;155]  
Notably, circulating concentrations of hsCRP, IL-6 and TNF-α have been shown to be 
influenced by several environmental factors, including SES and associated negative health 
behaviours, such as smoking, alcohol abuse, poor dietary patterns, sedentary behaviour and 
contraceptive use [104;110;229], which in turn are known to influence CVD risk and 
outcome [90]. To my knowledge, IL-18 has not been explored in this context, nor has the 
impact of SES and behavioural/lifestyle factors on hsCRP been investigated in a South 
African population. Furthermore, in the case of hsCRP [122] and IL-6 [153], studies in 
America have shown that increased circulating concentrations of these proteins provided no 
improved prediction for T2DM and CVD beyond that of traditional risk factors, in particular 
SES and obesity. In contrast, data from the Women’s Health study [138] and Nurses’ Health 
study [139] have shown that high IL-18 concentrations were predictive of future CVD events 
and T2DM incidence, respectively, independent of possible mediating/confounding factors. 
However, neither of these studies investigated whether these findings were consistent across 
different ethnic groups. This may be of particular relevance as ethnic differences in disease 
risk, level of SES and circulating inflammatory markers have been shown to exist. 
Furthermore, based on the results from Chapter 2 of this thesis, central obesity measures 
















hypothesise that circulating inflammatory markers hsCRP and IL-18 would be of added 
benefit for identifying black and white women at increased risk for CVD and T2DM. 
Accordingly, the aims of this chapter were to investigate the association between SES, health 
behaviour/lifestyle factors and obesity with circulating concentrations of IL-18 and hsCRP, 
and to determine the ethnic-specific associations between circulating concentrations of IL-18 
and hsCRP with metabolic risk factors for CVD in black and white South Africans women, 
taking into account central obesity, socioeconomic and behavioural/lifestyle factors known to 
influence both inflammation and CVD risk. 
3.3. METHODS 
3.3.1. Subjects 
This cross-sectional study consisted of a convenience sample of 223 black and 177 white 
apparently healthy premenopausal South African women. Further information on the 
inclusion and exclusion criteria is provided in the methods section of Chapter 2. The Faculty 
of Health Sciences Research Ethics Committee of the University of Cape Town gave the 
study ethics approval. Written informed consent was obtained from all subjects prior to 
participation. 
3.3.2. Socioeconomic status and health behaviour/lifestyle measures 
A questionnaire was administered that included measures of SES and behaviour/lifestyle 
factors. Three indicators of SES were assessed: education, asset index and housing density. 
Categories for education were none, grade 1-7, Grade 8-11, completed high school and post-
high school education. An asset index score was based on 16 items reflecting individual and 
household wealth and resources. This included indoor access to running water and/or flushing 
















washing machine, telephone, video machine, microwave, computer, cellular telephone, 
MNET or DSTV. Housing density was defined as the number of persons per room living in 
the household. For the purpose of this analysis, both asset index and housing density were 
categorized into quintiles.   
Health behaviour variables included: Smoking status, categorized as smoker, ex-smoker or 
non-smoker; Alcohol consumption based on average weekly intake of alcohol and 
categorized as non drinker, ≤ 1 drink/day, or >1drink/day; physical activity (PA) levels 
(minutes/week of moderate intensity activity), were measured using the Global Physical 
Activity Questionnaire (GPAQ) [230], and based on a cut-point of 150min/week and 
categorized into Active Total PA (≥ 150 min/week), and Sedentary Total PA (< 150 
min/week), as previously suggested [231]. Contraceptive use was defined as none, oral 
contraceptives or injectable contraceptives.  
3.3.3. Body composition and metabolic outcomes 
Central obesity (WC), BP, fasting plasma concentrations of glucose, and serum 
concentrations of insulin, TG, TC and HDL-C were measured. HOMA-IR was estimated 
from fasting insulin and glucose concentrations as previously described [214]. The 
measurements and biochemical analysis of these variables are described in detail in the 
methods section of Chapter 2. 
3.3.4. Inflammatory markers 
Serum concentrations of hsCRP (Immun Diagnostik AG, Bensheim, Germany) and IL-18 
(Biosource, Nivelles, Belgium) were analyzed using commercially available ELISA kits 
according to the manufacturer’s protocols. Women with CRP >10 µg/ml (N=12) were 
















3.3.5. Statistical analysis 
Normally distributed data are presented as means ± SD with ranges in parentheses. Non-
normally distributed parameters were logarithmically transformed for parametric analysis and 
are presented as geometric means with 95% confidence intervals.Differences in SES, health 
behaviour characteristics and circulating concentrations of hsCRP and IL-18 between black 
and white women were compared using chi-squared analysis for categorical variables and 
ANCOVA, adjusting for age, for continuous variables. In separate analyses for black and 
white women, general linear models were used to compare circulating concentrations of 
hsCRP and IL-18 across categories of SES and health behaviour variables, adjusting for age. 
P values for trend represent differences between lowest and highest SES categories. To 
determine whether inflammatory markers relate to metabolic risk factors independent of SES 
and behaviour/lifestyle variables, linear regression analyses were used. First, univariate 
analyses were performed to analyze the relationship between single determinants (hsCRP and 
IL-18) and metabolic risk factors (model 1). Second, a multiple regression analysis with a 
forward selection procedure was performed in which age, SES and behaviour/lifestyle 
variables were included as possible determinants (model 2). A third model (model 3) further 
included WC as a measure of central adiposity. Independent variables with P value .05 were 
left in the model. Data were analyzed using STATISTICA version 9 (Statsoft Inc., Tulsa, 
OK).   
3.4. RESULTS 
3.4.1. Basic subject characteristics 
Socioeconomic, health behaviour and health status characteristics of black and white women 
are presented in Table 3.1. As described previously, black women were significantly younger 
















Marked differences in socioeconomic variables were observed between black and white 
women. Black women had lower levels of education, asset index and greater housing density 
than white women. A significantly smaller proportion of black women were current smokers, 
consumed alcohol or used oral contraceptives, whereas a larger proportion of black women 
used injectable contraceptives and were sedentary (PA < 150 min/week) compared to white 
women.  
A higher proportion of black women had a family history of T2DM; however there was no 
ethnic difference in the proportion of women with family history of CVD (including stroke 
and heart attack). Similar to results reported in the previous chapter, there was no difference 
in WC between black and white women (89.9 ± 1.1 cm vs. 90.0 ± 1.2 cm, respectively. 
P=0.087). Further, there were no differences between ethnic groups in the proportion of 
women above the risk threshold for elevated systolic and diastolic BP (p=0.330 and p=0.357, 
respectively), HOMA-IR (P=0.570) and TC/HDL-C ratio (P=0.235). A significantly higher 
proportion of white women had elevated TG’s compared to black women (P<0.010). 
Conversely, a higher proportion of black women had reduced HDL-C concentrations 
compared to white women (P<0.001) (Figure 2.1).  
For both ethnic groups, a higher percentage of smoking, sedentary behaviour, alcohol 
consumption, and metabolic risk factors were present in women with a low level of 
educational attainment and asset index (Appendix 1, Tables A1 and A2). No differences in 
health status or health behaviour variables were observed across quintiles of housing density 
















Table 3.1. SES, health behaviour, health status and circulating inflammatory markers of black and 
white women 
 Black Women (N=223) White Women (N=177)  
 Mean ± SD or % Mean ± SD or % P value 
Demographic and Socioeconomic variables  
Age (years) 27 ± 7 31 ± 8 <0.01 
Education   <0.01 
None 0 0  
Grade 1-7 7 0  
Grade 8-11 35.2 5.0  
Completed High School 40.1 22.8  
Tertiary Education 17.6 72.2  
Housing Density   <0.01 
Q1 (<0.59) 19.0 79.9  
Q2 (0.60-0.83) 23.4 17.3  
Q3 (0.84-1.18) 17.7 2.8  
Q4 (1.19-1.59) 21.2 0.0  
Q5 (>1.60) 18.6 0.0  
Asset Index   <0.01 
Q1 (<5) 29.2 0.0  
Q2 (5-7) 16.8 0.0  
Q3 (7-10) 21.7 5.6  
Q4 (10-12) 13.7 14.0  
Q5 (>12) 18.6 80.4  
Health Behaviour Variables 
Smoking Status    
Current smoker 7.8 18.2 <0.01 
Ex-Smoker 2.2 16.4 <0.01 
Never Smoked 90.0 65.4 <0.01 
Alcohol consumption    
Non-drinker 66.8 21.7 <0.01 
≤1 drink/day 18.0 44.0 <0.01 
>1 drink/day 15.2 34.2 <0.01 
PA     
Sedentary 
(<150min/week) 
84.9 65.3 <0.01 
Active (≥150min/week) 15.1 34.7 <0.01 
Contraceptive Use    
None 65.0 65.5 0.452 
Oral  5.7 29.8 <0.01 
Injection 29.3 4.7 <0.01 
Health Status 
Variables 
   
Family history of 
T2DM 
23.0 16.0 <0.01 
Family History of 
CVD 







hsCRP (µg/ml) 2.38 (0.98-5.30) 2.52 (0.99-6.08) 0.321 
IL-18 (pg/ml) 195.4 (107.3-315.9) 186.9 (111.2-267.5) <0.05 
P values adjusted for age. Q1-Q5, quintiles 1-5; PA, physical activity; T2DM, type 2 diabetes 

















3.4.2. Ethnic differences in circulating inflammatory markers 
White women had significantly lower circulating IL-18 concentrations compared to black 
women (Table 3.1), however no difference in circulating hsCRP was observed between 
ethnic groups. Ethnic differences in IL-18 concentrations were independent of age and WC 
(P<0.01). 
3.4.2.1. Socioeconomic status (SES) 
In black women, lower education and asset index were associated with higher circulating 
concentrations of hsCRP and IL-18 (Figure 3.1). In white women, lower education and asset 
index were associated with higher hsCRP circulating concentrations, and lower education 
was associated with higher IL-18 concentrations.  
3.4.2.2. Behavioural/lifestyle variables 
In black women, the use of injectable contraceptives (29.3% of black women) was associated 
with significantly higher circulating concentrations of both hsCRP and IL-18 compared to 
women not on contraception (P<0.01 and P=0.048, respectively) and current smokers had 
significantly higher circulating hsCRP concentrations than non-smokers (P=0.038; Figure 
3.2). In white women, the use of oral contraceptives (29.8% of white women) was associated 
with significantly higher hsCRP concentrations compared to women not on contraception 
(P=0.010) and current smokers had significantly higher circulating hsCRP and IL-18 
concentrations than non-smokers (P<0.010 and P=0.032, respectively; Figure 3.2). Reported 
alcohol consumption and PA levels did not influence circulating hsCRP and IL-18 










































































































































































































































































Figure 3.1. Circulating hsCRP and IL-18 concentrations in black (a, b) and white (c, d) women 
across socioeconomic status categories of  education,  asset index and  housing 
density. Values are age-adjusted means ± SE. CHS, completed high school; TE, tertiary 

































































































































































































































































































Figure 3.2. Relationship between behaviour/lifestyle variables and circulating hsCRP and IL-18 
concentrations in black women (a, b) and white women (c,d).  Contraceptive Use
a
. 
Alcohol consumption. Smoking status. Physical Activity status. * P<0.05 Injectable 
vs. no contraception; ** Oral vs. no contraception, ***Smoker vs. non smoker. Values are age-
adjusted means ± SE. 
a
 Due to the small numbers in black and white women for oral 
contraceptive and injectable contraceptive use, respectively, only the relationship between 
inflammation and injectable contraceptives are reported for black women and inflammation 
















3.4.2.3. Central obesity 
Circulating concentrations of hsCRP and IL-18 correlated significantly with WC in both 
black and white women (Figure 3.3), but the strength of the association was greater for 
hsCRP than IL-18 in both groups. 









































Figure 3.3. Correlations between WC and circulating hsCRP and IL-18 in black and white 
women. 
3.4.2.4. Metabolic risk factors 
In black women, circulating concentrations of IL-18 and hsCRP were weakly, but 
significantly associated with all metabolic risk factors (Table 3.2, model 1). In white women, 
circulating concentrations of IL-18 were significantly associated with only diastolic BP, 
HOMA-IR and TC/HDL-C, while the associations between circulating hsCRP and all 
metabolic risk variables were significant (Table 3.3, model 1). 
3.4.3. Multivariate associations with metabolic risk factors for cardiovscular disease 
and type two diabetes 
3.4.3.1. Black women 
In black women, the inflammatory markers alone accounted for less than 10% of the variance 
in metabolic outcomes. Addition of SES, smoking and contraceptive use to the model (Table 
















associations between circulating IL-18 and hsCRP and all metabolic risk variables, except for 
systolic BP and TG in the case of CRP, were independent of age, SES, smoking and 
contraception (Table 3.2, Model 2). However, the association between circulating IL-18 and 
hsCRP and the majority of metabolic risk factors were not independent of WC (Table 3.2, 
model 3). In the model including lifestyle/behavioural variables and WC, IL-18 was only 
independently associated with diastolic BP, whereas hsCRP was only independently and 
negatively associated with HDL-C. WC was significantly and independently associated with 
all metabolic outcomes (except systolic BP), and explained the majority of the variance in 
metabolic outcomes, contributing an additional 6-25% to the total explained variance (Table 
3.2, model 3). Independent of WC and inflammatory markers, low SES (education and/or 
housing density) was significantly associated with diastolic BP and serum lipid 
concentrations (Table 3.2, models 2 and 3), while the use of injectable contraceptives was 
significantly associated with all metabolic risk factors, and current smoking was significantly 
associated with diastolic BP. 
3.4.3.2. White women 
In white women, the inflammatory markers alone accounted for less than 18% of the variance 
in metabolic outcomes. Addition of SES, smoking and contraceptive use to the model (Table 
3.3, Model 2) explained an additional 7-12% of the variance in metabolic outcomes. The 
associations between circulating hsCRP and all metabolic risk variables, except for TG, were 
independent of age, SES, smoking and contraception (Table 3.3, Model 2). However, the 
association between circulating hsCRP and the majority of metabolic risk factors were not 
independent of WC (Table 3.3, model 3). In contrast, the associations between IL-18 with 
diastolic BP, HOMA-IR and TC/HDL-C were not independent of age, SES and contraceptive 
use (Table 3.3, model 2). In the model including lifestyle/behavioural variables and WC, 
















independently associated with all metabolic outcomes (except systolic and diastolic BP), and 
explained the majority of the variance in metabolic outcomes, contributing an additional 7-
28% to the total explained variance (Table 3.3, model 3). Independent of WC, inflammatory 
markers and low SES, age was significantly associated with BP, HOMA-IR and TC/HDL-C, 
and notably accounted for all the variance (13%) in systolic BP (Table 3.3, models 2 and 3). 
The use of oral contraceptives was significantly associated with TG and HDL-C, and SES 















Table 3.2. Regression models for metabolic risk factors in black women, including serum IL-18, hsCRP, lifestyle/behavioural factors and body 
composition 
 IL-18   hsCRP 






































































































































































    WC 
0.27 ± 
0.06 















Table 3.2. Continued 
IL-18  hsCRP 
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0.35 ± 
0.07 


















































      
  

















Table 3.2. Continued 
IL-18  hsCRP 
 Model 1 Model 2 Model 3   Model 1 Model 2 Model 3 
TC/HDL-
C 
R2=0.06 β±SE R2=0.17 β±SE R2=0.21 β±SE 
 TC/HDL-
C 





































































injectable contraceptives), waist 
circumference. IL-18, interleukin-18; hsCRP, high sensitivity C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model 
















Table 3.3. Regression models for metabolic risk factors in white women, including serum IL-18, CRP, lifestyle/behavioural factors and body 
composition 
 IL-18   hsCRP 
 Model 1 Model 2 Model 3   Model 1 Model 2 Model 3 
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0.16 ± 
0.08 
        
DBP R2=0.03 β±SE R2=0.15 β±SE R2=0.25 β±SE  DBP R2=0.04 β±SE R2=0.18 β±SE R2=0.24 β±SE 
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0.35 ± 
0.07 








R2=0.06 β±SE R2=0.15 β±SE R2=0.43 β±SE  
HOMA-
IR 
R2=0.17 β±SE R2=0.26 β±SE R2=0.43 β±SE 















































































Table 3.3. Continued 
 IL-18   hsCRP 
 Model 1 Model 2 Model 3   Model 1 Model 2 Model 3 































   Contraceptionb 
-0.21 ± 
0.07 
          
TC/HDL-
C 
R2=0.03 β±SE R2=0.13 β±SE R2=0.29 β±SE  
TC/HDL-
C 
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0.16 ± 
0.08 













injectable contraceptives), waist 
circumference. IL-18, interleukin-18; hsCRP, high sensitivity C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model 


















In both black and white South African women, central obesity, low SES, smoking status and 
contraceptive use were associated with increased circulating concentrations of inflammatory 
markers hsCRP and IL-18, which in turn were associated with metabolic risk factors for T2DM 
and CVD. The association between IL-18 and CRP and metabolic risk factors was largely 
mediated by obesity and not SES or behavioural/lifestyle variables, supporting previous studies 
suggesting that AT is a putative source of inflammation characteristic of CVD and T2DM risk 
factors [201]. These findings suggest that compared to a simple WC measurement, there was no 
added benefit in measuring circulating inflammatory markers for added risk prediction in 
apparently healthy black and white South African women. 
In the present study, circulating concentrations of IL-18 and hsCRP were significantly associated 
with metabolic risk factors in both black and white South African women. This is in agreement 
with several other cross-sectional studies in America showing an association between these 
inflammatory markers and metabolic risk factors for CVD [127-129]. IL-18 is involved in the 
induction of pro-inflammatory cytokines from mature TH1 cells and macrophages [232] and 
there is evidence to suggest IL-18 is involved in atherogenic pathways [131].  Upregulation of 
IL-18 gene expression involves NF B, which in turn has been implicated in disruption of insulin 
signalling pathways [132]. CRP is secreted by the liver in response to inflammatory cytokines 
[97], and compared to IL-18 concentrations, which are likely representative of upstream events 
within the inflammatory cascade, increased hsCRP concentrations are more a reflection of 
















It has been suggested that circulating inflammatory markers, including IL-18 and hsCRP, may be 
of added use for early identification of individuals at increased risk for CVD and T2DM [103]. 
However, several environmental factors known to influence inflammation and CVD risk could 
impact on the use of inflammatory markers in a clinical setting. In both black and white women, 
low SES (assessed by education and asset index), smoking, contraceptive use (oral in white 
women and injectable in black women) and central obesity (WC) were associated with elevated 
circulating concentrations of IL-18 and hsCRP. Although the impact of SES and behavioural 
factors on hsCRP has been well documented in other populations [104;110;229;233], to my 
knowledge this is the first study investigating the impact of SES and behavioural/lifestyle factors 
on circulating IL-18 concentrations, and on hsCRP in South African women. Importantly, the 
association between circulating IL-18 and hsCRP concentrations and metabolic risk factors, 
although independent of SES and behavioural/lifestyle factors (with the exception of IL-18 in the 
white women), were not independent of central obesity. Furthermore, the amount of variance in 
metabolic risk factors explained by these inflammatory markers was relatively small (ranging 
between 2 and 9% in black and 1 and 18% in white women for all metabolic risk factors) 
compared to that of SES, smoking, contraceptive use and WC combined, which ranged between 
12 and 26% in white women and 15 and 30% in black women. These results suggest that 
measuring circulating concentrations of IL-18 or hsCRP in this study provided no added benefit 
compared to a simple measurement of WC for identifying CVD and T2DM risk in these women. 
Furthermore, as the cost and methods for measuring inflammatory markers are high and 

















Notably, in Chapter 2, I found that central obesity measures explained a smaller proportion of 
variance in metabolic risk factors in black compared to white women, and as a result suggested 
that other factors, including inflammatory markers and/or SES and behavioural/lifestyle 
variables, may help explain a greater proportion of risk. In contrast to this, the association 
between IL-18 and hsCRP and metabolic risk factors was attenuated by the inclusion of WC in 
the model. These results do support the hypothesis that AT may be a major source of increased 
circulating inflammatory markers associated with CVD and T2DM [201]. Indeed, although IL-
18 is secreted by several cell types, adipose tissue has been shown to secrete IL-18 and the 
expression of IL-18 in adipose tissue and circulating concentrations are increased in obese 
individuals compared to lean controls [234]. Furthermore, WC was significantly and 
independently associated with the majority of metabolic risk factors in both black and white 
women, despite ethnic differences in abdominal VAT and SAT discussed in Chapter 2, 
supporting previous research, which has shown obesity to be an independent risk factor for CVD 
and T2DM [6;44]. Importantly, in addition to WC, age, SES and contraceptive use were 
independently associated with metabolic risk factors, and did add to the explained variance in 
risk in both black and white women. Specifically, age was a significant independent contributor 
to models for diastolic and systolic BP in both ethnicities; to TC/HDL-C and HOMA-IR models 
in white women and TG models in black women. The risk for CVD and T2DM increases with 
age [235] and although the women included in this study were relatively young, the white 
women were significantly older than the black women, which may explain why age contributed 
to more risk variables in these women. A low SES (education and/or housing density) was 
independently associated with diastolic BP and lipids in black women and with HOMA-IR in 
















CVD and T2DM [91]. White women were of higher SES compared to black women, and there 
was a smaller range in SES indices in the white women, which may explain the lack of 
association with other risk variables. However, the findings in this study are consistent with the 
current socio-political environment within South Africa, as the majority of blacks live in poorer 
communities compared to whites [89]. Furthermore, in black women, use of injectable 
contraceptives contributed significantly and independently to all metabolic risk models and in 
white women, use of oral contraceptives contributed significantly and independently to models 
for TG and HDL-C. Previous studies have shown that both oral contraceptive and injectable 
contraceptive are associated with increased risk for CVD and in particular have been shown to 
alter lipid metabolism by increasing triglyceride and decreased HDL-C-cholesterol 
concentrations [236]. These findings highlight the need for the prioritisation of the management 
of potentially modifiable risk factors, which include SES, contraceptive use and obesity, 
especially in primary prevention of CVD and T2DM in black and white women. 
Despite being an established CVD risk factor [90], smoking only contributed significantly and 
independently to models for diastolic BP in black women. In addition, as physical activity levels 
and alcohol intake were not associated with IL-18 and hsCRP concentrations, they were not 
included in risk models, to which they may have contributed. Furthermore, behavioural/lifestyle 
factors used in this study were self-reported, and it is possible that more objective measurements 
would yield different results. Indeed, Hamer et al. have recently shown in a cross-sectional 
sample of black (n=192) and white (n=206) South African men and women, that the prevalence 
of self-reported smoking and alcohol consumption was lower when compared to objectively 
















transferase) consumption [237]. Accordingly, future studies should focus on more objective 
measures of SES and lifestyle.  
In conclusion, central obesity, low SES, smoking status and contraceptive use were associated 
with increased circulating concentrations of inflammatory markers hsCRP and IL-18, which in 
turn were associated with metabolic risk factors for T2DM and CVD in apparently healthy black 
and white South African women. The association between IL-18 and hsCRP with metabolic risk 
factors was largely mediated by central obesity and not SES and behavioural/lifestyle factors. 
Based on these findings, measuring circulating hsCRP and IL-18 concentrations provides no 
added benefit to a simple WC measurement for identification of metabolic risk factors for CVD 
and T2DM in both black and white premenopausal women. Indeed, many of the effects of 
inflammatory proteins are mediated in a paracrine fashion, and therefore further research needs 


















ASSOCIATION BETWEEN IL-18 -137G/C POLYMORPHISM WITH CIRCULATING 
IL-18 CONCENTRATIONS AND METABOLIC RISK FACTORS FOR 
CARDIOVSCULAR DISEASE AND TYPE TWO DIABETES IN SOUTH AFRICAN 
WOMEN 
Data from this chapter have been published in part in: Evans J, Collins M, Jennings C, van 
der Merwe L, Söderström I, Olsson T, Levitt NS, Lambert EV, Goedecke JH. The association of 
interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. 
2007 Nov Eur J Endocrinol;157(5) 633-40. 
 
4.1. ABSTRACT 
Ethnic differences in circulating IL-18 concentrations may be explained, in part, by ethnic 
differences in the distribution of the G allele of the -137G/C polymorphism within the promoter 
region of the IL-18 gene. The G allele of this polymorphism has previously been shown to 
influence circulating IL-18 concentrations, and has a higher frequency in black compared to 
white American women. Therefore the aim of the third study of this thesis was to investigate the 
association between the -137G/C polymorphism within the IL-18 gene and circulating IL-18 
concentrations and metabolic risk factors for cardiovascular disease in black and white South 
African women.  
Body composition (kg of total body fat), fat distribution (VAT and subcutaneous adipose tissue, 
SAT), as well as BP, fasting glucose, insulin, lipid profile, IL-18 concentrations and IL-18 -
137G/C genotype were measured in 206 black and 174 white South African women. The 


















P<0.001). Circulating IL-18 concentrations remained higher in black compared to white women 
after adjusting for age, total body fatness, VAT and genotype. A significant independent 
association between the IL-18 -137 C-allele and BP was observed in black and white women. 
Black women with the C-allele had higher systolic (115.7 ± 1.2 vs. 110.2 ± 1.3 mmHg, P<0.001) 
and diastolic BP (78.7 ± 1.9 vs. 74.5 ± 1.1 mmHg, P<0.005) than women with the GG genotype. 
Conversely, white women with the C-allele had significantly lower systolic BP (108.9 ± 1.6 vs. 
113.2 ± 1.6 mmHg, P<0.001) than women with the GG genotype.   
In conclusion, ethnic differences in circulating IL-18 concentrations could not be explained by 
variation within the distribution of the IL-18 -137G/C polymorphism, suggesting the functional 
relevance of this polymorphism needs to be further explored in different populations. Although 
the -137 G/C polymorphism could not explain ethnic differences in circulating concentrations, 
the C-allele was independently associated with BP in both ethnic groups. However, the direction 
of this relationship was different in black and white women, with the C-allele associated with 
higher BP in black women and lower BP in white women. The mechanisms underlying this 
association are not known and require further investigation. 
4.2. INTRODUCTION 
As discussed in Chapter 3, increased circulating levels of the pro-inflammatory cytokine IL-18 
were associated with metabolic risk factors for CVD, including central obesity, elevated BP, 
dyslipidaemia and insulin resistance (IR), in our sample of both black and white South African 
women, as well as other European cohorts [127;129].  Further, we showed that black South 
















Ethnic differences in circulating IL-18 levels and CVD risk factors may be explained, in part, by 
genetic variation within the IL-18 gene. A previous study in a European population showed that 
haplotype-based analysis of variants of the IL-18 gene influenced circulating IL-18 
concentrations and clinical outcomes in patients with cardiac disease, suggesting that IL-18 is 
involved in the development of atherosclerosis and its complications [238]. Furthermore, the G-
allele of a potentially functional polymorphism at position -137 within the promoter region of the 
IL-18 gene, previously associated with higher circulating IL-18 concentrations in monocytes 
[137;239], has a higher frequency in black compared to white American women [106]. However, 
it is not known if ethnic differences in genotype frequency are associated with ethnic differences 
in circulating IL-18 concentrations. Furthermore, a putative link between the IL-18 -137 G/C 
polymorphism and variation in circulating IL-18 concentrations in association with metabolic 
risk factors for CVD in different ethnic groups has not been explored.  
Therefore, I tested the hypothesis that ethnic difference in circulating IL-18 concentrations and 
metabolic risk factors could be explained, in part, by ethnic differences in the distribution of the 
IL-18 -137G/C polymorphism. Specifically, the aim of this study was to examine the association 
between the -137 G/C polymorphism within the IL-18 gene with serum IL-18 concentrations and 
metabolic risk factors for CVD in black and white South African women. 
4.3. METHODS 
4.3.1. Subjects 
The study population consisted of 206 black and 174 white premenopausal South African 
women. Only subjects successfully genotyped for the IL-18 -137G/C polymorphism were 
















detail in the methods section of Chapter Two.  The Faculty of Health Sciences Research Ethics 
Committee of the University of Cape Town gave the study ethics approval. Written informed 
consent was obtained from all subjects. 
4.3.2. Testing Procedures 
Weight, height, waist circumference, and hip circumference (at the largest part of hips) were 
measured as described in Chapter 2. Dual-energy X-ray absorptiometry (DXA) was used to 
measure whole body fat mass (Hologic QDR 4500 Discovery-W dual-energy X-ray 
absorptiometry, software version 4.40; Hologic, Bedford, MA) according to standard procedures. 
In vivo precision (% coefficient of variation) was determined for fat mass (1.7%) by measuring 
30 individuals two times on the same day with repositioning. CT-derived VAT and SAT area 
were measured at the level of L4-L5 (as described in Chapter 2). BP, fasting plasma glucose, and 
serum insulin, IL-18, TC, TG and HDL-C, as well as IR, as estimated by HOMA-IR, were 
measured. The measurement of these variables is described in detail in the methods section of 
Chapters Two and Three. 
4.3.3. DNA extraction and genotype analysis 
After DNA was extracted from the venous blood samples (5 ml) using the method of Lahiri and 
Nurnberger [240], the -137 G/C polymorphism (rs187238) within the promoter of the IL-18 gene 
was genotyped by using PCR-SSP. Two PCR reactions were performed. Each contained a 
common reverse primer 5′-AGG-AGGGCAAAATGCACTGG-3′, a control forward primer 5′-
CCAATAGGACTGATTATTCCGCA-3′ and sequence specific forward primers: 5′-CCC-
















CCCCAACTTTTACGGAAG-AAAAC-3′ for reaction 2 (G-specific). The forward and reverse 
control primers were used to amplify a 446-bp fragment covering the polymorphic site to serve 
as an internal positive amplification control. PCR reactions were performed in a final volume of  
50μl consisting of 50 mM KCl, 10 mM Tris–HCl pH 8.3, 1.5 mM MgCl2, 0.25 mM dNTP, 20 ng 
genomic DNA and 0.5 U Taq polymerase. Final primer concentrations within the reaction 
mixtures were as follows: 0.3 μM of the control forward primer, 0.5 μM of the common reverse 
primer and 0.5μM of each sequence specific primer. PCR reactions were denatured for 2 minutes 
at 94°C. This was followed by five cycles of 94°C for 20 seconds and 68°C for 60 seconds and 
25 cycles of 94°C for 20 seconds, 62°C for 20 seconds and 72°C for 40 seconds.  The PCR 
fragments were resolved on 2% Agarose gels and stained with ethidium bromide for 
visualisation under ultra-violet light. 
4.3.4. Statistical Analysis 
Data is presented as means ± standard error. Chi-squared tests were used to compare genotype 
frequencies between black and white women. In separate analyses for black and white women, 
general linear models were used to compare medians of body composition variables and 
metabolic risk factors between individuals with the different genotypes, adjusting for age, body 
fatness (kg) and VAT. Multiple linear regression analysis were used to determined if IL-18 -
137G/C genotype was associated with metabolic risk factors independently of age, circulating 
IL-18 concentrations, body fatness (kg) and VAT. Because of the rarity of the C-Allele, the GC 
and CC genotypes were combined in all genotype analysis and in relation to circulating IL-18 
















(StatSoft Inc., Tulsa, OK, USA) statistical programme. Hardy-Weinberg equilibrium was tested 
using the Genepop web version 3.4 program (http://wbiomed.curtin.edu.au/genepop/). 
4.4. RESULTS 
4.4.1. Subject characteristics 
Black women (n=206) included in this analyses were significantly younger than the white 
women (n=174; 27 ± 1 vs. 31 ± 1 years, respectively. P<0.01), as a results all subsequent 
analysis included age as a covariate.  The majority of the black subjects reported being of Xhosa 
ancestry (N=175, 85%), with the other 31% being of mixed (N=31) South African tribal 
ancestry. The white South African women were all of European ancestry. 
4.4.2. Distribution of IL-18 genotype among ethnic groups  
No black women were homozygous for the C-allele. The C-allele was less frequent and the G 
allele more frequent in both black and white women. IL-18 -137 genotype distributions (GG, GC 
and CC) were significantly different between black and white women (Figure 4.1, P<0.001). The 
frequency of the C-allele was significantly lower in black (n=50/412) compared to white 
(n=103/348) women (χ
2
=34.6, p<0.001). Similar results were obtained when genotype 
distributions of the black subjects of only Xhosa ancestry (n=170) were compared to the white 
women (P<0.001), indicating that there was no population stratification in the black women. IL-
18 genotype distributions of the black and white women included in this study were in Hardy-

















4.4.3. Association between IL-18 genotype with circulating IL-18 concentrations  
There was no association between IL-18 -137G/C polymorphism with circulating IL-18 
concentrations in black (P=0.99) and white women (P=0.67). Irrespective of genotype, 
circulating IL-18 concentrations were significantly higher in black compared to white women, 





























Figure 4.1. Genotype frequency of the IL-18-137G/C polymorphism in black and white women.  































Figure 4.2. Ethnic differences in circulating IL-18 levels according to IL-18 -137G/C genotype.   
Black women, White women. Black vs. White women * P<0.01. Data are presented as 
unadjusted means, with error bars indicating standard error. 
4.4.4. Differences in IL-18 -137G/C genotypes, body composition and metabolic risk 
factors for cardiovascular disease and type two diabetes between black and white 
South African women. 
 
Differences between IL-18 -137G/C genotype and body composition and metabolic risk factors 
for CVD, according to ethnicity, are shown in Tables 4.1 and 4.2. There were no significant 
differences in age, height, weight, body fatness or fat distribution, between genotype groups, in 
both black and white women (P>0.05).  
Blood pressure differed significantly according to IL-18-137G/C genotype, in both black and 
white women. Black women with the C-allele had significantly higher systolic and diastolic BP 
compared to women with the GG genotype. Conversely, white women with the C-allele had 
















IL-18 genotype (GC/CC: β= 0.16, P=0.024), age (β=0.37, P<0.01) and circulating IL-18 
concentrations (β=0.18, P=0.012) were significant predictors of systolic BP (Adjusted R
2
=0.21, 
P<0.01); and IL-18 genotype (GC/CC: β= 0.15, P=0.023), age (β=0.27, P<0.01), body fat (kg) 
(β=0.25, P<0.01) and circulating IL-18 concentrations (β=0.22, P<0.01) were significant 
predictors of diastolic BP (Adjusted R
2
=0.30, P<0.01). In white women, IL-18 genotype 
(GC/CC: β= -0.18, P=0.023), age (β=0.29, P<0.01) and body fat (kg) (β=0.19, P=0.010) were 
significant predictors of systolic BP (Adjusted R
2
=0.16, P<0.01).  
IL-18 genotype was not associated with measures of insulin sensitivity or blood lipid parameters 














Table 4.1. Subject characteristics for genotypes of the -137 G/C polymorphism within the IL-18 gene in black and white South African 
women 
Black women  White women 
 
GG Genotype GC Genotype  
 
GG Genotype GC or CC Genotype  
(N=156) (N=50)  (N=85) (N=89)  
 n Means ± SE  n Means ± SE P-value  n Means ± SE n Means ± SE P-value 
Age (yrs) 156 26 ± 1 50 27 ± 1 0.211 
 
 
85 31 ± 1 89 32 ± 1 0.976 
Height (m) 156 1.60 ± 0.01 50 1.61 ± 0.01 0.226 
 
 
85 1.67 ± 0.01 89 1.67 ± 0.01 0.085 
Weight (kg) 156 74.6 ± 2.0 50 81.9 ± 3.5 0.059 
 
 
85 76.7 ± 2.5 89 77.6 ± 2.5 0.696 
Body fat (%) 155 39.6 ± 1.3 48 42.1 ± 2.4 0.194 
 
 
85 34.9 ± 1.8 89 35.2 ± 1.6 0.324 
WC (cm) 156 88.1 ± 0.1 50 94.3 ± 2.9 0.088 
 
 
85 80.5 ± 2.1 89 90.9 ± 2.1 0.534 





85 0.81 ± 0.01 89 0.81 ± 0.01 0.469 
VAT (cm
2
) 120 70.7 ± 5.3 40 85.1 ± 9.1 0.163 
 
 
68 102.9 ± 6.6 89 102.6 ± 6.4 0.832 
SAT (cm
2
) 120 371 ± 20 40 427 ± 35 0.068 
 
 
68 311 ± 26 89 341 ± 25 0.629 
















Table 4.2. Metabolic outcomes for IL-18-137G/C genotypes and serum Il-18 concentrations in black South African women 
Black Women  White Women 
 
GG genotype  
(N=156) 
GC  Genotype 
(N=50) 
P-Value  
GG genotype  
(N=85) 
GC or CC genotype 
(N=89) 
P-Value 
 n Means ± SE n Means ± SE n  n Means ± SE n Means ± SE  
Blood Pressure            
Systolic BP (mmHg) 156 110.2 ± 1.3 50 115.7 ± 1.2 0.007  85 113.2 ± 1.6 89 108.9 ± 1.6 0.043 
Diastolic BP (mmHg) 156 74.5 ± 1.1 50 78.7± 1.9 0.004  85 77.1 ± 1.3 89 75.6 ± 1.3 0.968 
Insulin Sensitivity            
Glucose (mmol/L) 150 4.4 ± 0.1 48 4.5 ± 0.1 0.101  85 4.6 ± 0.1 89 4.7 ± 0.1 0.380 
Insulin (mU/L) 150 11.5 ± 0.7 50 11.2 ± 1.1 0.308  85 8.2 ± 0.8 89 8.8 ± 0.8 0.594 
HOMA-IR 150 2.32 ± 0.15 48 2.25 ± 0.18 0.279  85 1.69 ± 0.18 89 1.87 ± 0.17 0.586 
Lipid Profile            
Triglycerides 
(mmol/L) 
145 0.7 ± 0.1 48 0.8 ± 0.1 0.123  85 0.9 ± 0.1 89 1.0 ± 0.1 0.757 
Cholesterol (mmol/L) 145 3.8 ± 0.1 48 4.1 ± 0.2 0.166  85 4.9 ± 0.1 89 4.7 ± 0.1 0.366 
HDL-C (mmol/L) 145 1.3 ± 0.1 48 1.4 ± 0.1 0.729  85 1.6 ± 0.1 89 1.7 ± 0.1 0.474 
TC/HDL-C 145 3.1 ± 0.1 48 3.1 ± 0.2 0.211  85 3.19 ± 0.13 89 3.05 ± 0.12 0.797 
BP, blood pressure; HOMA IR, homeostasis model of insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipoprotein 

















The main and novel finding of this study was that the C-allele of the -137 G/C polymorphism 
within the IL-18 gene was associated with BP in apparently healthy black and white South 
African women. However, the direction of the relationship between genotype and BP was 
different between black and white women. In contrast to my original hypothesis, variation within 
the IL-18-137 G/C polymorphism could not explain ethnic differences in circulating IL-18 
concentrations. This is despite black women having a higher frequency of the G allele, which has 
previously been associated with higher IL-18 concentrations. 
IL-18 genotype, circulating IL-18 concentrations, age and VAT were all significantly associated 
with BP, accounting for 22.6% of the variability in the black women and 16.8% in the white 
women; however the direction of association between genotype and BP was different between 
the two ethnicities. The C-allele was associated with higher BP in black women, whereas it was 
associated with lower BP in white women. The actual difference in BP between genotype groups 
was ~5mmHG. And though seemingly little, this is similar to results from weight-loss 
intervention studies, that have shown that 5kgs in weight loss corresponds to an average drop of 
5.6mmHg in systolic BP [241]. The C-allele of this polymorphism has previously been 
associated with several inflammatory diseases including cancer [242] and type 1 diabetes [243-
245]. However in a Finnish population, hypertension was a risk factor for sudden cardiac death 
and coronary atherosclerosis only in carriers of the -137 G allele, but not the C allele [246]. 
Although the exact reasons for the differential relationship between IL-18 genotype and BP 
between ethnic groups in the present study are unknown, the presence of strong linkage 
















linked to the -137G/C genotype may underlie this association [238]. In support of this, Tiret et al. 
(2005) examined the genetic variability of four functionally important variants in the IL-18 
system in relation to circulating IL-18 concentrations and cardiovascular mortality. Their 
analysis of other polymorphisms (G-887T, C-105T, S35S, A+183G and T+533C) within the IL-
18 gene did not show an association between any of the individual SNP’s and IL-18 
concentrations or cardiovascular outcomes. However, a haplotype (GCAGT) of these 
polymorphisms was associated with circulating IL-18 concentrations and clinical outcome in 
patients with cardiac disease, but the association with cardiovascular risk was not independent of 
circulating IL-18 concentrations and explained less than 2% of the inter-individual variability in 
IL-18 concentrations [238].  
Although the mechanisms are unclear, both endothelial cells and smooth muscle cells express the 
IL-18 receptor, which show enhanced expression in response to other inflammatory cytokines, 
namely, IL-1 , TNF- , IL-6 and IFN-  [131], and the potent vasoconstrictor, angiotensin II 
[247].  Stimulation of endothelial and smooth muscle by IL-18 produces biologically active IFN-
, as well as IL-1 , IL-6 and TNF-  [124;248;249]. The reciprocal inducibility of these 
cytokines by IL-18 signalling suggests a positive feedback loop in the vasculature, which might 
contribute to dysregulation in the inflammatory response [131]. This is of particular relevance to 
BP regulation as high concentrations of TNF-α in the vascular lumen inhibit nitric oxide 
synthase activation and nitric oxide production [250], leaving unopposed vasoconstriction of 
endothelin-1 [251]. Alternatively, or in addition, IL-18 may exert its effects on BP via the RAS 
system, as IL-6, IL-1, TNF-α and IFN-γ have been shown to up regulate angiotensin gene 
















Similar to findings by Ness et al., white women in the present study had a higher frequency of 
the C-allele compared to black women, however the genotype distribution was lower in our 
study cohort compared to theirs (White Americans: GG= 51.8%, GC=40.0%, CC=8.2% vs. 
white South Africans: GG=48.6%; GC=43.5%; CC=7.9%; and black Americans: GG=59.1%, 
GC=36.3%, CC=4.7% vs. black South Africans: GG=77%; GC=23%; CC=0%) [106], Notably, 
this discrepancy is similar to that observed between Zulus and African-Americans when 
comparing the distribution of the 592C/A polymorphism within the IL-10 gene [253]. However, 
despite the differences in distribution and even though both the -137 G/C polymorphism, and 
baseline IL-18 concentrations were associated with individual metabolic risk factors, there was 
no association between the -137 G/C polymorphism and circulating IL-18 concentrations in 
either ethnic group in this study. The IL-18 -137 G/C promoter polymorphism has been found to 
have clear promoter activity when blood monocytes were stimulated with phorbol 12-myristate 
13-acetate (PMA) and ionomicin, yet non-significant differences in IL-18 expression was 
observed between alleles [137], suggesting that the functional relevance of this polymorphism 
warrants further investigation.   
In conclusion, ethnic differences in circulating IL-18 concentrations could not be explained by 
differences in the distribution of the -137G/C polymorphism within the IL-18 gene in black and 
white South African women. However, differences in BP reported across IL-18 genotypes, 
together with the results from the previous chapter, strengthen the putative role of IL-18 as an 
inflammatory mediator of obesity-related CVD. Further research is required to verify the 
association between the -137 G/C polymorphism within the IL-18 gene and BP in a higher risk 


















DEPOT- AND ETHNIC-SPECIFIC ASSOCIATIONS BETWEEN ADIPOSE TISSUE 
INFLAMMATION AND INSULIN SENSITIVITY 
Data from this chapter have been published in part in: Evans J, Goedecke JH, Söderström I, 
Búren J, Alvehus M, Blomquist C, Jonsson F, Hayes PM, Adams K, Dave JA, Levitt NS, 
Lambert EV, Olsson T. Depot- And Ethnic-Specific Differences In The Relationship Between 
Adipose Tissue Inflammation And Insulin Sensitivity. 2011 Clin Endocrinol (Oxf);74:51-59. 
 
5.1. ABSTRACT 
Ethnic differences in circulating inflammatory markers may be mediated by ethnic differences in 
body fat distribution, as black women have less central fat, specifically VAT, and more 
peripheral fat than white women. Indeed the relationship between abdominal AT depots and SI 
has been shown to differ between black and white women, with abdominal SAT more closely 
related to SI in black women. It is not clear as to whether these differences are associated with 
differences in inflammatory gene expression between abdominal and gluteal SAT. We therefore 
tested the hypotheses that SAT inflammatory gene expression is greater in the abdominal 
compared to the gluteal depot and SAT inflammatory gene expression is associated with 
differential SI in black and white women.  
SI (frequently sampled intravenous glucose tolerance test), and abdominal SAT, and gluteal SAT 
gene expression levels of 13 inflammatory genes were measured in a subgroup of normal-weight 
(body mass index (BMI): 18-25 kg/m
2
) and obese (BMI >30 kg/m
2
) black (n=30) and white 
(n=26) South African women. Black women had higher abdominal and gluteal SAT expression 
















Multivariate analysis showed that inflammatory gene expression in the white women explained 
56.8% of the variance in SI (P<0.005), compared to 20.9% in black women (P=0.30). Gluteal 
SAT had lower expression of adiponectin, but higher expression of inflammatory cytokines, 
macrophage markers and leptin than abdominal SAT depots (P<0.05).  
In conclusion black South African women had higher SAT inflammatory gene expression levels 
than white women; however the relationship between SAT inflammation and SI was stronger in 
white compared to black women. Further research is required to explore the contributions of 
inflammation from other tissues, which may affect SI in black populations. Contrary to our 
original hypothesis, gluteal SAT had a greater inflammatory gene expression profile than 
abdominal SAT depots. The protective nature of gluteo-femoral fat therefore requires further 
investigation. 
5.2. INTRODUCTION 
As described in Chapter 3, chronic low-grade inflammation, with a putative origin in AT, has 
been suggested to be a key link between obesity and IR [97].  Expression of inflammatory genes 
within AT are increased in obese individuals [185] and AT mRNA levels of inflammatory 
cytokines, chemokines and adipokines have been shown to be associated with metabolic risk 
factors for CVD and T2DM [254]. As described in Chapter 2 and 3, abdominal obesity is 
associated with IR, and increased risk of T2DM and CVD [6], with the added increased 
metabolic risk of VAT versus abdominal SAT having been attributed to its apparent higher 
expression of inflammatory cytokines [70;71].  
This may be of particular importance in explaining ethnic differences in circulating inflammatory 
















and SI discussed in Chapter 2. Notably, previous studies have shown that while both VAT and 
abdominal SAT depots were similarly correlated to SI in white women, SAT was more closely 
related to SI in black women [12]. Further, in Chapter 2 I found that WC, which reflects both 
VAT and SAT, was better than VAT for identifying black and white women with IR (upper 
tertile of HOMA-IR), suggesting that certain properties of SAT contribute to IR, especially,  in 
black women.  Notably, DSAT, a sub-compartment within the abdominal SAT depot, has been 
reported to have an inflammatory gene expression greater than superficial SSAT [75] and in the 
case of TNF-α expression, similar to that of visceral AT [75]. Indeed, TNF-α expression 
correlated positively with IR in healthy normal-weight subjects [75]. Therefore, ethnic 
differences in the relationship between abdominal AT tissue depots and IR might be explained, 
in part, by differences in depot-specific inflammation.  
In contrast, lower body obesity (fat stored in the femoral-gluteal region), which is associated 
with a lower risk of metabolic complications [64] has been suggested to be protective due to a 
more favorable metabolic profile [7]. Importantly, however, to my knowledge no studies have 
compared inflammatory gene expression between gluteal and abdominal SAT depots. Thus for 
this study I explored the process of AT inflammation from macrophage recruitment (macrophage 
marker and chemokine mRNA) to adipocytokines (cytokines and adipokines). 
I therefore tested three hypotheses: 1) SAT inflammatory gene expression is greater in black 
compared to white South African women; 2) SAT inflammatory gene expression is greater in the 
abdominal compared to the gluteal depot; 3) a depot-specific inflammatory profile is associated 


















The study consisted of a sub-sample of 15 normal-weight (BMI 18-25 kg/m
2
) black, 13 normal-
weight white, 15 obese (BMI >30 kg/m
2
) black and 13 obese white South African women, who 
were recruited by advertisement as described previously in Chapter 2. The study was approved 
by the Research Ethics Committee of the Faculty of Health Sciences of the University of Cape 
Town and written informed consent to participate in the study was obtained from all subjects 
prior to participation in the study.  
5.3.2. Testing procedures 
5.3.2.1. Body composition assessment  
As previously described in Chapter 2, 3 and 4, basic anthropometric measurements, including 
weight, height, WC and hip circumference were taken, and fat mass and gynoid region of interest 
[255] were measured using DXA (Discovery-W, Software version 4.40, Hologic Inc., Bedford, 
MA, USA). Abdominal VAT, DSAT and SSAT areas were measured using CT-scan (Toshiba X-
press Helical Scanner, Japan) at the level of L4-L5 lumbar vertebrae, with the fascia superficialis 
used to discriminate DSAT vs. SSAT [222].  
5.3.2.2. Fat biopsies 
After a 4 hr fast, fat biopsies were obtained from the abdominal DSAT, SSAT and gluteal areas, 
using a mini-liposuction technique. After local anaesthesia with Lignocaine hydrochloride (2%, 
Intramed, Port Elizabeth, South Africa), a small incision was made directly above the umbilicus. 
















Lignocaine (0.75%, Intramed, Port Elizabeth, South Africa) was infused using an infiltration 
cannula (Lamis 14ga x 15cm, Byron Medical Inc., Tucson, AZ). An aspiration cannula 
(Coleman, 12ga x 15cm, Byron Medical Inc, Tucson, AZ) attached to a 10ml syringe was used to 
aspirate fat from above (SSAT) and below (DSAT) the fascia superficialis, under ultrasound 
guidance by a radiologist. Gluteal samples were obtained from the right upper quadrant using the 
same procedure. Approximately 2 ml of fat was extracted from each site and washed three times 
with normal saline or until no blood was visible. AT was then placed into vials and frozen 
immediately in liquid nitrogen and stored at –80° C for subsequent analyses. 
5.3.2.3. Adipocyte area 
Frozen SAT samples were cut into 25µm sections and stained with haematoxylin and eosin, as 
previously described [256]. Images of intact adipocytes were captured using an inverted 
fluorescent microscope (Zeiss Axiovert 200, Zeiss, Jena, Germany) connected to an Axiocam 
(black and white, Zeiss, Jena, Germany) with Axiovision software (Axiovision Rel 4.5, Zeiss, 
Jena, Germany). Computer image analysis (WCIF Image J software, Java, Maryland, USA) was 
used to measure adipocyte area as previously described [257]. Mean adipocyte area was 
calculated from the average area of 200 cells.  
5.3.2.4. Insulin sensitivity (SI) 
After an overnight fast, subjects underwent an insulin-modified FSIGT to quantify insulin 
sensitivity.  Baseline samples were drawn at -15, -5 and -1 min prior to the infusion of glucose 
(50% dextrose; 11.4 g/m2 body surface area) over 60 seconds commencing at time 0.  At 20 min, 
human insulin (0.02 unit/kg; Actrapid, Novo Nordisk) was infused over 5 min at a constant rate.  
















and the 32 samples drawn over 240 min following commencement of the glucose infusion.  
Glucose and insulin data from the FSIGT were used to calculate the insulin sensitivity index (SI) 
using Bergman’s minimal model of glucose kinetics [258]. 
5.3.2.5. Biochemical Analysis 
Plasma glucose concentrations were determined using the glucose oxidase method (YSI 2300 
STAT PLUS; YSI Life Sciences, Yellow Springs, OH) and serum insulin by 
immunochemiluminometric assays using the ADVIA Centaur (Bayer Diagnostics, Tarrytown, 
NJ). Serum concentrations of leptin (Linco Research, St Charles, Missouri, USA), high 
molecular weight (HMW) adiponectin (Linco Research, St Charles, Missouri, USA), hsCRP; 
(Immun Diagnostik AG, Bensheim, Germany) and IL-18 (Biosource, Nivelles, Belgium) were 
all analyzed using commercially available ELISA kits according to the manufacturer’s protocols. 
5.3.2.6. RNA extraction, reverse transcription, and real-time PCR 
Total RNA was extracted from SAT biopsies using the RNeasy Lipid Tissue Mini and RNeasy 
Lipid Tissue Midi Kit
 
(QIAGEN, Hilden, Germany). The yield and purity were determined by 
spectrophotometer (ND-1000 spectrophotometer; NanoDrop Technologies, Wilmington, DE) 
and RNA integrity was a alyzed by 1% agarose gel electrophoresis in the presence of ethidium 
bromide. 
Two micrograms of RNA were reverse transcribed, using TaqMan RT reagents (High
 
Capacity 
cDNA Reverse Transcription Kit, Applied Biosystems, Foster City,
 
CA) and RNase inhibitor 
(Applied Biosystems) at a final concentration
 
of 1.0 U/ml. Subsequently, mRNA levels of 
chemokines (Chemokine (C-C motif) ligand 2 (CCL2) and its receptor CCR2), macrophage 
















migration inhibitory factor (MIF), TNF- α, Interleukin (IL)-6, IL-10 and IL-18) and adipokines 
(leptin and adiponectin) were quantified (relative
 
quantification standard curve method) using 
TaqMan Universal PCR
 
Master Mix (Applied Biosystems) and the following TaqMan gene 
expression
 
assays (Applied Biosystems): CD14 (Hs00169122_g1), CD68 (Hs00154355_m1), 
CD163 (Hs01016657_m1), CCL2 (Hs00234140_m1), CCR2 (Hs00356601_m1), CSF-1 
(Hs00174164_m1), MIF (Hs00236988_g1), TNF-α (Hs00174128_m1), IL-6 (Hs00985639_m1), 
IL-10 (Hs00174086_m1), IL-18 (Hs99999040_m1), leptin (Hs00174877_m1), adiponectin 
(Hs00605917_m1), peptidylprolyl isomerase A (PPIA) (Hs999999904_m1), as well as ribosomal 
protein P0 (RPLP0) (Hs99999902_m1). Each sample was run in duplicate on an ABI Prism
 
7900HT sequence detection system (Applied Biosystems) and the relative expression level was 
calculated from the standard curve. Reference genes were evaluated by running PPIA and 
RPLP0 on the full study cohort. NormFinder algorithm identified PPIA as the best normalization 
gene, expression levels of which were not altered by obesity (p=0.476), ethnicity (p=0.075) or 




5.3.2.7. Measurement of protein expression in adipose tissue 
Frozen SAT samples (250-350mg) were washed in phosphate buffer solution and homogenized 
in lysis buffer (20mM TrisHCL, 1mM EDTA, and 0.1mM phenylmethanesulfonyl fluoride pH 
7.5).  The homogenate was centrifuged for 30 minutes (+4°C, 14,000rpm), and the infranant used 
to determine, in duplicate, human leptin (Millipore Corporation, Billerica, MA, USA), IL-18 
(BioSource Europe S.A. Nivelles, Belgium), CSF-1 and CCL2 (R&D Systems Europe, Ltd. 
Abingdon, United Kingdom), using commercial ELISA kits according to the manufacturer’s 
















5.3.3. Statistics  
5.3.3.1. Univariate data analysis 
As previously described [12], power calculation was based on data from Lovejoy et al. [59], 
which showed that we had 80% power to detect a difference of 2 × 10−5/min/pmol/l in SI at P < 
0.05 with 25 subjects per ethnic group. Normally distributed data are presented as means ± SD 
with ranges in parentheses. Non-normally distributed parameters were logarithmically 
transformed for parametric analysis and are presented as geometric means with 95% confidence 
intervals. Two-way ANCOVA, adjusting for age, was used to compare body composition, fat 
distribution, adipocyte area, SI and circulating inflammatory markers between normal-weight 
and obese, black and white women. To explore the differences in gene and protein expression 
between SAT depots, and how obesity and ethnicity alter this, two-way ANOVA, with repeated 
measures and Tukey’s post-hoc analysis was used. Ethnic comparisons were adjusted for age, 
total body fatness (fat kg) and VAT. Spearman’s correlation coefficients were used to explore 
the relationships between circulating inflammatory markers and inflammatory gene and protein 
expression levels. Data were analyzed using STATISTICA version 9 (Statsoft Inc., Tulsa, OK).   
5.3.3.2. Multivariate data analysis 
Partial least squares (PLS) regression, a multivariate linear projection method, was used to 
explore the association between SAT gene expression and SI, in two separate models for black 
and white women. The predictor variables included in each model were total body fatness (fat 
kg) and gene expression levels of the 13 genes measured in the three different SAT depots (40 
predictor variables in total). ANOVA was used to test the significance of each model. The VIP 
















both with respect to the other predictor variables (gene expression levels) and the response 
variable, SI. Confidence intervals were computed by jack knife from the cross validation using 
the standard formula [259]. A predictor variable was considered significant to the model if it had 
a combination of a VIP greater than 1, and the lower limit of the VIP confidence interval (CI) not 
below 0.5 [260]. Regression coefficients show the effect of the different genes on SI. For the 
multivariate analysis commercial software was used (SIMCA 12.0 from Umetrics AB, Umeå 
Sweden).   
5.4. RESULTS 
5.4.1. Body composition, fat distribution, insulin sensitvity and circulating adipokines 
Subject characteristics, as described previously [12], are shown in Table 5.1. In brief, black and 
white groups were well matched for BMI, total adiposity (DXA-derived fat mass), waist and hip 
circumferences, and DXA-derived measure of gluteal fat. However, obese black women had 
significantly less VAT, but more SSAT than obese white women, independent of total body 
fatness. There were no ethnic diffe ences in adipocyte area, but mean gluteal adipocyte area was 
significantly greater than DSAT and SSAT adipocyte area in both normal-weight and obese 
women (P<0.01).  
SI was lower in normal-weight and obese black compared to white women (P<0.001). Both 
obese black and white women had significantly lower SI than normal-weight women (P<0.05).  
In contrast to the findings in the larger cohort, reported in Chapter 3, no ethnic differences in 
circulating hsCRP, IL-18, leptin or adiponectin concentrations were observed. Circulating 
















circulating adiponectin concentrations were lower (P<0.001). Plasma IL-18 concentrations did 
not differ between normal-weight and obese groups.  
5.4.2. Subcutaneous adipose tissue gene expression 
Gene expression levels of the chemokines, macrophage markers, cytokines and adipokines are 
shown in Figures 5.1-5.33. When examining the differential effects of ethnicity on SAT gene 
expression, we found that both normal-weight and obese black women had significantly higher 
expression of CCL2, CD68, CSF-1 and TNF-α in all three depots than white women. 
Additionally, black women had significantly higher abdominal DSAT and SSAT expression of 
leptin, and DSAT expression of CCR2, than white women. Further, MIF expression was 
significantly higher in obese black compared to obese white women in all three depots. Ethnic 
differences in gene expression were still significant after adjusting for age, total body fatness (kg 
fat) and VAT. 
When exploring the effect of depot differences in SAT inflammatory gene expression, we found 
that gluteal SAT had significantly lower expression of adiponectin, but higher expression of 
CCR2, CD68, CD14, CD163, MIF, TNF-α, IL-18, IL-10 and leptin, than DSAT and SSAT 
(P<0.01). Further, DSAT had higher CSF-1 and IL-6 mRNA levels than both SSAT and gluteal 
SAT depot, as well as lower leptin and higher IL-10 mRNA levels than SSAT (P<0.01).  
We then explored the effect of obesity on SAT gene expression.  Adiponectin mRNA levels were 
lower in all depots in obese compared to normal-weight women. In contrast, the expression of 
leptin and all inflammatory markers, except IL-6 (unchanged), were higher in obese compared to 
















Table 5.1. Subject Characteristics 






































































































Fat cell Size 












































Ci culating inflammatory markers 

































Values are expressed as mean ± SD for normally distributed variables. VAT, SI and IL-18 had a skewed 
distribution, therefore the median and interquartile ranges are displayed in parenthesis. P-value adjusted 
for age. BMI, body mass index; DSAT, deep subcutaneous adipose tissue; SSAT, superficial subcutaneous 
adipose tissue; VAT, visceral adipose tissue area; hsCRP, high sensitivity C-reactive protein; IL-18, 
Interleukin 18. Matching superscripts represent differences between groups. 
a
 Normal-weight black vs. 
obese black (P<0.001);
b
 Normal-weight white vs. obese white (P<0.001); 
c
 Normal-weight black vs. 
normal-weight white (P<0.01); 
d 































































Figure 5.1. Adipose tissue chemokine gene expression. Normal-weight black women;  
Normal-weight white women; Obese black women;  Obese white women. DSAT, deep 
subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose tissue; GLUT, gluteal adipose 
tissue. mRNA levels are normalized to PPIA. Each bar represents mean ± SE. 
δ
 P<0.001, GLUT, vs. 
DSAT and SSAT. 
#
 P<0.001, Normal-weight vs. obese. 
*

















































































Figure 5.2. Adipose tissue macrophage marker gene expression. . Normal-weight black 
women;  Normal-weight white women; Obese black women;  Obese white 
women. DSAT, deep subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose 
tissue; GLUT, gluteal adipose tissue. mRNA levels are normalized to PPIA. Each bar 
represents mean ± SE. 
δ
 P<0.001, GLUT, vs. DSAT and SSAT. 
#
 P<0.001, Normal-weight vs. 
obese. 
*



































































































































































































Figure 5.3. Adipose tissue cytokine and adipokine gene expression. Normal-weight black women;  Normal-weight white women; 
Obese black women;  Obese white women. DSAT, deep subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose 
tissue; GLUT, gluteal adipose tissue. mRNA levels are normalized to PPIA. Each bar represents mean ± SE. 
δ
 P<0.001, GLUT vs. DSAT 
and SSAT. 
λ
 P<0.05, DSAT vs. SSAT and GLUT 
#
 P<0.001, Normal-weight vs. obese. 
*
















5.4.3. Relationship between insulin senstivity and subcutaneous adipose tissue gene-
expression and circulating concentrations 
Multivariate analysis was used to assess the relationship of SAT inflammatory gene expression 
and total body fatness (kg fat) to SI, in 2 separate models for white and black women (Figure 5.4 
a and b). In both models, with the exception of adiponectin which showed a positive association 
with SI, all other markers were negatively associated with SI, irrespective of depot.  
The model for white women was able to explain 56.8% of the variation in SI (P<0.005). Nineteen 
of the 40 predictor variables were considered significant to the model (VIP>1 and lower VIP-CI 
limit > 0.5). The majority of these were genes expressed in the abdominal depots, whereas only 
CCR2 and IL-18 expression in the gluteal depot added significantly to the model.  
Conversely, the model for SI in black women was only able to explain 20.9% of the variation. 
Although the overall model was not able to account for a significant variation in SI in these 
women (P=0.30), 12 of the 40 predictor variables were considered significant (VIP>1 and lower 
VIP-CI limit > 0.5). Similar to the model for SI in white women, the majority of genes were 
those expressed in the abdominal depots. 
Similar to the findings for gene expression, circulating hsCRP (r=-0.59, P=0.002), adiponectin 
(r=0.49, P=0.045) and leptin (r=-0.62, p=0.007) were significantly associated with SI
 
in white, 
but not black women (hsCRP: r=-0.17, p=0.35; adiponectin: r=0.03, p=0.86; leptin: r=-0.15, 
p=0.44).  Circulating IL-18 concentrations were not associated with SI in either ethnicity (Black 






























































































































































































































Figure 5.4. Relationship between adipose tissue gene expression and insulin sensitivity (SI) in white 
women (a) and black women (b). Deep subcutaneous adipose tissue, Superficial 
subcutaneous adipose tissue, Gluteal subcutaneous adipose tissue. Positive regression 
coefficients have a positive influence on SI, whereas negative regression coefficients have a negative 
influence on SI. 
*
 Variables significant to the model (combined VIP greater than 1 and lower VIP-
















5.4.4. Subcutaneous adipose tissue protein expression 
SAT protein levels are shown in Table 5.2. There were no differences between normal-weight 
and obese groups, or between ethnic groups in SAT leptin and CSF-1 protein levels in all 3 
depots, nor for gluteal IL-18 protein levels. As with leptin mRNA levels, leptin protein levels in 
the gluteal depot were higher than in the abdominal DSAT and SSAT depots (p<0.001). 
Conversely, despite higher DSAT CSF-1 mRNA levels, DSAT CSF-1 protein levels were lower 
than in the SSAT and gluteal SAT depots (P<0.05).  
SAT protein levels of CCL2 were below the detection level (<31.5pg/ml) in all depots. Similarly 
IL-18 protein levels were below the detection limit (<12.5pg/ml) for a majority of the abdominal 
DSAT (66%) and SSAT (64%) samples, and as a result, only data relating to the gluteal depot 
are presented. 
5.4.5. Relationship between subcutaneous adipose tissue gene expression, protein levels 
and corresponding circulating adipokine concentrations 
CSF-1 mRNA levels did not correlate with SAT CSF-1 protein levels (data not shown). 
Similarly, SAT leptin mRNA levels did not correlate with corresponding SAT protein levels, but 
did correlate with circulating leptin levels (DSAT: r=0.72, P<0.001; SSAT: r=0.73, P<0.001; 
Gluteal: r=0.56, P<0.001). Conversely, gluteal IL-18 mRNA levels correlated with gluteal IL-18 
protein levels (r=0.35, p<0.05), but SAT IL-18 mRNA in all depots and gluteal IL-18 protein 
levels did not correlate with circulating levels (data not shown).  In contrast, SAT adiponectin 
mRNA in all depots correlated significantly with circulating adiponectin levels (DSAT: r=0.56, 
















Table 5.2. Adipose tissue protein expression levels in normal-weight and obese, black and white 
women 
 Normal-weight  Obese  
 Black White Black White 
 Leptin (ng/ml) 
 N=14 N=12 N=15 N=13 
DSAT 
1.82 ±0.49     
(0.66-5.57) 
1.36 ± 0.30 
(0.62-3.24) 
2.09 ± 0.44  (0.72-
5.91) 
1.20 ± 0.13  (0.61-
2.02) 
SSAT 
2.72 ± 0.70    
(0.52-6.89) 
1.92 ± 0.46 
(0.57-6.67) 
2.35 ±0.38   (0.52-
5.52) 

















 CSF-1 (ng/ml) 















474.03 ± 52.79 
(85.92-788.67) 
512.06 ± 42.70 
(189.78-703.23) 
394.10 ± 42.07 
(125.5-689.80) 
428.67 ± 45.35 
(243.51-746.97) 
GLUT 
498.26 ± 79.03 
(129.64-1305.02) 
461.26 ± 41.65 
(286.78-755.10) 
430.81 ± 61.11 
(155.93-866.87) 
490.27 ± 48.61 
(265.76-777.04) 
 IL-18 (ng/ml) 
 N=10 N=9 N=10 N=9 
GLUT 
45.86 ± 19.3  
(20.1-214.67) 
23.74 ± 6.88 
(12.50-78.1) 
52.40 ± 5.73 
(14.33-87.39) 
37.50 ± 9.56 
(14.07-28.69) 
Values are expressed as mean ± SD, with ranges in parentheses. DSAT, deep subcutaneous adipose 
tissue; SSAT, superficial subcutaneous adipose tissue; GLUT, gluteal subcutaneous adipose tissue; CSF-
1, macrophage colony stimulating factor 1; IL-18, interleukin – 18. 
a
P<0.05, GLUT vs. DSAT and SSAT; 
b
















5.4.6. Relationship between adipocyte size and circulating inflammatory 
markers and inflammatory gene expression 
Adipocyte area in all three AT depots correlated positively with circulating hsCRP and leptin, 
and negatively with circulating adiponectin (P<0.005), however, the associations with the 
regional fat depots and adipocyte area were no longer significant after adjustment for total body 
fatness. Circulating IL-18 concentrations did not correlate with any measures of regional 
adiposity or with adipocyte area (P>0.05). Gluteal, deep SAT and superficial SAT gene 
expression correlated with adipocyte area in all three AT depots, showing a positive correlation 
for leptin, the macrophage markers, cytokines (excluding IL-6), and chemokines mRNA levels, 
and a negative association with adiponectin expression (p<0.001). However, after adjusting for 
age and total body fatness, the positive correlation between adipocyte area and gene expression 
for all genes measured was no longer significant (P>0.05). 
5.5. DISCUSSION 
This study reports two novel findings: Firstly, in support of the original hypothesis, black South 
African women had higher SAT inflammatory gene expression compared to white South African 
women. However this only explained a small non-significant proportion (less than 21%) of the 
variance in SI, whereas in white women, their SAT inflammatory gene expression profile 
explained 56% of the variance in SI. Secondly, inflammatory gene expression was higher in 
gluteal compared to abdominal SAT, independent of adiposity and ethnicity. This is in contrast 


















5.5.1. Ethnic differences in gene expression 
To my knowledge, this is the first study to show ethnic differences in SAT inflammatory gene 
expression. Black women had a higher expression of the chemokine CCL2 and its receptor 
CCR2, macrophage marker CD68 and cytokines TNF-α, CSF-1, MIF than white women; 
independent of age, total adiposity and VAT. The relevance of these findings are highlighted by 
studies showing that increased expression of CD68 is positively related to macrophage content 
within AT [71], and the recruitment of additional macrophages into AT is signalled by the 
release of chemo-attractants, such as CCL2 [261]. Activated macrophages secrete increasing 
amounts of cytokines such as TNF-α, MIF and CSF-1 in a feed-forward manner, further 
amplifying the inflammatory response. This is in line with reports from genetic studies showing 
that African-American and sub-Saharan populations are more likely to carry allelic variants 
associated with a higher inflammatory response [106]. 
Despite the higher inflammatory profile in black women, SAT inflammatory gene expression 
only accounted for 20% of the variance in SI in black women, compared to 56% of the variance 
in SI in white women. In white women, 10 of the 13 genes measured were significantly 
negatively associated with SI. These included the chemokines CCL2 and CCR2, macrophage 
markers CD68, CD14 and CD163, and cytokines IL-18, CSF-1, TNF-α, IL-10 and leptin. 
Similarly, CCL2, CD68, CD14, IL-18, MIF and IL-10 were significantly negatively associated 
with SI in black women. Our findings support both murine [192;262] and human studies 
[72;73;75;263-265] that have examined the expression of these genes individually in relation to 
SI, and support the presence of AT macrophage recruitment and proinflammatory activation 
















Differences in the magnitude of association between SAT inflammatory gene expression and SI 
in black and white women were mirrored at a circulating level, with leptin, adiponectin and 
hsCRP concentrations correlating significantly with SI in white, but not black women. Although 
the results from Chapter 3 showed that hsCRP concentrations were significantly associated with 
HOMA-IR in both black and white women, the unadjusted R
2
 was much higher in the white 
compared to the black women (0.19 vs. 0.06, respectively). In the present study, there were no 
differences in circulating concentrations of IL-18, as was found in the larger cohort in Chapter 3. 
Indeed, a possible explanation for these differences could be due to the smaller sample size in the 
present Chapter. Further, SI of the women in the current study was significantly different 
between ethnicities, whereas black and white women included in Chapter 3 had similar levels of 
IR, based on HOMA-IR. In support of this, a recent study that showed that African-American 
women were more insulin resistant than Caucasian women, independent of obesity, fat 
distribution and higher circulating inflammatory markers [37]. Notably, we have evaluated SI 
using FSIGT, which relates to peripheral skeletal muscle insulin sensitivity, while HOMA 
reflects the sensitivity of insulin-stimulated glucose uptake at basal levels. It therefore seems 
important to explore whether ethnic differences exist in insulin signalling in skeletal muscle. Of 
note, African-Americans have been shown to have greater intramuscular AT, which is associated 
with lower SI [266]. It is also possible that inflammation in VAT may be associated with SI in 
black women. Unfortunately, as we did not collect VAT we could not test this hypothesis. 
However, black women have less VAT than white women, and studies in America and South 


















5.5.2. Depot differences in gene expression 
The second novel and important finding was that gluteal SAT had higher mRNA levels of the 
chemokine CCL2, macrophage markers CD14, CD68, and CD163, inflammatory cytokines MIF, 
TNF-α, IL-18 and IL-10, and leptin, and lower expression of adiponectin, compared to the 
abdominal depots.  This is in direct contrast to the hypothesis that gluteo-femoral SAT secretes 
less pro-inflammatory cytokines compared with abdominal SAT [7]. Accumulation of gluteal 
SAT has been regarded as protective, with some [7;64], but not all [65;66], studies showing a 
positive association between increasing hip circumference and/or leg fat mass and favourable 
metabolic risk profiles.  
Despite lower expression levels compared to the gluteal depot, the majority of inflammatory 
genes contributing to the model for SI were from abdominal DSAT and SSAT, suggesting that 
inflammation in gluteal SAT does not contribute to IR as much as other sources. Inflammatory 
gene expression increases proportionately with adipocyte size [186] and the higher inflammatory 
profile in the gluteal depot may be an appropriate response due to the greater adipocyte size of 
the gluteal AT. This may also possibly explain the lower adiponectin and higher leptin 
expression in the gluteal compared to abdominal SAT. Indeed, Bruun et al. have demonstrated in 
humans in vitro that there is a cytokine-induced reduction in adiponectin mRNA [267]. This 
contrasts to two previous studies with limited sample size, which found no differences in 
adiponectin gene expression when comparing abdominal SAT and gluteal (n=5)[205] or thigh 
(n=3) [206] SAT.   
Despite the consistent relationship among white women between mRNA and circulating 
















of gluteal IL-18) did not correlate with protein levels. Previous studies have shown that marked 
disparity can exist between the relative gene expression levels and those of their corresponding 
proteins [268]. This could be due to methodological issues, including low sensitivity of detection 
and/or biological factors, such as post-transcriptional and translational regulation of the gene 
measured. Further research is therefore needed to identify which are the functionally relevant 
inflammatory mediators of SI in AT.  
In conclusion, black South African women had higher inflammatory gene expression levels than 
white women but this only explained a small proportion of the variance in SI. In contrast, in 
white women, the SAT inflammatory gene expression profile explained 56% of the variance in 
SI. Further research is required to explore the contribution of inflammation in other tissues, 
which may affect insulin sensitivity in black populations, in particular the role of skeletal muscle, 
the major site for glucose disposal. Secondly, gluteal SAT had a greater inflammatory gene 
expression profile than abdominal SAT depots, which is in direct contrast to the hypothesis that 
gluteal SAT is ‘protective’ due to its lower inflammatory profile. The protective nature of gluteo-


















SUMMARY AND CONCLUSIONS 
 
Inflammation is thought to be one of the main factors linking obesity to increased risk for CVD 
and T2DM. A better understanding of the role of inflammation in CVD and T2DM risk in 
different ethnic groups, who differ according to body fat distribution, SES and inflammation may 
help with improved disease prevention and future intervention strategies. Therefore the main 
objective of this thesis was to explore the ethnic-specific associations between obesity and 
inflammation, at a circulating, genetic and adipose tissue-specific level, with risk factors for 
CVD and T2DM in apparently healthy black and white South African women. The main findings 
of this thesis are summarized in Table 6.1 and further discussed below. 
Obesity, in addition to being an independent risk factor for CVD and T2DM, is associated with 
other risk factors, namely elevated BP, dyslipidaemia and IR. As a result, several indices of 
obesity, including WC, WHtR and VAT are used for early detection of individuals at increased 
risk for CVD and T2DM. The level of obesity associated with risk differs according to ethnicity 
and population group, and currently there are no recommendations for a South African 
population. Further, it is important to establish which is the best measure of obesity that 
identifies individuals at increased risk for CVD and T2DM. Therefore, the first study of this 
thesis examined the discriminative ability (using ROC curves) of anthropometric measures (WC 
and WHtR) and CT-derived VAT to identify black and white women with elevated BP, 
dyslipidaemia and IR. The main finding was that central obesity measures were better at 
















risk in the white compared to the black women). Furthermore, the level of obesity that predicted 
risk was generally lower in black compared to white women, however WHtR differed the least 
between ethnic groups and therefore may be useful for studies involving ethnic comparisons. In 
addition, there was little difference in the ability of anthropometric compared to a more high-cost 
CT-derived measure of VAT for identifying risk in both ethnicities and therefore recommend 
that anthropometric measures be used. To my knowledge, this is the first study to investigate 
obesity thresholds in black and white South African women and to compare the effectiveness of 
anthropometric indices to the gold standard CT measure.  
As central obesity measures were less effective in identifying black c mpared to white women at 
increased risk for CVD and T2DM, novel risk markers, such as circulating inflammatory 
markers IL-18 and hsCRP, may provide improved prediction of CVD and T2DM risk, especially 
in black populations. However, several environmental factors, including SES and 
behavioural/lifestyle factors, which influence both inflammation and CVD and T2DM risk, need 
to be considered when investigating the independent association between inflammation and CVD 
risk. Therefore, the second study of this thesis investigated the ethnic-specific association 
between  circulating concentrations of IL-18 and hsCRP and CVD and T2DM risk factors, taking 
into consideration SES, health behaviour/lifestyle factors and central obesity. Circulating 
concentrations of IL-18 and hsCRP were associated with CVD and T2DM risk factors in both 
black women, and these associations were largely independent of SES and behavioural/lifestyles 
factors, but were not independent of WC. These results suggest that the measurement of 
circulating inflammatory proteins is not of added benefit to a simple WC measure for identifying 
women at increased risk for CVD and T2DM. These results also support the hypothesis that AT 
















my knowledge, this is the first study to investigate the relationship between SES and 
behavioural/lifestyle factors and circulating IL-18 concentrations. In addition, this is the first 
study to investigate whether circulating IL-18 and hsCRP concentrations are associated with 
CVD and T2DM risk factors, independent of SES and behavioural/lifestyle factors in black and 
white South African women.  
Ethnic differences in circulating IL-18 concentrations observed in Chapter 3 may be explained, 
in part, by ethnic differences in the distribution of the -137G/C polymorphism within the IL-18 
gene. The G allele has previously been shown to be associated with variation in circulating 
concentrations and to be more frequent in black compared to white American women. Therefore, 
the third study aimed to investigate the association between the -137G/C polymorphism with 
circulating IL-18 concentrations and metabolic risk factors for CVD. Although the black women 
had a higher frequency of the G allele, this did not explain ethnic differences in IL-18 
concentrations. Circulating IL-18 concentrations were higher in black compared to white women 
independent of age, genotype and body fatness (P<0.01). Further research examining the 
functional relevance of this polymorphism is therefore needed. In addition, the -137G/C 
genotype was associated with BP in both black and white women, with the G/C genotype 
associated with approximately 55mHg difference in BP compared to the GG genotype. However, 
the direction of this relationship was different between black and white women, as the C-allele 
was associated with higher BP in black women, whereas it was associated with lower BP in 
white women. This is the first study to investigate whether ethnic differences in the distribution 
of the IL-18 -137G/C genotype is associated with ethnic differences in circulating IL-18 
concentrations, and to investigate the association between the -137 G/C polymorphism with 
















This thesis has identified that the association between circulating inflammatory markers with 
metabolic risk factors for CVD and T2DM in South African women was largely mediated by 
central obesity. Whether there are ethnic- and depot- specific differences in AT inflammatory 
gene and protein expression, and whether this is related to a differential SI in South African 
women is not known. Therefore in a subsample of black and white women, the final study 
investigated the ethnic and depot-specific association between inflammatory gene and protein 
expression of abdominal and gluteal AT with SI. I report a higher inflammatory gene expression 
in black compared to white women. However, despite higher AT inflammatory gene expression 
in black women, this was not able to explain their lower SI. Therefore, ethnic differences in SI 
might be due to metabolic effects of other insulin-sensitive tissues, such as the muscle, which 
have also been shown to have inflammatory properties. Furthermore, the gluteal depot had a 
higher inflammatory gene expression compared to the abdominal AT depots, suggesting that the 
protective properties of gluteal adipose tissue are not due to a more favourable inflammatory 
profile and therefore need to be investigated further. This study provides novel insight into the 
inflammatory profile of abdominal and gluteal SAT, and is the first to investigate the ethnic –
specific differences in AT inflammatory gene expression.  
The thesis has some limitations that should be noted. The subjects were not randomly sampled 
but recruited through advertisements in local newspapers and universities. Therefore, the data 
may not be representative of the black and white South African population. Notably, although 
the women included in this study reported having no known disease, it is possible that 
undiagnosed or undisclosed confounding factors such as HIV, TB, depression or other 
physiological states relating to stress, could have influenced the findings in this study. Type of 
















being on injectable contraceptives, whereas the majority of white women were on oral 
contraceptives. Notably, both these forms of contraception have been linked to metabolic 
disturbances and alterations in fat distribution (as reviewed by Johan Verhaeghe [269]). The 
metabolic effects of contraceptives appear to be dose- and hormone specific. Therefore, ethnic 
differences in type of contraception used may have influenced results of this thesis, particularly 
in chapters 2, 4 and 5, where contraceptive use was not accounted for in the analyses. 
Importantly, these results need to be verified in other cohorts. Specifically, the women included 
in the study were relatively young (~27years) and apparently healthy (no known disease), 
therefore the relationship between body composition, inflammation and metabolic risk needs to 
be explored in similar groups with known disease or pathophysiology. Furthermore, with the 
majority (over 70%) of black women being of Xhosa ancestry, it is also not known whether 
obesity and risk thresholds established in Chapter 2 are applicable to other Sub-Saharan 
populations.  Due to the cross-sectional nature of the study, it is not known whether the risk 
factor thresholds used (NCEP ATPIII criteria derived from European cohorts [31]) translates to 
equal risk in black and white women. Ideally the determination of the WC cut-point of risk 
(Chapter 2), and establishing whether circulating inflammatory markers are of added benefit to 
risk prediction (Chapter 3), would be based on the results of prospective investigations that link 
WC and inflammation to the development of T2DM, CVD or death. However, evidence from 
large prospective studies in South Africa is currently not available. In Chapter 3, SES and 
behavioural/lifestyle factors were self reported by means of a questionnaire. Although this 
questionnaire has been validated in a South African population, there may be reporter bias and 
more objective measures of lifestyle need to be used in future studies. In Chapter 5 of this thesis, 
















differences in SI, the findings of this study need to be confirmed in a larger sample.  
Furthermore, despite ethnic differences in gene expression levels, these findings were not 
mirrored at a protein level. Notably, inflammation acts via endocrine and paracrine effects, with 
the latter being difficult to quantify. Other sites of inflammation, particularly those associated 
with ectopic fat deposition (pancreas, skeletal muscle, liver, and heart), may also contribute to 
disease risk; to our knowledge, this has not been explored in multi-ethnic populations.  
Despite these limitations, this thesis has important novel findings (Table 6.1) regarding the 
ethnic specific role of obesity and inflammation (at a circulating, genetic and AT-specific level) 
with metabolic risk factors for CVD and T2DM in apparently healthy black and white South 
African women. The practical implications of these findings are that basic anthropometric 
indices provided the most cost-effective marker of CVD and T2DM risk in both black and white 
South African women. Currently, due to the cost and methods for measuring inflammatory 
markers being high and invasive, they are not practical markers of risk, especially in a primary 
prevention setting. Notably, several modifiable risk factors, namely SES and contraceptive use, 
influenced both circulating inflammatory markers and CVD risk and should be targets for future 
disease prevention. Furthermore, although inflammation has previously been associated with 
increased risk for CVD and T2DM, ethnic differences in circulating inflammatory markers and 
expression of inflammatory genes in AT do not fully account for the disparity in disease risk 
between black and white women.  
Based on the findings of this study, future research should investigate the contribution of 
inflammation from other tissues, which may affect metabolic risk factors, particularly in black 
populations.  As a large proportion of risk remained unexplained, future studies should focus on 
















physical activity and dietary intake. Furthermore, prospective studies are also required to 














Table 6.1. Summary, implications and novel aspects by chapter 
Chapter Summary Implications Novel Aspects 
Two Measures of central obesity (WC, 
WHtR and VAT) were significantly 
associated with metabolic risk 
factors (elevated BP, dyslipidaemia 
and IR) for CVD and T2DM in both 
black and white South African 
women. 
The ability of central obesity 
measures to identify metabolic risk 
factors was stronger in white 
compared to black women (based on 
ROC AUC). 
Anthropometric indices of central 
obesity could identify an equivalent 
amount of metabolic risk as CT-
derived VAT, in both black and 
white women. 
Thresholds for WHtR varied the 
least between ethnicities and may be 
more useful than WC or VAT for 
comparisons of risk between black 
and white women. 
 
This finding supports the use of 
anthropometry as a measure of 
central obesity and for use as a 
diagnostic tool for identifying 
black and white South African 
women at increased risk for CVD 
and T2DM.   
 
This was the first study to identify central 
obesity thresholds for identifying black and 
white South African women at increased risk 
for CVD and T2DM. This is also the first study 
to compare the ability of anthropometric obesity 
measures to CT-derived VAT for identifying 
black and white South African women at 

















Table 6.1 Continued 
Chapter Summary Implications Novel Aspects 
Three Low SES, smoking, 
contraceptive use and central 
obesity were associated with 
higher circulating concentrations 
of IL-18 and hsCRP. 
Circulating concentrations of the 
inflammatory markers IL-18 and 
hsCRP were associated with 
metabolic risk factors for CVD in 
both black and white women. 
WC, but not SES or 
behavioural/lifestyle factors 
attenuated the relationship 
between hsCRP and IL-18 and 
metabolic risk factors in black 
and white women.  
Although WC, SES and 
contraceptive use explained a 
significant proportion of risk, a 
large amount of variation 
remained unexplained by factors 
explored in this thesis. 
These findings does not support the 
use of circulating inflammatory 
markers IL-18 and hsCRP for 
identification of CVD and T2DM risk 
in a primary prevention setting. 
However, they do support the 
hypothesis that chronic inflammation 
associated with metabolic risk has a 
putative origin in AT.  
Further attention needs to be given to 
managing potentially modifiable risk 
factors, including SES and 
contraceptive use, in primary 
prevention of CVD and T2DM in 
black and white women. 
 
This was the first study to explore the impact of 
SES and behavioural/lifestyle factors on 
circulating concentrations of IL-18 and hsCRP 
and to explore the possible mediating effects of 
obesity, SES and behavioural/lifestyle factors 
on the relationship between IL-18 and hsCRP 
with metabolic risk factors for CVD and T2DM 
















Table 6.1 Continued. 
Chapter Summary Implications Novel Aspects 
Four The distribution of the C-allele 
(protective allele) of the -137G/C 
polymorphism within the IL-18 
gene was lower in black compared 
to white South African women. 
Despite a higher frequency of the 
G-allele in black women, this could 
not explain their higher circulating 
IL-18 concentrations. 
The IL-18-137 C-allele was 
differentially associated with BP in 
black and white South African 
women. 
These findings suggest that 
further investigation into the 
functional relevance of the IL-
18 – 137 G/C polymorphism 
is required.  
These findings suggest a 
potential genetic basis linking 
IL-18 to BP variation in black 
and white South African 
women. 
This was the first study to investigate an association 
between the IL-18 -137G/C polymorphism with 
metabolic risk factors for CVD and to investigate 
whether ethnic differences in circulating 
concentrations of IL-18 are influenced by ethnic 
















Table 6.1 Continued. 
Chapter Summary Implications Novel Aspects 
Five Abdominal and gluteal SAT 
inflammatory gene expression was 
higher in black compared to white 
South African women. 
Abdominal and gluteal SAT 
inflammatory gene expression and 
circulating inflammatory markers 
were significantly associated with SI 
in white (P<0.01) but not black 
women (P=30). 
The gluteal SAT depot had a higher 
inflammatory gene expression 
compared to abdominal SAT depots,  
Abdominal SAT inflammatory gene 
expression was more closely related 
to SI than gluteal SAT gene 
expression, supporting the higher risk 
attributed to central obesity. 
 
These findings show that ethnic differences 
SAT inflammatory gene expression cannot 
explain ethnic differences in SI. In addition 
they highlight the need for further research into 
the proposed protective nature of peripheral fat 
accumulation. 
This was the first study to 
compared SAT inflammatory 
gene expression between black 
and white women and between 
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Grade 1-7 - - - - - - - - - - 
Grade 8-11 23.3 12.8 26.4 22.5 0.0 18.6 31.3 20.2 21.4 28.5 
Completed 
High School 
28.7 30.8 34.5 33.0 48.0 38.5 28.8 37.0 25.2 26.6 




- - - - - - - - - - 
Quintile 3 
(9-12) 
8.9 14.2 26.4 22.5 0.0 17.0 31.3 15.8 22.2 25.0 
Quartile 4 
(13-16) 
37.4 33.0 33.4 28.6 51.0 31.5 28.8 35.6 27.5 26.1 
Quintile 5 
(>12) 
53.7 52.8 39.9 48.9 49.0 51.5 44.0 48.4 50.3 48.9 
Values are %. BP, blood pressure; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; TC/HDL-C, total-cholesterol/high density lipoprotein 



















Physical Activity Contraception Use Metabolic Risk Factors 















Grade 1-7 0.0 0.0 22.0 0.0 1.0 14.0 5.9 18.3 18.0 12.0 
Grade 8-11 0.0 12.8 20.8 0.0 5.0 18.6 13.3 21.8 22.0 10.0 
Completed 
High School 
48.6 32.8 28.6 39.0 46.0 33.0 28.8 28.9 19.3 34.0 
Tertiary 51.4 54.4 28.6 61.0 48.0 34.4 52.0 31.0 40.7 44.0 
Asset Index 
Quintile  1 
(<5) 
0.0 0.0 7.4 0.0 0.0 12.0 7.0 12.0 0.0 2.9 
Quintile 2 
(5-8) 
0.0 7.4 18.2 4.5 9.2 12.0 15.5 19.3 10.0 0.0 
Quintile 3 
(9-12) 
4.1 22.6 11.3 0 3.9 25.0 25.5 12.0 20.4 14.7 
Quartile 4 
(13-16) 
15.0 35.0 38.2 62.2 46.9 32.3 20.0 26.7 34.8 32.4 
Quintile 5 
(>12) 
80.9 35.0 24.9 33.3 40.0 18.7 30.0 30.0 34.8 50.0 
Values are %. BP, blood pressure; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; TC/HDL-C, total-cholesterol/high density lipoprotein 
cholesterol ratio; HOMA-IR, homeostasis model of insulin resistance. 
 
